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More than a century ago the distinguished neurologist and physiologist Charles 
Edouard Brown-Séquard published an article in leading medical journal The Lancet titled 
“The effects on man by subcutaneous injections of a liquid obtained from the testicles 
of animals.” (Brown-Séquard, 1889). In this article he describes enthusiastically how he 
extracted a liquid from a mixture of dog and guinea pig blood, semen, and testicles, pain-
fully injected it in his own thigh, and subsequently experienced huge invigorating effects. 
Despite the fact that the experiment was not received well by his colleagues, it gave an 
important boost to “the study of the internal secretion of glands, a branch of physiology 
which gives promise of leading to important advances in therapeutics.” (Bowditch, 1897, 
p. 96).
Nowadays we know that the effects reported by Brown-Séquard must be ascribed 
to a placebo response, but we also know that the substance he was after is the gonadal 
steroid hormone testosterone (Cussons, Bhagat, Fletcher, & Walsh, 2002). Besides having 
virilizing and anabolic effects, more recent psychophysiological research has shown that 
testosterone also bears anxiolytic properties and stimulates social approach motivation. It 
plays a crucial role in the regulation of social behavior, together with the steroid hormone 
cortisol, which is associated with stress and social avoidance. Imbalances in testosterone 
and cortisol levels are linked to psychopathology. This thesis will focus on social anxiety 
disorder (SAD), characterized by increased cortisol responses and persistent avoidance 
of social situations. Although the role of cortisol in social fear and avoidance in SAD has 
been explored, studies on the actions of testosterone thus far are lacking. The research 
presented in this thesis investigates whether testosterone levels are deviating in SAD, 
tests whether administering testosterone could counteract the persistent social avoid-
ance tendencies in SAD, and explores some of the neuroendocrinological mechanisms. 
This not only advances our theoretical understanding of steroid involvement in social 
emotional behavior, but also may have implications for the treatment of SAD.
Psychoneuroendocinology of social motivational behavior
Social environment, emotion, and motivation
Like many social species, humans organize themselves in social status hierarchies, 
which help stabilize the social organization of individuals (Gilboa-Schechtman & Shachar-
Lavie, 2013; Sapolsky, 2005). Emotional facial expressions play an important role in social 
communication within this system and ensure a non-violent regulation of the status 
hierarchy. Smiling faces initiate social interaction, but also function as a signal of ap-
peasement, whereas angry expressions typically convey social dominance and are being 
perceived as a threat (Öhman, 1986). For a socially anxious individual such a sign of a 
potentially aggressive encounter is highly distressing and therefore avoided. In contrast, 
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a more dominant approach-oriented individual would rather engage in the confronta-
tion, because such an encounter may end up in a possibly rewarding outcome, such as 
increased social status and its benefits. Accordingly, SAD may be based on this ubiquitous 
social hierarchy system, with patients displaying exaggerated socially submissive behav-
ior (Gilbert, 2001; Hermans & van Honk, 2006; Öhman, & Wiens, 2003; Weisman, Aderka, 
Marom, Hermesh, & Gilboa-Schechtman, 2011)
Adaptive regulation of social approach or avoidance responses is crucial for suc-
cessful social functioning. In response to a social stimulus (e.g., an angry facial expres-
sion), the individual will show a quick and automatic sequence of response stages, the 
freeze-fight-flight response (Bradley, Codispoti, Cuthbert, & Lang, 2001). After the initial 
freeze response in which the individual ceases all ongoing activity, and quickly and 
subconsciously assesses the situation, it will select either to approach the situation (i.e., 
fight), or to avoid it (i.e., flight; Blanchard, Griebel, Pobbe, & Blanchard, 2011). Typically, 
the automatic evaluation directly results in a behavioral disposition towards the stimulus: 
appetitive stimuli will elicit approach responses, whereas aversive stimuli will elicit avoid-
ance tendencies. These types of automatic tendencies are suggested to play a prominent 
role in the maintenance of psychopathology (Blanchard et al., 2011; Turk, Lerner, Heim-
berg, & Rapee, 2001; Wong & Moulds, 2011). When the system is impaired they may lead 
to aggression in case the fight response is triggered too easily, or in persistent avoidance 
when the flight-response is too prominent (Blanchard et al., 2011), as is the case with SAD. 
The hormones testosterone and cortisol are important in the regulation of such social 
motivational behavior, as will be described below.
Neurobiology underlying social motivational behavior
Approach-avoidance responses are mediated by complex interacting neural net-
works, which can be categorized in the so called Emotional Network, Reward Network, 
and the Cognitive Control Network (Cremers & Roelofs, 2016), which will be broadly de-
scribed hereafter. The amygdala plays a central role in the Emotion Network: its subnuclei 
process salient information from the environment, such as emotional facial expressions, 
and trigger behavioral responses in response to these environmental stimuli. The Baso-
lateral Amygdala (BLA) receives input from the thalamus and sensory cortices (such as 
fusiform gyrus, involved in face processing), whereas the Central Amygdala (CeA) orches-
trates autonomic responses by projections to the Periaqueductal Grey (PAG) initiating 
freeze, to brainstem nuclei for release of neurotransmitters, and the hypothalamus for 
release of Corticotropin Releasing Hormone (CRH) and Gonadotropin Releasing Hormone 
(GnRH), which eventually leads to enhanced cortisol and testosterone levels respectively. 
The amygdala is also connected to the Reward Network, which comprises the ventral 
tegmental area (VTA), striatum (including the nucleus accumbens (NAcc), and medial 
prefrontal cortex (mPFC) (Haber & Knutson, 2010). Striatal dopamine transmission is es-
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sential for the adaptive regulation of social behavior as it is involved in reward learning, 
(i.e., obtaining social reward but also avoiding punishment; see Delgado, Jou, LeDoux, & 
Phelps, 2009), behavioral activation, and motivational behavior (Cools, 2008; Yacubian & 
Büchel, 2009). The anterior prefrontal cortex plays a crucial role in the Cognitive Control 
Network as it is involved in the regulation of emotion (Damásio, 1994; Rolls, 1999), and 
in social motivational behavior as it inhibits the amygdala, making it possible to control 
and override automatic behavioral approach and avoidance tendencies (Roelofs, Minelli, 
Mars, van Peer, & Toni, 2009; Volman, Roelofs, Koch, Verhagen, & Toni, 2011), and modu-
lates mesolimbic striatal activity (Grace, Floresco, Goto, & Lodge, 2007; Wager, Davidson, 
Hughes, Lindquist, & Ochsner, 2008). Naturally, this description is a highly simplified one, 
and many other brain regions partake in these networks.
Hormonal regulation of social motivational behavior
The Hypothalamus-Pituitary-Gonadal (HPG) axis with its end product testosterone 
plays a key role in the neuroendocrine regulation of social motivational behavior in both 
sexes. Testosterone levels follow a pulsatile, seasonal, and diurnal cycle in which levels 
are highest upon waking and typically decline with 50% during the day (Dabbs, 1990). 
Under influence of signals from mainly the amygdala Gonadotropin-releasing hormone 
(GnRH) is secreted from the hypothalamus, which stimulates the production of lutein-
izing hormone (LH) and follicle-stimulating hormone (FSH) in the pituitary gland, which 
in turn triggers production of testosterone and estradiol in the gonads (i.e., testes and 
ovaries). In addition, small amounts of testosterone are produced in the adrenal cortex, 
and synthesized in the brain from cholesterol and other steroid precursors. Testosterone 
is able to cross the blood-brain barrier, and besides having (epigenetic) organizational 
effects on brain structure during pre- and early postnatal development, testosterone 
also influences emotion, motivation, and behavior later in life (i.e., activational effects; 
Lombardo et al., 2012; McHenry, Carrier, Hull, & Kabbaj, 2014). Actions of testosterone are 
brought about directly via androgen receptors but also via metabolites such as estra-
diol, dihydrotestosterone, and 3α-diol, which binds to the γ-aminobutyric acid (GABA-A) 
receptor (Balthazart & Ball, 2006; Wood, 2008). The effects can either be slow and long-
lasting (i.e., hours-days) via a genomic pathway featuring intracellular steroid receptors, or 
rapid (i.e., seconds-minutes) via membrane-bound (steroid) receptors, which exert non-
genomic actions in the cell. Importantly, testosterone acts through a steroid-responsive 
network which includes the amygdala, hypothalamus, hippocampus, and PAG, among 
other limbic areas (Wood, 1996), and hence influences the flight-fight response. Naturally, 
testosterone interacts with other neurotransmitters and -peptides, such as serotonin 
(probably via estradiol), vasopressin, oxytocin, and dopamine. With regard to the latter, 
testosterone enhances dopamine transmission in the mesolimbic system, which in turn 
can lead to increased reward sensitivity and augmented motivational behavior (de Souza 
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Silva, Mattern, Topic, Buddenberg, & Huston, 2009; Hermans et al., 2010; Welker, Gruber, & 
Mehta, 2015).
The HPG-axis works in antagonism with the Hypothalamus-Pituitary-Adrenal (HPA) 
axis, in such a way that the end product of the latter (i.e., cortisol, released in response to 
stress) disrupts production and inhibits actions of testosterone, which in turn inhibits the 
stress-induced activation of the HPA-axis at the hypothalamus (Viau, 2002). Both neuroen-
docrine axes are important in the regulation of social-motivational behavior: higher basal 
cortisol levels, and low testosterone, are associated with social subordination stress and 
avoidance behavior, whereas higher basal testosterone and low cortisol facilitates social 
dominance and approach behavior (Bedgood, Boggiano, & Turan, 2014; Mehta & Josephs, 
2010; Sapolsky, 1990, 1991; Honk et al., 1999).
Baseline hormone levels are in general predictive of psychological traits and behavior 
(Welker, 2015), whereas social events are typically associated with a temporary surge or 
decline in hormone levels (Casto & Edwards, 2016; Maner, Miller, Schmidt, & Eckel, 2008; 
Sapolsky, 1991). The social challenge hypothesis states that testosterone levels rise in 
preparation to a challenging encounter in which social status might be threatened, 
thereby initiating approach motivation and simultaneously reducing fear (Archer, 2006; 
Mazur & Booth, 1998; Wingfield, Hegner, Dufty Jr., & Ball, 1990). Several studies featuring 
single dose testosterone administration, which leads to a transient increase in testos-
terone levels, to healthy female participants confirmed the causal relationship between 
testosterone and its effects on the social motivational system. The findings show that tes-
tosterone administration reduces fear and sensitivity to threat and punishment, enhances 
reward sensitivity, and promotes social approach motivation aimed at achieving social 
status (i.e., social reward; see for a review Bos, Panksepp, Bluthe, & van Honk, 2012). These 
actions are brought about by anxiolytic effects (GABA, androgen receptors; McHenry 
et al., 2014) and upregulation of the dopaminergic system (de Souza Silva et al., 2009), 
in addition to biasing the amygdala towards threat approach (Radke et al., 2015), and 
reducing prefrontal control over the amygdala (Schutter & van Honk, 2004; van Wingen, 
Mattern, Verkes, Buitelaar, & Fernández, 2010; Volman, Toni, Verhagen, & Roelofs, 2011). 
Although associated with aggression (Montoya, Terburg, Bos, & van Honk, 2012), the 
effects of testosterone on social motivational behavior depend on social context and 
individual differences, and thus do not entail aggressive behavior per se, but could also 
lead to prosocial behavior when this is more appropriate to ensure an increase in social 
status (Boksem et al., 2013; Carré et al., 2016; Eisenegger, Haushofer, & Fehr, 2011; Mehta & 
Josephs, 2010; Stanton & Schultheiss, 2009; van Honk, Terburg, & Bos, 2011).
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Social Anxiety Disorder
Clinical description
Social Anxiety Disorder (SAD) is characterized by an intense fear of social situations 
in which the individual may be scrutinized by others (American Psychiatric Association, 
2013). The affected individual fears that he/she will behave, or show anxiety symptoms, in a 
way that will be negatively evaluated and will lead to rejection by others. Social situations, 
such as social interactions, are therefore avoided or endured with intense fear or anxiety. 
Avoidance behavior plays a crucial role in the persistence of the disorder, and hinders 
extinction of fear in social situations as it reduces the opportunity for accommodation 
to and reevaluation of the situation (Clark & Wells, 1995). In addition, when engaging in 
social interaction, someone with SAD typically avoids eye contact (Stein & Stein, 2008). As 
eye contact is important in social communication, this characteristic hinders social inter-
actions and influences how others respond to the person with SAD, reinforcing the social 
fear-avoidance cycle. Furthermore, there is evidence that SAD persists because of biased 
processing of social information, favoring disorder-relevant information, which leads to 
interpretation of the situation as more negative than it was in reality (Heeren, Lange, 
Philippot, & Wong, 2014; Stein & Stein, 2008). With a lifetime prevalence rate of 7-12% 
SAD is the most common anxiety disorder and among the most common psychiatric 
disorders (Kessler, Berglund, et al., 2005). Onset occurs in childhood or early adolescence, 
and SAD affects more women than men. The disorder typically leads to significant dis-
tress, and - when left untreated - tends to follow a chronic, unremitting course leading to 
substantial impairments in vocational and social functioning. Treatment of SAD consists 
of pharmacotherapy and/or psychotherapy, mainly cognitive behavioral therapy aiming 
at acquiring the behavioral and cognitive skills to function effectively. Exposure therapy is 
part of the latter, and aims at fear extinction by repeated or prolonged exposure to feared 
social situations, leading to a reduction of anxiety and avoidance behavior. Notwithstand-
ing the efficacy of current evidence based psychological and pharmacological treatments 
in SAD, nonresponse rates in large clinical trials have been up to 50% (Hofmann & Bögels, 
2006; Stein & Stein, 2008), leaving considerable room for improvement.
Neurobiology of SAD
SAD is associated with deviations in the neuroendocrine brain circuits underlying 
social motivational behavior. Several meta-analytic studies have consistently shown a 
hyperactive amygdala in response to social threat, probably reflecting enhanced pro-
cessing of and attention to threat (Brühl, Delsignore, Komossa, & Weidt, 2014; Cremers 
& Roelofs, 2016; Fouche, van Der Wee, Roelofs, & Stein, 2013). In addition, prefrontal 
structures are also more active than in healthy controls, however prefrontal-amygdala 
connectivity seems to be reduced (Cremers & Roelofs, 2016; Fouche et al., 2013; although 
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evidence is inconsistent, see Brühl et al., 2014), indicating an inability to regulate sub-
cortical regions. Interestingly, pharmaco- and psychotherapy seem to “normalize” these 
responses (Fouche et al., 2013; Freitas-Ferrari et al., 2010). Studies also show alterations 
in striatal functioning in SAD, but findings are mixed (Freitas-Ferrari et al., 2010). A recent 
fMRI study in patients with SAD compared to healthy controls reported reduced striatal 
activity in anticipation of social reward and relative increased striatal activity for avoiding 
social punishment (Cremers, Veer, Spinhoven, Rombouts, & Roelofs, 2014). These findings 
suggest that patients with SAD show a reduced motivation to obtain social reward and 
relative increased motivation to avoid social punishment compared to healthy controls. 
In addition, patients with SAD showed a reduced pattern of fronto-striatal connectivity 
during reward and punishment anticipation, relative to healthy controls.
Hormonal regulation in SAD
Patients with SAD show an increased cortisol response to social stress, compared 
to healthy participants and patients with Post-Traumatic Stress Disorder (PTSD), and this 
response was associated with social avoidance behavior (Roelofs, van Peer, Berretty, de 
Jong, et al., 2009). Studies combining cortisol administration with Electroencephalog-
raphy (EEG) in patients with SAD confirmed a causal relationship between cortisol and 
increased early processing of emotional faces during social avoidance (Van Peer, Spin-
hoven, & Roelofs, 2009), and modulation of early threat processing depending on motiva-
tional context and symptom severity (van Peer, Spinhoven, & Roelofs, 2010). In addition, 
both higher baseline levels of cortisol and exogenous cortisol are associated with EEG 
wave activity patterns related to anxiety and behavioral inhibition (Schutter & van Honk, 
2005; van Peer, Roelofs, & Spinhoven, 2008), whereas testosterone has an opposite effect 
(Schutter & van Honk, 2004). This thesis contains the first published studies on the role of 
the HPG-axis and testosterone in SAD. Studies on testosterone in social anxiety are scarce, 
and although testosterone levels in socially anxious men dropped in response to losing 
a competition, no differences in baseline levels of testosterone were reported (Gerra et 
al., 2000; Maner et al., 2008). Previous research mainly focused on the role of testosterone 
in depression, and found that reduced testosterone levels are associated with depressive 
moods and anxiety (Ebinger, Sievers, Ivan, Schneider, & Stalla, 2009; McHenry et al., 2014). 
Interestingly, testosterone administration for the treatment of depression has been ap-
plied since mid-twentieth century (Altschule & Tillotson, 1948), and positive effects on 
mood have been reported (Ebinger et al., 2009). Besides cortisol and testosterone, also 
other neuropeptides and hormones are involved in social anxiety and avoidance, such 
as oxytocin, vasopressin, and progesterone (Crespi, 2016; Maner, Miller, Schmidt, & Eckel, 
2010; Meyer-Lindenberg, Domes, Kirsch, & Heinrichs, 2011).
General introduction
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Aim of this thesis
In sum, individuals with SAD show alterations in the regulation of social motiva-
tional behavior characterized by persistent social avoidance, increased cortisol responses, 
enhanced threat sensitivity, and probably reduced reward processing, a pattern that is 
associated with socially submissive behavior. Considering that testosterone is associated 
with social dominance, entailing enhanced approach motivation, and reduced fear and 
threat sensitivity, it is striking that so far no studies have investigated the role of testoster-
one in SAD. This thesis aims to elucidate the role of testosterone in the neuroendocrine 
mechanisms underlying social fear and avoidance in SAD. We hypothesize that 1) SAD is 
associated with reduced testosterone levels compared to healthy controls, and 2) that 
administering testosterone to people with SAD will alleviate social fear and avoidance, 
and will promote prosocial behavior. The first hypothesis was tested by assessing salivary 
testosterone levels in a large group of people including SAD patients and healthy controls. 
We tested the second hypothesis by investigating the effects of single dose testosterone 
administration in women with SAD as compared to healthy controls, on several indexes 
of motivational behavior and attention. The background of the used methods is briefly 
outlined in Box 1.1. In addition, based on animal and human evidence on the role of 
dopamine in social approach and avoidance behavior, and given the important interac-
tions between testosterone and striatal dopamine signaling (de Souza Silva et al., 2009; 
Hermans et al., 2010), an initial study was performed to explore the interaction between 
striatal dopaminergic polymorphisms and social approach-avoidance tendencies.
Outline of this thesis
Social reward processing is of importance for the adaptive regulation of social be-
havior, but it has not yet been explored how it affects actual social approach-avoidance 
behavior. Chapter 2 describes a first study on the effect of alterations in the mesolimbic 
reward system on social approach-avoidance tendencies. An implicit social AAT is per-
formed by two groups of participants who carry different variants of a gene involved in 
striatal dopamine transmission, which affects their reward sensitivity.
Thus far no studies have systematically tested the effects of testosterone on actual 
social approach–avoidance action tendencies. Chapter 3 presents a first study testing 
whether single dose testosterone administration diminishes threat avoidance and 
promotes behavioral approach actions that have an immediate effect on the relative dis-
tance of the social threat stimulus, by using an implicit social AAT performed by healthy 
individuals.
16
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Low endogenous levels of testosterone have been associated with major depression, 
but data on testosterone levels in anxiety disorders are scarce. Chapter 4 maps salivary 
testosterone levels in the Netherlands Study of Depression and Anxiety (NESDA; Penninx 
2008)), a longitudinal cohort study comprising 2981 participants.
Chapter 5 presents a first study that tests the effects of testosterone on actual social 
approach–avoidance action tendencies in SAD. Using the same implicit social AAT as in 
chapter 3, we investigate whether administering a single dose of testosterone can coun-
teract the automatic social avoidance tendencies in patients with SAD.
Previous eye tracking studies have confirmed that avoidance of eye contact is a 
characteristic and persistent social feature in SAD. Chapter 6 tests the hypothesis that 
Box 1.1. General methodology
Exogenous testosterone Administering testosterone enables determination of a causal relationship between a 
rise in testosterone levels and its effects on the social motivational system. We applied sublingual administration of 
testosterone cyclodextrin, a method that has been used for over a decade in healthy and highly anxious individuals, 
and has convincingly shown consistent psychophysiological and behavioral effects approximately 4-6 hours after 
administration (see for a review Bos et al., 2012). Its pharmacodynamic profile has been established using a reliable 
automatic and non-habitual measure (Tuiten et al., 2000). The delay between administration and subsequent effects 
is related to how much of the substance crosses the blood brain barrier, which also depends on the free fraction 
of testosterone and serum SHBG saturation, and the fact that effects are due to slow genomic effects via steroid 
receptors, and other routes of action (van der Made et al., 2009; van Rooij et al., 2012). 
Action tendenciesG The automatic and motivationally driven tendency to approach or avoid a certain stimulus 
translates to motor responses, and can be objectively measured by using a social approach–avoidance task (AAT; 
Chen & Bargh, 1999; Heuer et al., 2007; Roelofs et al., 2005; Rotteveel & Phaf, 2004). This reaction time task requires 
participants to approach and to avoid socially appetitive and aversive visually presented stimuli (happy and angry 
faces, respectively) by pulling (approach) or pushing away a joystick (avoidance). Pulling or pushing the joystick 
increases or decreases the size of the picture respectively, giving the impression of moving towards or moving away 
from the participant. Affect congruent responses (i.e., approaching happy or avoiding angry faces), lead to quicker 
responses than when these automatic tendencies need to be overrided as is the case with affect-incongruent 
responses (i.e., Approaching angry of avoiding happy faces). Highly socially anxious individuals have consistently been 
shown to push away angry faces faster compared to neutral ones (Heuer et al., 2007; Roelofs et al., 2010).
Gaze behavior Avoidance of eye contact is a characteristic and persistent social feature in people with SAD, and 
is typical socially submissive behavior aimed at reducing social threat (Horley et al., 2003, 2004; Öhman, 1986). Gaze 
behavior can be assessed by using eye-tracking, which is the process of measuring where the participant is looking on 
a screen by tracking eye movements. The eye tracker uses infrared light that is reflected from the eye and sensed by a 
video camera: moving the eye causes changes in reflections which are used to extract information on the position of 
the eye. Eye movements are typically categorized into fixations (i.e. when the gaze stops in a certain position for about 
100ms) and saccades (i.e., when it moves from one to another position). Individuals with SAD tend to avoid looking 
at the eyes of emotional facial expressions presented on computer screens (e.g., Horley et al., 2004; Moukheiber et al., 
2010).
Electroencephalography We used EEG to capture early attention processes, which lay at the basis of the flight-
fight response. Cognitive processes in the brain cause waves of electric currents that can be measured at the scalp 
using EEG. In response to sensory events, certain patterns in voltage changes emerge at typical topographical 
locations on the scalp, called Event Related Potentials (ERPs). We performed a spatiotemporal clustering analysis 
(Brunet et al., 2011; Murray et al., 2008) on the ERPs, as it can tease apart the following two ERP effects: 1) topographic 
modulations, which reflect a change in neural sources, indicating the activation of different cognitive processes (a 
qualitative change in processing), and 2) amplitude modulations, which, in absence of a concurrent topographic 
modulation, reflect the increase or decrease in strength of a common cognitive process (a quantitative change in 
processing; Murray et al., 2008; Pourtois et al., 2008). 
administering a single dose of testosterone promotes socially dominant gaze behavior 
and thus will be able to alleviate submissive gaze avoidance in individuals with SAD.
It remains unknown whether testosterone affects early automatic or later, more 
controlled, processing-stages of social threat. In Chapter 7 we therefore investigate the 
effects of testosterone on social threat processing in participants with SAD and healthy 
participants, using temporally fine-grained recordings of event-related brain potentials 
(ERPs) during an emotional Stroop task with subliminally presented angry, happy and 
neutral faces.
Finally, chapter 8 presents a summary and integration of the empirical chapters, 
discusses the strengths and limitations, and considers future theoretical and clinical 
perspectives.

2
Dopamine transporter polymorphisms 
aff ect social approach–avoidance 
tendencies
Enter, D., Colzato, L. S., & Roelofs, K. (2012). Genes, 
Brain and Behavior, 11(6), 671–676. 
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Chapter 2
Abstract
There is increasing interest in the role of striatal dopaminergic activity in social ap-
proach–avoidance motivation. The 9-repeat allele of the dopamine transporter (DAT) 
gene, associated with increased striatal dopamine levels, has been found to be related 
to increased sensitivity to reward. However, it remains unexplored whether this poly-
morphism influences automatic action tendencies in the social domain. We set out to 
test experimentally whether human carriers of the 9-repeat allele show increased ap-
proach–avoidance tendencies compared to non-9-repeat carriers. One hundred and one 
healthy adults, genotyped for the DAT gene, performed the social Approach–Avoidance 
Task, a reaction time task requiring participants to approach or avoid visually presented 
emotional (happy and angry) faces, by pulling a joystick towards them or pushing the 
joystick away from themselves, respectively. In accordance with expectations, 9-repeat 
carriers showed stronger approach–avoidance effects compared to non-9-repeat carri-
ers. These results suggest a role for striatal dopaminergic polymorphisms in motivational 
responses to social-emotional cues. Our findings may be relevant in the selection of 
candidate genes in future studies involving social behavior.
DAT1 affects approach–avoidance tendencies
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Introduction
The dopamine transporter (DAT) is responsible for dopamine (DA) reuptake in the 
striatum (Sesack, Hawrylak, Matus, Guido, & Levey, 1998). Genetic variations in the dopa-
mine transporter gene (DAT1, SLC6A3) relate to deviations in expression. The chromo-
some 5p15.3 (Giros et al., 1992; Vandenbergh et al., 1992) contains a 40 base pair variable 
number of tandem repeats in the 30-untranslated region (3_UTR-VNTR). Alleles with a 
number of repeats ranging from 3 to 13 have been described, but the alleles with 9 and 
10 repeats are the most frequently reported (Kang, Palmatier, & Kidd, 1999; Mitchell et 
al., 2000). The 9-repeat allele is associated with a reduced expression of the transporter, 
resulting in higher DA concentrations in the striatum as compared to the 10-repeat allele 
(Heinz et al., 2000; VanNess, Owens, & Kilts, 2005).
Typically, striatal dopaminergic activity is associated with motivational processes, and 
there is emerging evidence for a significant role of repeat polymorphisms in DAT genes. 
For example, DAT1 9-repeat carriers showed more striatal activity during processing of a 
monetary reward than 10-repeat carriers (Dreher, Kohn, Kolachana, Weinberger, & Berman, 
2009; Forbes et al., 2009), suggesting increased reward sensitivity in 9-repeat carriers (see 
also Aarts et al., 2010). Recent work has also provided evidence for striatal involvement 
in the processing of social rewards. For instance, Spreckelmeyer and colleagues (2009) 
found increased striatal responding during the anticipation of social reward, signaled by 
emotional facial stimuli in healthy individuals. Interestingly, activity in overlapping brain 
regions was also related to the motivation to avoid social punishment (signaled by angry 
faces) in patients with social phobia (Cremers et al., 2014). These findings suggest that 
striatal functioning is not restricted to the sensitivity to obtaining social reward but also to 
avoiding punishment (see also Beninger, Mason, Phillips, & Fibiger, 1980; Darvas, Fadok, & 
Palmiter, 2011; Delgado et al., 2009). Indeed, also in healthy individuals changing a picture 
of an angry facial expression to one of a neutral look, elicits reward related activity in the 
ventral striatum (Mühlberger et al., 2011).
On the basis of these studies, it can be suggested that striatal functioning, and the 
specific role of DAT1 polymorphisms, is of crucial importance for the adaptive regulation 
of social behavior (e.g., Caldú & Dreher, 2007; Yacubian & Büchel, 2009). However, direct 
evidence for such relation is lacking. The aim of this study was therefore to test the rela-
tionship between DAT1 polymorphisms and alterations in social motivational behavior 
directly, by using an implicit social approach–avoidance task (AAT). The AAT is a valid and 
reliable measure of social approach–avoidance tendencies (Heuer, Rinck, & Becker, 2007; 
Roelofs et al., 2010; Roelofs, van Peer, et al., 2009; Roelofs, Minelli, et al., 2009). This reaction 
time task requires participants to approach and avoid socially appetitive and aversive 
visually presented stimuli (happy and angry faces, respectively) by pulling (approach) or 
pushing away a joystick (avoidance). Happy and angry faces elicit automatic approach 
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and avoidance tendencies, respectively (Chen & Bargh, 1999; Roelofs et al., 2010; Seidel, 
Habel, Kirschner, Gur, & Derntl, 2010).
On the basis of the rewarding nature of approaching happy faces and avoiding social 
threat, we hypothesized that healthy individuals carrying the DAT1 9-repeat polymor-
phism would show increased social approach–avoidance tendencies on the AAT.
Methods
Participants
One hundred and one young Caucasian healthy adults (26 male/75 female), with a 
mean age of 23 years (SD = 2.4, range 19–31), served as participants in exchange for par-
tial fulfillment of course credits or a financial reward. The sample was drawn from adults 
in the Leiden and Rotterdam metropolitan area (The Netherlands) who volunteered to 
participate in studies of behavioral genetics. Exclusion criteria were any major medical 
illness that could affect brain function, current substance abuse, neurological conditions, 
a history of head injury, or a personal history of psychiatric treatment. Participants were 
selected by a phone interview on the basis of the Mini International Neuropsychiatric In-
terview script (M.I.N.I.; Lecubier et al., 1997). Written informed consent was obtained from 
all participants after the nature of the study had been explained to them; the protocol 
was approved by the local ethical committee.
Approach–Avoidance Task (AAT)
During this reaction time (RT) task, participants were asked to classify stimuli on the 
basis of an aspect (color) that was orthogonal to the aspect of interest (facial emotion). 
Participants responded to emotional face pictures presented on a computer screen, by 
pulling a joystick either towards their body (approach movement) or pushing it away 
from their body (avoidance movement) (task adapted from (Heuer et al., 2007). Pulling or 
pushing the joystick increased or decreased the size of the picture respectively. The speed 
of the size change was proportional to the amplitude of the joystick movement. As soon 
as the joystick reached its target position (i.e. the required direction; full movement in-
volved a 30° rotation from the upright position) the picture disappeared from the screen. 
The time between the onset of the stimulus and its disappearance from the screen was 
recorded with >1 ms accuracy. After each completed trial, the participant moved the 
joystick back to its central position and initiated a new trial by pressing the fire button 
near the top of the joystick. Face stimuli were selected from the Karolinska Directed 
Emotional Faces database (Lundqvist, Flykt, & Öhman, 1998). Happy, Angry, Neutral, and 
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Disgusted1 facial expressions were taken from the same model (five male and five female 
models in all) and each picture was presented either with a yellowish or a greyish filter. In 
addition, checkerboards (10 yellow, 10 grey) were included as non-facial control stimuli. 
This resulted in a total of 100 different stimuli, which were presented in random order. All 
participants were instructed to push away yellow stimuli and to pull grey stimuli towards 
them, and to respond as fast and as accurately as possible. Usually, response latencies are 
shorter for affect-congruent (e.g., happy-approach; angry-avoid) as compared to affect 
incongruent response conditions (e.g., angry-approach; happy-avoid). Before the real test 
started, participants were presented with 18 practice trials, which were similar to the test 
trials except for the fact that the pictures showed different models.
DNA laboratory analysis
Genomic DNA was extracted from saliva samples by means of the Oragene™ DNA 
self-collection kit, and following the manufacturer’s instructions (DNA Genotek, Inc., 
Kanata, Ontario, Canada; 2006). The DAT1 polymorphism was amplified on an MJ DNA 
engine thermal cycler (MJ Research), with an initial denaturation at 94°C for 4 min, fol-
lowed by 32 cycles of 45 s at 94°C, 45 s at 68°C, 60 s at 72°C, and a final elongation of 5 min 
at 72°C. The 25 ml reaction mixture consisted of 50 mM Tris (pH 9.0), 20 mM NH4SO4, 3 
mM MgCl2, 200 mM dNTPs, 0.5 mM primers, and 1U Taq polymerase (Invitrogen, Carlsbad, 
CA, USA). Products were electrophoresed on 2% agarose gel and visualized by means of 
ethidium bromide. The oligo primer sequences used to amplify the VNTR are DAT1-F: 5’-
TGT GGT GTA GGG AAC GGC CTG AG-3’ DAT1-R: 5’-CTT CCT GGA GGT CAC GGC TCA AGG, 
as originally described in Waldman et al. (1998). Each individual was genotyped twice.
Procedure
All participants were tested individually. They completed a 30 min reasoning-based 
intelligence test (SPM; Raven, Court, & Raven, 1988), and subsequently performed the 
AAT, which took about 10 min.
Statistical analyses
Independent samples t -tests were performed for analyses of age and gender be-
tween 10/10 homozygous and 9-repeat carriers. RT outliers were filtered using a <150 
and >1500 ms cut-off. For each participant, the median of the remaining RTs (97%) for the 
correct responses was calculated per cell (defined by: Emotion and Movement). Follow-
ing previous studies (Heuer et al., 2007; Roelofs, Elzinga, & Rotteveel, 2005; Roelofs et al., 
1 The disgusted face stimuli have not yet been validated for the AAT (see also Seidel, Habel, Kirschner, Gur, 
& Derntl, 2010), and were added for the benefit of a research question beyotond the scope of this study. 
These stimuli were therefore not included in the analyses but treated as filler stimuli.
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2010; Roelofs, van Peer, et al., 2009; Roelofs, Minelli, et al., 2009; Rotteveel & Phaf, 2004; van 
Peer et al., 2007; van Peer, Spinhoven, van Dijk, & Roelofs, 2009; Volman, Roelofs, Koch, Ver-
hagen, & Toni, 2011) the analysis was based on RTs for happy and angry faces, both known 
to elicit reliable approach–avoidance effects. RTs for neutral faces were used for baseline 
correction. Median RTs were baseline corrected by subtracting the corresponding RTs for 
neutral faces (e.g., RT angry push–RT neutral push; RT angry pull–RT neutral pull; RT happy 
push–RT neutral push; RT happy pull–RT neutral pull). Corrected RTs for angry and happy 
faces were entered in a three-way repeated-measures Analysis of Variance (rmANOVA), 
with as between-subject factor Group (DAT1 9-repeat carriers; DAT1 10/10 homozygotes) 
and within-subject factors Valence (angry; happy) and Movement (push; pull). Alpha was 
set at .05, and effect sizes are reported in partial eta squared (ηp2).
For display purposes (Figure 2.1), AAT-effect scores were calculated for each participant 
and for each emotion separately by subtracting median pull RTs from the corresponding 
median push RTs (e.g., RT angry push–RT angry pull; RT happy push–RT happy pull). These 
AAT-effect scores for angry and happy faces were baseline-corrected by subtracting the 
AAT-effect scores for neutral faces (e.g., AAT-effect angry–AAT-effect neutral; AAT-effect 
happy–AAT-effect neutral). Corrected AAT-effect scores were entered in a two-way re-
peated measures Analysis of Variance (rmANOVA), with as between-subject factor Group 
(DAT1 9-repeat carriers; DAT1 10/10 homozygotes) and within-subject factor Emotion 
(happy; angry). AAT-effect scores with a negative sign (push is faster than pull) reflect a 
relative avoidance tendency, and AAT-effect scores with a positive sign (pull is faster than 
push) reflect a relative approach tendency.
Results
Genotypes
The genotype distribution of the DAT1 polymorphism in our population was 61 
(16 males; age ± SD: 23.6 ± 2.5) 10/10 homozygous subjects (62.9%) and 36 (9 males; 
age ± SD 22.8 ± 2.0) 9-repeat carrier subjects (37.1%). The allelic distribution of the gene 
corresponded to the Hardy Weinberg equilibrium (χ2 = 2.77, P = 0.096). No significant 
differences among genotype frequencies were found with respect to age (t(93) = −1.57, 
p = 0.121) or gender (t(95) = 0.13, p = 0.895).
Approach–Avoidance Task (AAT)
Owing to technical problems, data were missing for 4 participants, leaving 97 partici-
pants for the analyses. Table 2.1 provides an overview of the outcomes for RTs. Error rates 
were low: 3.3% for 10/10-homozygotes, and 3.7% for 9- repeat carriers.
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The three-way (Group (10/10 homozygotes, 9-repeat carriers) × Valence (happy, 
angry) × Movement (push, pull)) rmANOVA for the RTs showed a main effect of Valence 
(F(1,95) = 4.36, p = 0.039, ηp2 = 0.044), a main effect of Movement (F(1,95) = 5.63, p = 
0.020, ηp2 = 0.065), and a Valence × Movement interaction (F(1,95) = 6.80, p =0.011, ηp2 = 
0.067). Most critically, there was a significant Group × Valence × Movement interaction 
(F(1,95) = 4.09, p = 0.046, ηp2 = 0.041). In order to explore the nature of this group interac-
tion, we conducted separate two-way (Valence (happy, angry) × Movement (push, pull)) 
rmANOVAs for each group, demonstrating a significant Valence × Movement interaction 
in the 9-repeat carriers group (F(1,35) = 5.92, p = 0.020, ηp2 = 0.145), but not in the 10/10 
homozygous group (F(1,60) = 0.312, p = 0.578, ηp2 = 0.005). Further one-way rmANOVAs 
for the 9-repeat carriers group revealed a significant effect for movement for happy faces 
(F(1,35) = 7.54, p = 0.009, ηp2 = 0.177), but not for angry faces (F(1,35) = 0.21, p = 0.653, 
ηp2 = 0.006). However, no Group × Movement effects were found when testing effects 
for happy and angry faces separately (happy: F(1,95) = 1.12, p = 0.292, ηp2 = 0.012; angry 
F(1,95) = 1.49, p = 0.225, ηp2 = 0.015). Together, these findings indicate that 9-repeat 
carriers show increased social approach–avoidance tendencies, as compared to 10/10 
homozygous subjects (Figure 2.1).
In order to control whether the RTs were affected by individual differences related 
to physical characteristics of the joystick movement (unrelated to stimulus valence) we 
added the AAT-effect scores for the control stimuli (checkerboards) as covariate in the 
analyses and found that the Group × Valence × Movement interaction remained unaf-
fected: F(1,94) = 4.11, p = 0.045, ηp2 = 0.042. When we checked for Gender we found that 
the Group × Valence ×Movement interaction also remained significant (F(1,94) = 4.03, p = 
0.048, ηp2 = 0.041), and no significant effects for Gender emerged (all ps > 0.700).
Discussion
The aim of this study was to explore the possible role of DAT1 polymorphisms in 
social-motivational behavior, as assessed by an objective measure of approach–avoid-
ance tendencies.
Table 2.1. Genotype-specific mean (ms ± SEM) reaction times for approach (pull) and avoidance (push) responses to 
angry and happy faces.
Valence
9-repeat carriers 10/10 homozygotes
Push Pull Push Pull
Angry 515 (11) 549 (12) 526 (9) 541 (10)
Happy 534 (14) 535 (12) 538 (10) 549 (10)
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Results indicated that DAT1 9-repeat carriers show increased approach-avoidance 
tendencies as compared to 10-repeat homozygotes. These increased approach–avoid-
ance effects of the DAT1 9-repeat carriers were particularly reflected in a significantly 
stronger approach vs. avoidance tendency of happy faces. The effects remained sig-
nificant after controlling for possible confounding factors such as gender and individual 
differences in joystick handling, and suggest that striatal dopaminergic polymorphisms 
do play a role in social motivation.
Increased synaptic DA availability is generally associated with increased reward-
related activity, and usually linked to augmented motivational behavior (see for a review 
Cools, 2008). In our study, the DAT1 9-repeat carriers showed increased emotion-driven 
action tendencies in reaction to stimuli that communicate a motivational drive to the 
observer, and with which their response was immediately rewarded in the sense that 
the speed by which the happy faces grew or the angry faces shrank and disappeared 
was a direct function of the speed with which participants pulled or pushed the joy-
stick respectively. These findings correspond to a study by Talmi and colleagues (2008) 
showing a positive relation between the vigor of an action and motivation to obtain 
a reward, which was also related to an increased blood oxygen level-dependent signal 
in the Nucleus Accumbens, suggestive of increased DA signaling. In addition, Huys and 
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Figure 1: Median AAT-effect scores (ms) for 
approach and avoidance movements to happy 
and angry faces for the 9-repeat carriers group 
and 10/10 homozygotes. DAT1 9-repeat carriers 
show increased avoidance tendencies to angry 
faces, but not happy faces, compared to 10-
repeat homozygotes.  *p ≤ .05. 
Angry faces
Happy faces
Figure 1. Median AAT-effect scores (ms) for approach and avoidance movements to happy and angry faces for the 
9-repeat carriers group and 10/10 homozygotes. DAT1 9-repeat carriers show increased avoidance tendencies to 
angry faces, but not happy faces, compared to 10-repeat homozygotes.  *p ≤ .05. 
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colleagues (2011) have shown that the motivation of healthy individuals to acquire a re-
ward equally influences both approaching of appetitive and avoiding of aversive stimuli. 
Note that the concept of avoidance used here does not imply a response that prevents 
exposure to the feared stimulus, but rather the tendency to withdraw as fast as possible 
when it appears, and relative to the tendency to approach the feared stimulus (e.g., Chen 
& Bargh, 1999; Rinck & Becker, 2007).
Interestingly, in our study the increased approach–avoidance effects of the DAT1 
9-repeat carriers, compared to the 10-repeat homozygotes, were particularly reflected 
in a significantly stronger approach vs. avoidance of happy faces, whereas the relative 
avoidance tendency for angry faces did not reach significance. This relatively strong ef-
fect for happy faces in the DAT1 9-repeat carriers is in line with findings relating striatal 
dopamine, thought to be specifically affected by DAT1 polymorphisms (Heinz et al., 2000; 
VanNess et al., 2005), particularly to the approach of appetitive stimuli (Boureau & Dayan, 
2011; Huys et al., 2011). However, it should be noted that the group difference was only 
significant when the approach–avoidance tendencies for happy faces were contrasted 
with the approach–avoidance tendencies for angry faces, suggesting a general increase 
in motivational behavior in 9-repeat carriers.
Our findings indicate that the responses of individuals carrying the 9-repeat polymor-
phism are affected by task irrelevant social-emotional features, whereas the responses of 
10-repeat homozygotes are not. It has been suggested that the 9-repeat allele is a vulner-
ability factor for psychopathologies such as PTSD (Segman et al., 2002). But alternatively, 
our findings might signal increased sensitivity to both positive and negative contextual 
conditions (Belsky et al., 2009). Belsky and Pluess (2009) argued that an individual with 
such increased sensitivity may not only be more vulnerable to the negative effect of an 
adverse environment, but may also be more susceptible to beneficial consequences of a 
positive context. For example, an aversive context may enhance social avoidance, which 
might explain (mixed) results from association studies of DAT1 with anxiety (Kennedy et 
al., 2001; Segman et al., 2002), and be in line with earlier findings of a relation between 
DAT alterations and the presence of social anxiety such as reduced density of DA uptake 
sites in the striatum of social phobic patients relative to healthy controls (Tiihonen et 
al., 1997), or low DAT binding in healthy participants, which was associated with the 
personality trait of detachment (Laakso et al., 2000; Schneier, Liebowitz, & Laruelle, 2001).
Although DAT1 polymorphisms are typically associated with deviations in striatal DA 
transmission and reward processing (Dreher et al., 2009; Sesack et al., 1998), we cannot 
rule out that our behavioral results may also have been affected by DA signaling in other 
relevant brain structures involved in social approach–avoidance behavior, such as the 
amygdala or frontal areas (Kienast et al., 2008; Volman, Roelofs, et al., 2011).
Our findings may also benefit the quest for clarifying issues concerning DAT expres-
sion by the DAT1 repeat polymorphism. Whereas imaging studies show mixed results for 
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the influence of the number of repeats in the DAT1 VNTR (see for a review Costa, Riedel, 
Müller, Möller, & Ettinger, 2011), several molecular genetic studies point to the possibility 
of an increase in DAT1 gene expression depending on the number of repeats (Fuke et al., 
2001; Michelhaugh, Fiskerstrand, Lovejoy, Bannon, & Quinn, 2001; Mill, Asherson, Browes, 
D’Souza, & Craig, 2002; VanNess et al., 2005; but see Greenwood & Kelsoe, 2003). These 
last findings support the idea of the 9-repeat allele accounting for decreased DAT1 avail-
ability when compared to the 10-repeat allele and are in line with our study, although 
much more research is necessary to elucidate the functional effects of the DAT1 repeat 
polymorphism and possible modulating factors (e.g., Shumay, Chen, Fowler, & Volkow, 
2011; Shumay, Fowler, & Volkow, 2010).
We acknowledge that complex human social behavior can never be attributed to 
one single genetic polymorphism, and that our results should therefore be considered 
preliminary, and for the benefit of generating hypotheses only. However, in our attempt 
to measure one single aspect of social behavior (e.g., behavioral approach–avoidance), 
we selected a sensitive, validated task that objectively measures subtle differences in 
implicit approach–avoidance tendencies (Heuer et al., 2007; Rinck & Becker, 2007; Roelofs 
et al., 2010; Wiers, Rinck, Dictus, & van den Wildenberg, 2009). The use of well-controlled 
sensitive paradigms such as fMRI or implicit RT tasks, has previously been shown to result 
in replicable results for serotonergic transporter gene polymorphisms associated with 
angry face processing, where earlier self-report studies failed to find relations (Bertolino 
et al., 2005; Hariri et al., 2002, 2005; Heinz et al., 2005; Pezawas et al., 2005; Smolka et al., 
2007). For these reasons, we believe that our findings may be relevant in the selection of 
candidate genes in future studies involving social motivational behavior, especially since 
previous studies using self-report measures of social anxiety and avoidance failed to find 
such correlations (e.g., Schneier et al., 2009; van der Wee et al., 2008).
In summary, this is the first attempt to relate striatal dopaminergic polymorphisms 
to an objective implicit measure of social approach–avoidance behavior. The findings 
demonstrate that DAT1 9-repeat carriers show increased approach–avoidance tenden-
cies to social-emotional cues and may help the selection of candidate genes in future 
studies concerning social behavior.
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Abstract
Testosterone is an important regulator of social-motivational behavior and is known 
for its dominance-enhancing and social-anxiolytic properties. However, to date no stud-
ies have systematically investigated the causal effect of testosterone on actual social 
approach-avoidance behavior in humans. The present study sets out to test the effects 
of testosterone administration in healthy female volunteers using an objective implicit 
measure of social motivational behavior: the social Approach- Avoidance Task, a reac-
tion time task requiring participants to approach or avoid visually presented emotional 
(happy, angry, and neutral) faces. Participants showed significantly diminished avoidance 
tendencies to angry faces after testosterone administration. Testosterone did not affect 
approach-avoidance tendencies to social affiliation (happy) faces. Thus, a single dose 
testosterone administration reduces automatic social threat avoidance tendencies in 
healthy females. These findings further the understanding of the neuroendocrine regula-
tion of social motivational behavior and may have direct treatment implications for social 
anxiety, characterized by persistent social avoidance.
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Introduction
The Hypothalamus-Pituitary-Gonadal (HPG) axis with its end product testosterone 
plays an important role in the regulation of social motivational behavior. Testosterone 
is associated with social dominance and approach behavior, and has socially anxiolytic 
effects (Eisenegger et al., 2011; Maner et al., 2008; Mazur & Booth, 1998; Mehta & Josephs, 
2010; Honk et al., 1999). According to the challenge hypothesis testosterone levels rise 
in preparation to a challenging encounter in which social status might be threatened, 
thereby initiating approach motivation and simultaneously reducing fear (Archer, 2006; 
Bos et al., 2012).
In the past decade, several studies of testosterone administration to healthy female 
participants confirmed the causal relationship between testosterone and its dominance-
enhancing and social-anxiolytic properties. Concerning the latter, testosterone admin-
istration has been shown to reduce fear-potentiated startle reflexes in highly anxious 
participants, attentional bias to fearful facial expressions, and conscious recognition 
of threat-related facial expressions (Hermans, Putman, Baas, Koppeschaar, & van Honk, 
2006; Hermans et al., 2007; van Honk & Schutter, 2007; van Honk, Peper, & Schutter, 2005). 
Enhancement of social dominance was indicated by increased heart rate acceleration, 
slower gaze aversion, and by an increase of activity in a social approach related brain 
circuit when viewing angry faces (Hermans, Ramsey, & van Honk, 2008; Terburg, Aarts, & 
van Honk, 2012; Honk et al., 2001).
Together, these findings indicate that testosterone administration reduces fear and 
sensitivity to threat, and enhances social dominance related behavior. However, so far 
evidence is constrained to processing of emotion and gaze behavior. No studies have 
systematically tested effects on actual social approach-avoidance actions. Elucidating the 
effects of testosterone on actual approach behavior would not only advance our theoreti-
cal understanding of steroid involvement in social emotional behavior, but it would also 
have great implications for the treatment of social avoidance related disorders associated 
with reduced testosterone levels such as social phobia and depression (Gerra et al., 2000; 
Giltay et al., 2012).
This study sets out to test whether testosterone administration diminishes threat 
avoidance and promotes threat approach, using an objective implicit measure of social 
motivational behavior: the Approach-Avoidance Task (AAT). The AAT is a valid and reliable 
measure of social approach-avoidance action tendencies (Heuer et al., 2007; Roelofs et 
al., 2010; Roelofs, van Peer, et al., 2009; Roelofs, Minelli, et al., 2009a; Volman, Roelofs, et 
al., 2011; Volman, Toni, et al., 2011). This reaction time (RT) task involves participants to 
approach and avoid socially aversive and appetitive visually presented stimuli (angry and 
happy faces, respectively) by pulling a joystick towards themselves (approach) or pushing 
the joystick away from themselves (avoidance). Angry faces with direct gaze constitute 
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a potent threat stimulus potentially signaling impending aggression, and elicit increased 
avoidance tendencies in high socially anxious individuals in particular (Adams, Gordon, 
Baird, Ambady, & Kleck, 2003; Öhman, 1986; Roelofs et al., 2010).
Based on the role of testosterone in social dominance and in enhancement of action 
motivation, we predict that administration of testosterone would reduce threat avoid-
ance and increase threat approach tendencies to angry faces on the AAT.
Methods
Participants
Twenty-four healthy females with a mean age of 29 years (SD = 8.4, range 20-50), 
served as participants for partial fulfillment of course credit or financial compensation. 
Only female participants were included, because there are as yet no known parameters 
(e.g., dose and time course) for inducing psychological effects in men after administration 
of a single dose of testosterone (Tuiten et al., 2000). The sample was recruited via adver-
tisement in the Leiden metropolitan area (The Netherlands). Exclusion criteria were age 
<18 and >50, use of medication, somatic illnesses, neurological conditions, recent or past 
psychiatric problems, history of head injury, left-handedness, peri- or postmenopause, 
and pregnancy or breast feeding. Fourteen women were using single-phase contracep-
tives, whereas ten women were normally cycling and evenly distributed over menstrual 
cycle phases.2 All participants had normal or corrected-to-normal vision, were unaware 
of the aim of the study and provided written informed consent. The study was approved 
by the Medical Ethics Committee of the Leiden University Medical Centre, and was in 
accordance with the declaration of Helsinki.
Testosterone administration
In a double-blind, randomized, placebo-controlled, crossover design participants 
received a single dose of 0.5 mg testosterone suspended in a clear solution (0.5 ml) with 
0.5 mg hydroxypropyl-beta-cyclodextrin, 0.005 ml ethanol 96%, and distilled water. The 
matched placebo contained the same ingredients, except the testosterone. Participants 
were asked to hold the liquid under their tongue for 60 s. During sublingual adminis-
tration of 0.5 mg testosterone cyclodextrin, testosterone is directly absorbed into the 
2 Of the fourteen women using contraceptives, nine were using single-phase estrogen/progestogen con-
traceptives, two were using a progestogen-only intra-uterine device, and three were using an estrogen/
cyproterone acetate contraceptive. Of the other ten – normally cycling – women, three were likely in the 
menstrual phase, two in the follicular phase, two in the ovulatory phase and three in the luteal phase 
during testing. Phase was defined by cycle day (Colzato, Hertsig, Van Den Wildenberg, & Hommel, 2010).
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bloodstream. In females, such a dose yields a sharp increase of 20-25 nmol/l in plasma 
testosterone levels within 15 min, which declines to baseline levels within the next 90 
min. Subsequently, pharmacodynamic effects are measurable approximately 4 to 6 h 
after testosterone intake (Tuiten et al., 2000).
Approach-Avoidance Task (AAT)
During this reaction time (RT) task, participants responded to emotional face pictures 
presented on a computer screen, by pulling a joystick either towards their body (approach 
movement) or pushing it away from their body (avoidance movement) (task adapted 
from Heuer et al., 2007). Pulling or pushing the joystick increased or decreased the size of 
the picture respectively, giving the impression of moving towards or moving away from 
the participant. The speed of the size change was proportional to the amplitude of the 
joystick movement. As soon as the joystick reached its target position (i.e., the required 
direction; full movement involved a 30° rotation from the upright position) the picture 
disappeared from the screen. The time between the onset of the stimulus and its disap-
pearance from the screen was recorded with <1 ms accuracy. After each completed trial 
the participant moved the joystick back to its central position and initiated a new trial by 
pressing the fire button near the top of the joystick. Face stimuli were selected from the 
Karolinska Directed Emotional Faces database based on quality of emotional expression 
(Goeleven, De Raedt, Leyman, & Verschuere, 2008; Lundqvist et al., 1998). Happy, Angry, 
and Neutral facial expressions were taken from the same model (five male and five female 
models in all) and each picture was presented either with a yellowish or a grayish filter. In 
addition, checkerboards (10 yellow, 10 gray) were included as non-facial control stimuli.3 
This resulted in a total of 80 different stimuli, which were presented in random order. All 
participants were instructed to push on yellow stimuli and to pull on gray stimuli, and to 
respond as fast and as accurately as possible. Usually, response latencies are shorter for 
affect-congruent (e.g., happy-approach; angry-avoid) as compared to affect incongruent 
response conditions (e.g., angry-approach; happy-avoid). Before the real test started, 
participants were presented with eighteen practice trials, which were similar to the test 
trials except for the fact that the pictures showed different models.
3 Checkerboard stimuli yielded significantly slower reaction times (p ≤ .009; RTs (ms ± SEM) for placebo 
condition: push 569 (22) and pull 542 (19); testosterone condition: push 548 (21) and pull 520 (16)). It is 
likely that this slowing is caused by an oddball effect as they were outnumbered by the facial stimuli (i.e., 
20 checkerboards to 60 emotional faces). Therefore the checkerboard stimuli have not been included in 
the main analyses.
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Social Phobia and Anxiety Inventory
Social Phobia and Anxiety Inventory (SPAI; Turner, Beidel, Dancu, & Stanley, 1989; vali-
dated Dutch version (Bögels & Reith, 1999) has good reliability (α = .99), and was used to 
assess the severity of social anxiety on a separate day prior to participation. It features 45 
items in total, of which 32 items assess social phobia, and 10 items measure agoraphobia. 
Following van Peer et al., (van Peer et al., 2009) only the social phobia score (α = .99; mean 
± SD: 49.6 (25.3)) was added to the statistical analysis of the RTs.
Procedure
Participants were tested individually at two identical testing sessions with two days 
in between. Testing sessions started at either 930h or 1330h, and participants were tested 
on the same time of day on both sessions. Four and a half hours after administration of 
testosterone or placebo participants performed the AAT in a dimly lit and sound attenuated 
room. There was no significant difference between the early and late testing sessions for the 
AAT-effect scores, F(1, 22) = 0.37, p = .549, nor SPAI-SP scores, t(22) = 0.67, p = .511, nor was 
there an influence of testing order, F(2, 42) = 0.82, p = .449. After completion of the two ses-
sions participants had to indicate in which session they thought to have had testosterone 
or placebo. Thirteen of the 24 participants were correct, which is at chance-level, Binomial 
P(X = 13) = 0.149, confirming that participants were unaware of the condition.
Statistical analyses
RT outliers were filtered using a <150 and a >1500 ms cut-off. A cut-off of three 
standard deviations from the mean was used for defining outliers in the remaining RTs. 
Error rates were calculated after removal of outliers. For each participant, the median 
of the remaining RTs (97%) for the correct responses was calculated per cell (defined 
by: Emotion and Movement). AAT effect scores were computed for each participant and 
for each emotion separately by subtracting median pull RTs from corresponding median 
push RTs (e.g., RT angry push – RT angry pull; RT happy push – RT happy pull; RT neutral 
push – RT neutral pull). As a result, more negative AAT-effect scores (push is faster than 
pull) reflect a relative avoidance tendency.
AAT effect scores were entered in a two-way repeated measures Analysis of Variance 
(rmANOVA) with Condition (testosterone; placebo) and Valence (angry; happy; neutral) 
as within-subject factors. Given the moderating role of social anxiety in social approach-
avoidance behavior (Radke, Roelofs, & de Bruijn, 2013; Karin Roelofs, van Peer, Berretty, 
de Jong, et al., 2009; van Peer et al., 2009), we controlled for the possibly confounding 
effects of social anxiety by adding the SPAI-scores as a continuous variable (ANCOVA) in 
the analyses. In addition we tested whether AAT-effect scores were significant in certain 
conditions (i.e., differed from zero) using one sample t-tests. Alpha was set at .05 and 
effect sizes are reported in eta squared (η2).
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Results
Due to technical problems data were missing for two participants. Table 3.1 provides 
an overview of the outcomes for RTs. The task was well performed, as indicated by low 
error rates (3.9%).
The two-way rmANOVA for the AAT-effect scores, with Condition (Placebo, Testos-
terone) and Valence (angry, happy, neutral) as within-subject factors, and SPAI-SP score 
as a continuous variable, revealed a significant Condition x Valence interaction, F(2, 44) 
= 3.69, p = .033, η2 = .05.4 To explore the nature of this interaction, we conducted one-
way rmANOVA’s with SPAI-SP as covariate for each valence separately, demonstrating a 
significant main effect for Condition for angry faces, F(1, 22) = 5.67, p = .026, η2 = .18, but 
not for happy, F(1, 22) = 0.78, p = .386, η2 = .03, and neutral faces, F(1, 22) = 1.14, p = .298, 
η2 = .05 (see Figure 1). Avoidance of angry faces was significant in the Placebo condition 
(AAT-effect score differed significantly from zero: t(23) = -2.22, p = .037), but not in the 
testosterone condition (see figure 3.1). Taken together, these results suggest a significant 
reduction of avoidance of angry faces by testosterone.
In order to check whether the effects of testosterone on AAT-effect scores were 
affected by individual differences related to physical characteristics of the joystick move-
ment (unrelated to stimulus valence) we added the AAT-effect scores for the control 
stimuli (checkerboards) as covariate and found that these had no influence (all ps > .127). 
Similar analyses checking for age (all ps > .130) showed that this variable did not affect the 
results. And finally, when we included use of contraceptives in the model, the main effect 
4 The same Condition × Valence rmANOVA for the AAT effect scores, without SPAI-SP scores added as a 
covariate, showed no significant Condition × Valence interaction [F(2,46)= 1.04, p = .363, η2= 0.02]. In 
addition, no significant Condition effects for angry, happy and neutral faces emerged without taking 
SPAI-SP in account (all ps > .224). These findings suggest that the reported Valence × Condition effect was 
modulated by social anxiety (Simmons, Nelson, & Simonsohn, 2011).
Table 3.1. Mean RTs (ms ± SEM) for approach (pull) and avoidance (push) responses to angry, happy, and neutral 
faces per condition.
 Placebo Testosterone 
Valence Push Pull Push Pull 
Angry 529 (15) 545 (17) 520 (15) 522 (18) 
Happy 524 (16) 534 (16) 517 (16) 530 (18) 
Neutral 524 (17) 531 (17) 517 (16) 531 (19) 
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of contraceptive use did not reach significance (p = .078), no interactions between con-
traceptive use and valence and/or condition emerged (all p > .529), and most importantly 
the Condition x Valence interaction remained unaffected, F(2, 42) = 3.52, p = .039, η2 = .05.
Discussion
The current study sets out to test whether a single administration of testosterone 
promotes threat approach relative to threat avoidance, using an objective implicit mea-
sure of social motivational behavior.
Participants showed significant avoidance of angry faces in the placebo condition 
and this effect shifted after testosterone administration, leading to a reduction of threat 
avoidance and an increase in relative threat approach tendencies. The finding of avoid-
ance of social threat in the placebo condition is in line with earlier findings on the AAT 
(e.g., Heuer et al., 2007a; Roelofs et al., 2010; von Borries et al., 2012). Testosterone admin-
istration significantly diminished avoidance tendencies to angry faces, but not to happy 
faces, a finding that concurs with a body of research on testosterone administration 
showing dominance-enhancing effects (e.g., Hermans et al., 2008; Terburg et al., 2012; van 
Honk et al., 2001). In addition, our results are in line with the challenge hypothesis, which 
states that endogenous testosterone levels rise in preparation to a socially challenging 
encounter, thereby initiating approach motivation and simultaneously reducing fear 
(Archer, 2006; Bos et al., 2012). The finding that significant avoidance of social threat faces 
in the placebo condition shifts to relative approach after administration of testosterone 
not only may be caused by fear reduction, but also could be the result of an increased 
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Figure 3.1. Mean AAT effect scores (ms) for approach and avoidance movements to angry and happy faces in the 
placebo and testosterone conditions. Participants show significant avoidance of angry faces in the placebo condi-
tion, but not in the testosterone condition. For display purposes, mean scores are baseline corrected (i.e., AAT effect 
scores for Neutral faces subtracted from the AAT effect scores of Angry and Happy faces respectively). *p ≤ .05.
Testosterone alleviates threat avoidance
39
aggressive tendency, although the two explanations are not mutually exclusive. This is 
the first study showing that testosterone directly influences behavioral approach actions 
that have an immediate effect on the relative distance of the social threat stimulus (Rinck 
& Becker, 2007). The current findings extend our knowledge by confirming the causal ef-
fect of testosterone on automatic social motivational action (Terburg & van Honk, 2013).
Previous work on the relation between endogenous testosterone and social approach 
action has shown that testosterone modulates prefrontal brain activity and prefrontal 
–amygdala connectivity when people had to control their automatic social approach-
avoidance tendencies. Higher endogenous testosterone levels were associated with 
reduced negative connectivity between the anterior prefrontal cortex and the amygdala 
(Volman, Toni, et al., 2011). Indeed performance on the AAT relies on prefrontal-amygdala 
crosstalk (Volman, Verhagen, et al., 2013; Volman, Roelofs, et al., 2011), but future inves-
tigations featuring testosterone administration should confirm whether the effect of 
testosterone indeed influences this neural mechanism. Testosterone administration has 
shown to enhance neural responsiveness of subcortical brain areas involved in social 
approach towards socially salient stimuli (Hermans et al., 2008; van Wingen et al., 2010). 
Together these findings suggest that testosterone induces automatic approach behavior, 
driven by subcortical brain areas (Bos et al., 2012).
The current findings may have implications for social psychopathologies such as 
social phobia or psychopathy. Concerning the latter, criminal offenders diagnosed with 
psychopathy, a condition associated with increased testosterone levels and reduced 
prefrontal inhibition, also showed reduced threat avoidance tendencies on the AAT (von 
Borries et al., 2012). As far as social avoidance related disorders are concerned, previous 
studies have indicated that social phobia and depression are associated with reduced 
testosterone (Gerra et al., 2000; Giltay et al., 2012; Haglund, Nestadt, Cooper, Southwick, 
& Charneya, 2007). Therefore, future research may explore whether testosterone admin-
istration reduces social fear and avoidance in social anxiety and may increase therapy 
efficacy (e.g., Hofmann, Fang, & Gutner, 2014).
A limitation of the present study was that only female participants were tested, which 
was due to the restrictions of the administration method used (Tuiten et al., 2000). Future 
research should investigate whether testosterone administration to men has similar 
effects as suggested by similarities in social behavior related to endogenous and exog-
enous testosterone across sexes (Hermans et al., 2007; van Honk et al., 2001; van Honk et 
al., 1999; van Honk & Schutter, 2007).
In sum, the current study shows that a single administration of testosterone directly 
diminishes automatic avoidance of social threat and promotes relative increase of threat 
approach tendencies. These findings may be particularly relevant for social psychopa-
thologies such as social anxiety disorder.

4
Salivary testosterone: Associations 
with depression, anxiety disorders, and 
antidepressant use in a large cohort 
study
Giltay, E. J., Enter, D., Zitman, F. G., Penninx, B. W. J. 
H., van Pelt, J., Spinhoven, P., & Roelofs, K. (2012). 
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Abstract
Low circulating levels of testosterone have been associated with major depression, 
but there is more limited evidence for differences in patients with anxiety disorders. The 
use of selective serotonin reuptake inhibitors (SSRIs) and other antidepressants is associ-
ated with sexual side effects, warranting testing for interactions with testosterone. Data 
are from 722 male and 1380 female participants of The Netherlands Study of Depression 
and Anxiety (NESDA), who were recruited from the community, general practice care, 
and specialized mental health care. Depressive and anxiety diagnoses were assessed 
using the DSM-IV Composite International Diagnostic Interview. To smooth the episodic 
secretion, the four morning saliva samples per participant and the two evening samples 
were pooled before testosterone analysis. Morning median testosterone levels were 25.2 
pg/ml in men and 16.2 pg/ml in women, with lower evening levels of 18.2 and 14.1 pg/
ml, respectively. Significant determinants of testosterone levels were sex, age, time of the 
day, use of contraceptives, and smoking status. Female patients with a current (1-month) 
depressive disorder (effect size 0.29; p = 0.002), generalized anxiety disorder (0.25; p = 
0.01), social phobia (0.30; p < 0.001), and agoraphobia without panic disorder (0.30; p = 
0.02) had lower salivary testosterone levels than female controls. Higher testosterone lev-
els were found in male and female participants using SSRIs than in non-users (effect size 
0.26; p < 0.001). Salivary testosterone levels are lower in female patients with a depressive 
disorder, generalized anxiety disorder, social phobia, and agoraphobia as compared to 
female controls. SSRIs may increase salivary testosterone in men and women.
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Introduction
There are important sex differences in prevalence proportions of psychiatric disor-
ders, with women having a more than double the risk of depressive disorder, generalized 
anxiety disorder, social phobia, and panic disorders with or without agoraphobia (Angst 
et al., 2002; Kessler, McGonagle, Swartz, Blazer, & Nelson, 1993; Kessler, Chiu, Demler, Meri-
kangas, & Walters, 2005; Kornstein, Sloan, & Thase, 2002; Marcus et al., 2005; van Noorden 
et al., 2010). Differences between the sexes have also been found for symptom profiles 
of depression, with an earlier age of onset, a higher symptom severity, more atypical 
depression, and a diminished libido in affected women compared to men (Angst et al., 
2002; Kornstein et al., 2002; Smith et al., 2008). Libido and other sexual functions may 
further worsen under the influence of antidepressant use (Gregorian et al., 2002; Serretti & 
Chiesa, 2009). Especially selective serotonin reuptake inhibitors (SSRI), generally preferred 
as the first-line pharmacotherapy treatments for mild to moderate outpatient depression 
and anxiety disorders, are associated with sexual problems such as diminished libido and 
difficulties with sexual arousal and orgasm in at least 30% of patients (Clayton, Keller, & 
McGarvey, 2006; Gregorian et al., 2002; Serretti & Chiesa, 2009).
Testosterone is an important circulating androgen. Its secretion is under the rapid 
pulsatile control of gonadotropin-releasing hormone (GnRH), which in turn stimulates 
the production of luteinizing hormone. Consequently, there are cyclic changes in serum 
testosterone levels (with a slight nocturnal rise), and therefore ideally at least several 
morning blood samples separated by 30-minute intervals are to be used to assess an-
drogenic status in a meaningful way (Brambilla et al., 1996). Salivary testosterone levels 
are strongly correlated with free serum testosterone levels in men (Arregger, Contreras, 
Tumilasci, Aquilano, & Cardoso, 2007; Cardoso et al., 2011), but less strongly in women, 
for whom there is less evidence (Granger, Shirtcliff, Booth, Kivlighan, & Schwartz, 2004; 
Wood, 2009).
Testosterone is involved in male secondary sexual characteristics, reproduction, and 
sexual function. The brain contains receptors for testosterone (Bao, Meynen, & Swaab, 
2008; Cooke, 2006; Sarkey, Azcoitia, Garcia-Segura, Garcia-Ovejero, & DonCarlos, 2008; 
Wang, Kamphuis, Huitinga, Zhou, & Swaab, 2008), and is capable of synthesizing and me-
tabolizing testosterone to, for instance, estradiol (Poletti & Martini, 1999; Puy et al., 1995; 
Stoffel-Wagner, 2003). In some studies, a low androgen status has been associated with 
symptoms of fatigue, irritability, dysphoria, declining vigor, low vitality, sexual dysfunc-
tion in men (Barrett-Connor, Von Mühlen, & Kritz-Silverstein, 1999; Rhoden & Morgentaler, 
2004; Seidman, 2003; Wang et al., 2009) and women (Bolour & Braunstein, 2005), and an 
increased risk of depressive symptoms and depression in most (Almeida, Yeap, Hankey, 
Jamrozik, & Flicker, 2008; Hintikka et al., 2009; Shores, Moceri, Sloan, Matsumoto, & Kiv-
lahan, 2005) but not all studies (Araujo, Durante, Feldman, Goldstein, & McKinlay, 1998; 
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Berglund, Prytz, Perski, & Svartberg, 2011). Findings were mixed, however, as several other 
epidemiological studies did not show or showed non-linear relationships between tes-
tosterone levels and depressive symptoms (Amiaz & Seidman, 2008). Inconsistencies may 
partly be due to the link or interaction with the genetic cytosine–adenosine–guanine 
(CAG) repeat length polymorphism. Longer CAG repeats may diminish the androgen 
receptor transactivation capacity and has been linked to the vulnerability to depression 
and anxiety (Härkönen et al., 2003; Seidman, Araujo, Roose, & McKinlay, 2001), though 
not consistently (Colangelo et al., 2007; Schneider et al., 2011; T’Sjoen et al., 2005). Evi-
dence on the role of testosterone in women is scarce, but there is some evidence that 
low DHEA(S) is involved in depression in women (Maninger, Wolkowitz, Reus, Epel, & 
Mellon, 2009; Schmidt et al., 2005). Androgen deprivation therapy in men with prostate 
cancer induces many of these symptoms, which are reversible after cessation of therapy 
(Cherrier, Aubin, & Higano, 2009; Shahinian, Kuo, Freeman, & Goodwin, 2006). However, 
androgen withdrawal induced adverse mood symptoms only in a subgroup of 10% (3 out 
of 31) of healthy male volunteers (Schmidt et al., 2004). Low testosterone levels have also 
been found in men with dysthymic disorder (Seidman et al., 2002). In a large community 
sample of almost 4000 elderly men, free testosterone concentration in the lowest quintile 
was associated with more depressive symptoms (Almeida et al., 2008). The evidence for 
a potential role of testosterone in anxiety disorders is much more limited. Low salivary 
testosterone levels were associated with depressive and anxiety symptoms in 106 adoles-
cent boys but not in 107 girls (Granger et al., 2003) and weakly with anxiety symptoms in 
3413 men (Berglund et al., 2011), but other studies found no relationship between social 
anxiety and basal salivary testosterone levels in 20 adolescents (Gerra et al., 2000) and 58 
students (Maner et al., 2008). Moreover, the urine testosterone level was comparable in 
16 patients with panic disorder versus 13 controls (Bandelow et al., 1997). Even so, tes-
tosterone has been associated with many behavioral aspects of dominance, competition, 
aggression, and sociality (Archer, 2006; Bos, Terburg, & van Honk, 2010; Gleason, Fuxjager, 
Oyegbile, & Marler, 2009; Hermans et al., 2008; Liening & Josephs, 2010; Sapolsky, 1991; 
van Honk et al., 1999; van Honk, Harmon-Jones, Morgan, & Schutter, 2010).
Data on serum testosterone level in anxiety disorders is scarce, whereas salivary 
testosterone levels have even less often been studied in small groups of patients with 
psychiatric disorders (Davies et al., 1992). Also, there are few studies on the effects of 
antidepressants on the hypothalamic–pituitary–gonadal (HPG) axis (Hendrick, Gitlin, 
Altshuler, & Korenman, 2000). We hypothesized that low salivary testosterone levels are 
associated with both depressive and anxiety disorders. Second, treatment of depressive 
and anxiety disorders with antidepressants decreases libido and this may be due to a 
reduction in testosterone levels. We measured salivary testosterone levels in the large 
Netherlands Study of Depression and Anxiety (NESDA). A number of 4 morning and 2 
evening salivary samples were pooled before testosterone was quantified in order to 
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minimize the effects of the pulsatile release of testosterone (Brambilla et al., 1996; Wood, 
2009). The use of a number of saliva samples had advantages over blood samples as they 
are more easily collected by participants themselves at several time points at their homes; 
it requires no pain- and stress-inducing venipunctures; and salivary testosterone reflects 
the free bio-available serum fraction.
Methods
Participants
Participants took part in NESDA (Penninx et al., 2008), a large longitudinal cohort 
study on the course of depressive and anxiety disorders. The NESDA sample consists of 
2981 participants (mean age 41.9 years, range 18–65; 1002 men and 1979 women), of 
whom 807 persons were recruited through mental health care organizations, 564 persons 
through the community setting and the remaining 1610 through primary care. Exclusion 
criteria were a primary diagnosis of psychotic, obsessive-compulsive, bipolar or severe 
addiction disorder and not being fluent in Dutch. The baseline assessment was consti-
tuted by a medical exam, a face-to-face interview, saliva collection and several written 
questionnaires. Detailed objectives and methods of NESDA are described elsewhere 
(Penninx et al., 2008). The research protocol was approved by the ethical committee of 
participating universities, and all of the respondents provided written informed consent.
There were 2329 participants with a lifetime diagnosis of depressive and/or anxiety 
disorder and 652 controls without a lifetime psychiatric diagnosis. Controls were defined 
as having no prior lifetime history of anxiety disorder (i.e., panic disorder, generalized 
anxiety disorder, or social phobia) or depressive disorder (i.e., major depressive disorder 
(MDD) or dysthymia).
Assessment of psychopathology and antidepressant use
Several instruments were used to assess psychopathology. The presence of a DSM-IV 
major depressive disorder or anxiety disorder (i.e., panic disorder, social phobia, general-
ized anxiety disorder, and agoraphobia) was assessed by the DSM-IV based Composite 
Interview Diagnostic Instrument (CIDI, WHO Version 2.1). The presence of psychiatric 
disorders within the past 12 months was used to categorize participants into those with 
no lifetime anxiety of depressive disorder (n = 522), those with a remitted (<1 year) 
disorder (n = 461), with a recent (1-year) or current anxiety disorder (n = 276), with a 
recent (1-year) or current depressive disorder (n = 412), and a recent or current comorbid 
disorder (n = 471). We also analyzed current psychiatric disorders within the preceding 
month for depressive disorder and anxiety disorders (i.e., social phobia, panic disorder 
and/or agoraphobia, and generalized anxiety disorder). The total score of the Inventory 
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of Depressive Symptomatology Self Report (IDS-SR) was used to assess overall depression 
severity (Rush, Gullion, Basco, Jarrett, & Trivedi, 1996), and subdivided into five severity 
groups, i.e., low (total score 0–13), mild (14–25), moderate (26–38), severe (39–48), and 
very severe (49–84). Item 22 (i.e., interest in sex) from the IDS-SR was analyzed separately 
as an internal validation of the salivary testosterone assessment, that was rated on a four-
point scale: 0 (i.e., usual interest), 1 (i.e., somewhat less interest or pleasure), 2 (i.e., little 
interest or pleasure), and 3 (i.e., no interest or pleasure). The total score of the Beck Anxiety 
Inventory was used to assess affective and somatic symptoms of anxiety (Beck, Epstein, 
Brown, & Steer, 1988), and subdivided into four severity groups, i.e., normal (total score 
0–9), mild (10–18), moderate (19–29), and severe (30–63) (Kabacoff, Segal, Hersen, & Van 
Hasselt, 1997). For 15-item Fear Questionnaire cut-off scores of 19 for the 5-item agora-
phobia AG subscale and 18 for 5-item social phobia (SO) subscale were used (Van Zuuren, 
1988).
Medication use during the month prior to baseline interview was registered by 
observation of drug containers brought to the interview or self-report. Using the World 
Health Organization Anatomical Therapeutic Chemical classification (WHO, 2009), psy-
choactive medication was categorized into antidepressants (i.e., tricyclic antidepressants 
[TCA; N06AA], SSRIs [N06AB], and other antidepressants [N06AF, N06AG, N06AX]), and 
benzodiazepine use (N03AE, N05BA, N05CD, N05CF) was dichotomized.
Salivary testosterone measurement
At baseline, respondents were instructed to collect saliva samples at home on a 
regular (preferably working) day shortly after the interview. The median time between 
the interview and saliva sampling was 9 days (25th–75th percentile, 4–22 days). In-
structions prohibited eating, smoking, drinking, or brushing teeth within 15min. Saliva 
samples were obtained using Salivettes (Sarstedt AG and Co., Nümbrecht, Germany) at 6 
time points: four morning samples (at awakening and at 30, 45, and 60 min later) and 2 
evening samples (at 22:00 h and 23:00 h). Indirect evidence suggests that compliance of 
participants to the protocol was good, as the cortisol awakening response showed the 
characteristic curve within the first hour of awakening in the large majority of participants, 
with a steep decline in both evening samples (Vreeburg et al., 2009). Samples were stored 
in refrigerators and returned by regular mail. After receipt, Salivettes were centrifuged at 
2000 g for 10min, aliquoted, and stored at −80 °C. Samples had been thawed once for the 
assessment of salivary cortisol, in which results have been published previously (Vreeburg 
et al., 2009). While storage at −80 °C of salivary samples does not affect testosterone levels 
during at least two years, the extra freeze thaw cycle may have contributed some error to 
testosterone measurement (Granger et al., 2004). Salivary testosterone levels have been 
shown to be relatively stable over time, with a test–retest stability of 0.65 in men and 0.78 
in women over two weeks (Liening, Stanton, Saini, & Schultheiss, 2010).
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To smooth the episodic secretion (Brambilla et al., 1996; Wood, 2009), 75 μl of each 
of the 4 samples collected in the morning (at wake-up and after 30, 45 and 60 min) were 
mixed to yield one morning sample, and 150 μl of each of the 2 evening samples col-
lected at 22:00 and 23:00 h were mixed to yield also one evening sample. So for every 
participant, one mixed morning sample and one mixed evening sample were assayed. 
If one of the samples was missing, a corresponding volume of the other sample(s) was 
taken. The 11 subjects who did not provide any evening sample were excluded. For every 
other subject who provided saliva, both a morning and evening sample could be com-
bined. Biochemical analysis of free testosterone in saliva was measured in duplo by the 
testosterone in saliva assay from Diagnostic Biochem Canada (EiAsy Testosterone Saliva, 
DBC: CAN-TE-300) using 2×100 μl material. The sensitivity of the kit is 1.0 pg/ml and there 
are hardly cross-reactivities with other steroids. In every assay a standard control was used, 
with a mean of 26.9 pg/ml (SD 2.1) that was reproducible with a coefficient of variation 
(CV) of 7.8%. The intra assay precision was 7.1, 3.4, and 6.7% at the concentrations of resp. 
14, 38 and 123 pg/ml (n = 10). In our study about 120 kits were used, all of the same lot. 
The CV over all testosterone measurements was 10.2%.
To validate the use of Salivettes for testosterone measurement, we also compared 
saliva obtained though Salivettes with those obtained through Salicaps (a passive drool-
ing device) in a repeated-measures design. We included 10 healthy volunteers (age 35 
[SD 12] year; 5 females). Saliva was collected at 6 time-points with alternating Salicaps 
(IBL International GMBH, Hamburg, Germany) (3 times) and Salivettes (Sarstedt, Newton, 
NC, USA) (3 times) with 10 min in between and always starting with a Salicap. Partici-
pants were instructed to minimize physical exercise and not to eat, drink or smoke, 1 h 
before the start and during the sampling period. Moreover, to avoid cross-contamination, 
participants were instructed to rinse the mouth with pure water immediately after each 
sample (always 10 min before the next sampling). All samples were frozen and after a 
single freeze–thaw cycle centrifuged for 10 min at 5000 g to remove mucins and to 
extract the saliva from the Salivettes. The three Salivette samples were also combined 
to one sample (mixed sample), and the same was done for the three Salicap samples. 
Testosterone was measured in duplo in every sample as well as the mixed samples using 
the method described above. There was a significant higher testosterone level in saliva 
obtained by Salivettes than by Salicaps (as was shown previously) (Granger et al., 2004), 
but this difference was highly constant. Pearson’s correlation coefficients between the 
individuals’ mean values obtained with Salivettes and Salicaps were r = 0.87 (p < 0.001) 
for the calculated mean and r = 0.87 (p < 0.001) for the measured value from the mixed 
samples. Using ranked-order Spearman’s correlation coefficients similar findings were 
obtained (r = 0.82 and r = 0.82, respectively).
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Potential covariates
Sociodemographic factors included sex, age, and educational level (years of attained 
education). Age was categorized by decade. Body mass index (BMI) was calculated as 
weight divided by length squared, and categorized into 4 groups (< 20 kg/m2/ 20 to 25 
kg/m2/ 25 to 30 kg/m2/ ≥ 30 kg/m2). Smoking status was dichotomized into nonsmoker 
or current smoker. Alcohol consumption was categorized into 3 groups (i.e., non-user/ a 
number of units of alcohol of less than 2 per day/ 2 or more per day). Physical activity was 
assessed using the International Physical Activity Questionnaire (Craig et al., 2003) and 
expressed per 1000 Metabolic Equivalent of Task (MET)/min a week, and subsequently 
categorized into 3 groups (i.e., < 3/ 3 to 6/ ≥ 6 of 1000MET/min per week). A MET/min 
is defined as the metabolic equivalent of the number of calories consumed by a person 
(of 60 kg) per minute in an activity relative to the basal metabolic rate (www. ipaq.ki.se), 
and ≥ 3 indicates activities of at least moderate intensity. Respondents reported work-
ing status on the sampling day (i.e., whether (61.8%) or not (38.2%) the participant went 
to their job that day). Sampling data was used to categorize weekday versus weekend 
day and season, which was categorized into dark months (i.e., October to February) and 
months with more daylight (i.e., March through September).
For subgroup analyses in women, information on the use of oral contraceptives and 
on menstrual phase was obtained. Duration of the menstrual cycle and the number of 
days since the last menstruation were used to yield the phase of the menstrual cycle at 
the time of saliva sampling for women reporting a menstrual cycle between 28 and 32 
days (i.e., 0–3 days of cycle was regarded as the early follicular phase, 4–13 days as the late 
follicular phase, and 14–32 days as the luteal phase). Remaining women were categorized 
as either using oral contraceptives or being post-menopausal.
Prevalent cardiovascular diseases (i.e., coronary disease, cardiac arrhythmia, angina 
pectoris, heart failure, and myocardial infarction) were ascertained using an algorithm 
based on self-report data and medication use.
Statistical analysis
The distributions of morning and evening salivary testosterone levels were strongly 
positively skewed and therefore naturally log transformed values were used for analyses. 
Back-transformed geometric mean values are presented in tables and figure. Pearson’s 
correlation coefficients were used to analyze the relationship between morning and 
evening salivary testosterone levels. Univariate analysis of variance was performed to 
evaluate the effects of sociodemographic factors, health indicators, and sampling factors 
on salivary testosterone levels, for morning and evening testosterone levels separately.
Because the morning and evening samples were highly inter-correlated, showing 
highly comparable associations with psychiatric characteristics, analyses reported in the 
paper were conducted over individual means of the z-scores of morning and evening 
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samples. The effects of psychiatric characteristics and psychotropic medication on 
testosterone levels were analyzed in unadjusted and adjusted analyses of (co)variance 
(adjusted for sex, age, menstrual status, years of education, smoking status, prevalent 
cardiovascular disease, and northern European ancestry), in men and women separately. 
When analyzing the associations with psychopathology measures, we also adjusted for 
SSRI use, because of its strong association with salivary testosterone levels.
Two-tailed p-values of less than 0.05 were considered to indicate statistical significance. 
For significant findings, effect sizes were calculated with Cohen’s d. All of the analyses were 
conducted using SPSS version 17.0 statistical software (SPSS Inc, Chicago, Illinois).
Results
Participants
The 722 men were on average 45.0 (range 18 to 64) years old and the 1380 women 
42.7 (range 18 to 65) (Table 4.1). The mean BMI was 26.2 kg/m2 for men and 25.3 for women, 
and around 17% of men and women were obese (i.e., BMI ≥30 kg/m2). Men were more 
often current smokers and consumed more often ≥2 units of alcohol per day than women. 
The prevalence of cardiovascular disease was approximately double in men versus women. 
There was a large range of salivary testosterone levels, that importantly overlapped in 
men and women. Nevertheless, men had higher median salivary testosterone levels than 
women both in the morning and evening samples (Table 4.1). Testosterone levels showed 
rank-order stability within each gender between morning and evening samples, with 
Spearman’s rank correlation coefficients of 0.62 in men and also 0.62 in women.
Determinants of salivary testosterone
The associations between age, menstrual status in women, health indicators (BMI, 
smoking, alcohol intake, and physical activity), and sampling factors (working status and 
season with more daylight) on salivary testosterone levels were analyzed as potential cor-
relates may be considered as covariates in epidemiological association studies. In men and 
women, age was strongly and inversely associated with both morning and evening salivary 
testosterone levels (all ps < 0.001). The lowest levels were found in men and women over 
age 50. Current smoking was associated with high salivary testosterone levels, especially for 
evening levels and more strongly so in women than in men. Although the menstrual status 
showed an association with salivary testosterone, this did not persist after adjustment for 
covariates (e.g., age, smoking status, and SSRI use; p = 0.20), but in post-hoc comparisons 
women using oral contraceptives (that increases SHBG which binds testosterone) had 
lower testosterone levels than premenopausal women not using oral contraceptives (p = 
0.03). No univariate associations were found with other potential determinants.
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Table 4.1. Characteristics in 2102 participants, according to gender.
Age — yr
Body–mass index — kg/m2
Mean
≥30 — no. (%)
Current smoker (no., %)
Alcohol consumption ≥2 units/d (no., %)
Physical activity — 1000 MET–min/wk (median, IQR)
Men (N = 722) Women (N = 1380)Variables
Prevalent cardiovascular disease (no., %)
Salivary testosterone level — pg/mL
Morning (geometric mean, 95% CI)
Table 1. Characteristics in 2102 participants, according to sex.
Plus–minus values are means ±SD, CI denotes confidence interval. 
P values are for the difference between the groups by analysis of variance or chi-squared test, when appropriate.
Northern European ancestry (no., %)
Education — yr
Evening (geometric mean, 95% CI)
692 (95.8%)
12.2 ± 3.3
272 (37.7%)
127 (17.6%)
26.2 ± 4.4
70 (9.8%)
2.83 (1.37–4.88)
181 (25.1%)
25.7 (24.5-27.1)
1313 (95.1%)
12.4 ± 3.3
426 (30.9%)
226 (16.4%)
25.3 ± 5.1
63 (4.6%)
3.08 (1.53–4.95)
166 (12.0%)
17.7 (17.0-18.5)
19.4 (18.4-20.5) 14.9 (14.1-15.6)
44.9 ± 12.6 42.8 ± 13.2
l s inus values are means ±SD, CI den tes confidence interval. P-values are for the difference between the 
groups by analysis of variance or chi-squared test, when appropriate
Salivary testosterone, psychopathology and antidepressant use
We combined the morning and evening testosterone levels using the mean of z-scores, 
because morning and evening levels were intercorrelated and associations with measures 
of psychopathology were highly consistent for morning and evening testosterones in both 
men and women (data not shown). Tables 4.2 and 4.3 show the associations with measures 
of psychopathology and medication use separately in men and women, respectively.
In adjusted models in men, there were no associations with measures of psychopa-
thology (Table 4.2). Those 106 men using SSRIs had higher testosterone levels than 558 
men not using antidepressants (effect size 0.207; p = 0.05). When repeating our analysis 
in men with recent (1 year) or current psychopathology the mean difference did not 
importantly change (92 versus 245 men; effect size 0.192).
In adjusted models in women, there was a group difference when taking into account 
the 12-month diagnostic status in adjusted analyses, indicating that women with any 
psychiatric disorder had on average a lower testosterone level. When zooming in on the 
1-month diagnostic categories, the female patients with a current depressive disorder (p 
= 0.002), current generalized anxiety disorder (p = 0.01), current social phobia (p < 0.001), 
current agoraphobia (without panic disorder; p = 0.02) had lower testosterone levels than 
the reference group of female participants having no lifetime history of depressive or 
anxiety disorder. The effect sizes were 0.287, 0.251, 0.299 and 0.304 for the depressive 
disorder, generalized anxiety disorder social phobia, and agoraphobia, respectively, indi-
cating modest strengths. Again, more markedly increased testosterone levels were found 
in 224 women using SSRI’s than 1052 non-users of antidepressants (effect size: 0.273; p 
< 0.001), but not in women using TCAs or other antidepressants. When repeating our 
analysis in women with recent (1 year) or current psychopathology the mean difference 
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Table 4.2. Forest plot for mean standard scores of salivary testosterone levels according to psychiatric characteristics in 
722 male subjects.Table 2. Forest plot for mean standard scores of salivary testosterone levels according to psychiatric characteristics in 722 male subjects.
Never
Remitted disorder
Anxiety disorder
Depressive disorder
Comorbid disorder
Unadjusted Adjusted*Variables
Tricyclic antidepressant
Selective serotonin reuptake inhibitor
Other antidepressant
No use
Present use
None
Mild
Moderate
Severe
Very severe
None
Mild
Moderate
Severe
No. Mean (SE) P Mean (SE) P
Usual interest
Somewhat less interest or pleasure
Little interest or plesaure
No interest or pleasure
No use
Never
Depressive disorder
Generalized anxiety disorder
Panic disorder with agoraphobia
Social phobia
Panic disorder without agoraphobia
Agoraphobia
No agoraphobia
Agoraphobia (≥19 on AG subscale)
No social phobia
Social phobia (≥18 on SO subscale)
200 −0.133 (SE 0.053) 0.03 −0.098 (SE 0.058) 0.14
132 −0.022 (SE 0.071) 0.013 (SE 0.068)
93 0.123 (SE 0.086) 0.104 (SE 0.082)
139 0.118 (SE 0.070) 0.095 (SE 0.067)
158 0.006 (SE 0.061) −0.038 (SE 0.065)
200 −0.133 (SE 0.053) −0.103 (SE 0.057)
98 0.043 (SE 0.087) 0.07 −0.030 (SE 0.087) 0.51
103 0.008 (SE 0.072) 0.12 −0.005 (SE 0.083) 0.25
135 −0.006 (SE 0.068) 0.14 −0.066 (SE 0.071) 0.76
71 0.095 (SE 0.085) 0.03 0.034 (SE 0.103) 0.24
40 0.098 (SE 0.123) 0.08 0.119 (SE 0.136) 0.09
37 −0.225 (SE 0.136) 0.50 −0.176 (SE 0.140) 0.86
426 −0.043 (SE 0.036) 0.20 −0.042 (SE 0.039) 0.18
210 0.097 (SE 0.060) 0.097 (SE 0.055)
56 −0.028 (SE 0.097) −0.040 (SE 0.106)
18 −0.080 (SE 0.247) −0.115 (SE 0.191)
558 −0.017 (SE 0.034) 0.04 −0.008 (SE 0.033) 0.04
12 −0.178 (SE 0.145) −0.193 (SE 0.225)
106 0.177 (SE 0.080) 0.156 (SE 0.077)
46 −0.171 (SE 0.101) −0.215 (SE 0.116)
624 −0.004 (SE 0.032) 0.79 −0.002 (SE 0.032) 0.97
98 0.019 (SE 0.077) 0.002 (SE 0.081)
282 −0.016 (SE 0.047) 0.21 0.013 (SE 0.048) 0.44
187 −0.069 (SE 0.060) −0.067 (SE 0.058)
161 0.124 (SE 0.063) 0.084 (SE 0.063)
65 −0.058 (SE 0.091) −0.075 (SE 0.098)
23 0.049 (SE 0.173) −0.022 (SE 0.175)
400 −0.030 (SE 0.039) 0.42 −0.014 (SE 0.040) 0.50
161 −0.023 (SE 0.067) −0.044 (SE 0.063)
116 0.107 (SE 0.075) 0.095 (SE 0.074)
41 0.025 (SE 0.118) −0.034 (SE 0.127)
652 −0.017 (SE 0.031) 0.13 −0.017 (SE 0.031) 0.18
66 0.137 (SE 0.106) 0.123 (SE 0.099)
555 −0.032 (SE 0.033) 0.06 −0.022 (SE 0.033) 0.27
158 0.100 (SE 0.066) 0.058 (SE 0.064)
The size of each square is proportional to the number of participants; horizontal lines indicate standard errors.
Standard scores were calculated as the mean of z−scores of the morning and evening testosterone levels, within each sex.
*: Adjusted for age, years of education, smoking status, prevalent cardiovascular disease, and northern European ancestry (as well as SSRI use [2 
categories] when appropriate).
**: Sexual interest was assessed with item 22 of the Inventory of Depressive Symptomatology Self Report (IDS–SR).
P values are for the difference between the groups by analysis of variance.
6–month diagnosis of psychopathology
-0.4 -0.2 0.0 0.2 0.4 -0.4 -0.2 0.0 0.2 0.4
Sexual interest**
Benzodiazepine use
Inventory of depressive symptomatology
Beck’s Anxiety Inventory
Antidepressant use
Fear Questionnaire
1–month diagnosis versus never–diagnosis of psychopathology
The i e of each squa e is prop rtio al to the number of p rticipants; horizontal lines indicate standard errors. 
Standard scores were calculated as the mean of z−scores of the morning and evening testosterone levels, within 
each sex.
*: Adjusted for age, years of education, smoking status, prevalent cardiovascular disease, and northern European 
ancestry (as well as SSRI use [2 categories] when appropriate).
**: Sexual interest was assessed with item 22 of the Inventory of Depressive Symptomatology Self Report (IDS–SR). 
p-values are for the difference between the groups by analysis of variance.
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Table 4.3. Forest plot for mean standard scores of salivary testosterone levels according to psychiatric characteristics in 
1380 female subjects.Table 3. Forest plot for mean standard scores of salivary testosterone levels according to psychiatric characteristics in 1380 female subjects.
Never
Remitted disorder
Anxiety disorder
Depressive disorder
Comorbid disorder
Unadjusted Adjusted*Variables
Tricyclic antidepressant
Selective serotonin reuptake inhibitor
Other antidepressant
No use
Present use
None
Mild
Moderate
Severe
Very severe
None
Mild
Moderate
Severe
No. Mean (SE) P Mean (SE) P
Usual interest
Somewhat less interest or pleasure
Little interest or plesaure
No interest or pleasure
No use
Never
Depressive disorder
Generalized anxiety disorder
Panic disorder with agoraphobia
Social phobia
Panic disorder without agoraphobia
Agoraphobia
No agoraphobia
Agoraphobia (≥19 on AG subscale)
No social phobia
Social phobia (≥18 on SO subscale)
307 0.084 (SE 0.051) 0.23 0.175 (SE 0.054) 0.009
320 −0.086 (SE 0.045) −0.015 (SE 0.052)
177 −0.027 (SE 0.079) −0.082 (SE 0.070)
267 −0.016 (SE 0.063) −0.041 (SE 0.056)
309 0.035 (SE 0.057) −0.068 (SE 0.054)
307 0.084 (SE 0.051) 0.139 (SE 0.053)
181 −0.056 (SE 0.073) 0.11 −0.151 (SE 0.072) 0.002
145 −0.038 (SE 0.081) 0.19 −0.131 (SE 0.082) 0.01
252 −0.091 (SE 0.061) 0.03 −0.161 (SE 0.061) < 0.001
156 0.177 (SE 0.084) 0.32 0.013 (SE 0.083) 0.15
51 0.032 (SE 0.119) 0.69 0.003 (SE 0.130) 0.55
73 −0.221 (SE 0.135) 0.01 −0.220 (SE 0.116) 0.02
690 0.025 (SE 0.035) 0.09 0.030 (SE 0.036) 0.06
298 0.070 (SE 0.058) 0.072 (SE 0.053)
251 −0.117 (SE 0.061) −0.100 (SE 0.059)
111 −0.072 (SE 0.089) −0.131 (SE 0.089)
1052 −0.044 (SE 0.029) 0.001 −0.040 (SE 0.028) 0.002
36 −0.008 (SE 0.174) 0.061 (SE 0.154)
224 0.242 (SE 0.063) 0.215 (SE 0.062)
68 −0.098 (SE 0.097) −0.116 (SE 0.112)
1176 0.009 (SE 0.028) 0.40 0.013 (SE 0.027) 0.29
204 −0.051 (SE 0.065) −0.063 (SE 0.066)
475 0.025 (SE 0.041) 0.50 0.094 (SE 0.043) 0.03
423 0.013 (SE 0.049) 0.017 (SE 0.045)
326 −0.064 (SE 0.053) −0.121 (SE 0.051)
112 −0.018 (SE 0.098) −0.083 (SE 0.089)
39 0.181 (SE 0.142) 0.021 (SE 0.149)
689 0.041 (SE 0.037) 0.10 0.101 (SE 0.036) 0.001
394 −0.100 (SE 0.046) −0.121 (SE 0.046)
218 0.031 (SE 0.065) −0.034 (SE 0.063)
76 0.067 (SE 0.107) −0.142 (SE 0.109)
1216 0.002 (SE 0.027) 0.90 0.022 (SE 0.026) 0.04
161 −0.008 (SE 0.076) −0.145 (SE 0.075)
1016 0.049 (SE 0.030) 0.002 0.074 (SE 0.029) < 0.001
359 −0.134 (SE 0.048) −0.200 (SE 0.049)
The size of each square is proportional to the number of participants; horizontal lines indicate standard errors.
Standard scores were calculated as the mean of z−scores of the morning and evening testosterone levels, within each sex.
*: Adjusted for age, years of education, smoking status, prevalent cardiovascular disease, and northern European ancestry (as well as SSRI use [2 
categories] when appropriate).
**: Sexual interest was assessed with item 22 of the Inventory of Depressive Symptomatology Self Report (IDS–SR).
P values are for the difference between the groups by analysis of variance.
-0.4 -0.2 0.0 0.2 0.4 -0.4 -0.2 0.0 0.2 0.4
6–month diagnosis of psychopathology
Sexual interest**
Benzodiazepine use
Inventory of depressive symptomatology
Beck’s Anxiety Inventory
Antidepressant use
Fear Questionnaire
1–month diagnosis versus never–diagnosis of psychopathology
The  of each square is pr portional to the number of participants; horizontal lines indicate standard errors.
Standard scores were calculated as the mean of z−scores of the morning and evening testosterone levels, within 
each sex.
*: Adjusted for age, years of education, smoking status, prevalent cardiovascular disease, and northern European 
ancestry (as well as SSRI use [2 categories] when appropriate).
**: Sexual interest was assessed with item 22 of the Inventory of Depressive Symptomatology Self Report (IDS–SR).
P-values are for the difference between the groups by analysis of variance.
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did increase slightly (184 versus 475 women; effect size 0.335). In women, the severity of 
anxiety symptoms (p = 0.001), agoraphobia (effect size 0.175; p = 0.04), and social phobia 
(effect size 0.294; p = 0.001) was related to lower testosterone levels. There was a linear 
trend for decreasing testosterone levels with increased social phobia scores (Figure 4.1). 
The comparison between the groups with severe anxiety versus no anxiety yielded an 
effect size of 0.254. Although, there was also a difference between categories of severity 
of depressive symptoms (p = 0.03), this was not a linear association.
Because associations between SSRI use and salivary testosterone levels were compa-
rable in men and women (combined effect size 0.258), we further explored the effects of 
antidepressants in all subjects combined. In adjusted analyses, SSRI users but not users of 
TCAs or other antidepressants showed higher salivary testosterone levels than non-users of 
antidepressants (Figure 4.1). In post-hoc tests, we found that differences were statistically 
significant for fluvoxamine and paroxetine, although differences for sertraline, fluoxetine 
and citalopram showed a similar tendency that did not reach significance. The mean tes-
tosterone difference between SSRI users and non-users of antidepressants was of similar 
strength in subjects with remitted disorders and current disorders (0.234 versus 0.268, 
respectively).
Figure 2. 
The mean standard scores (with error bars representing standard errors) for morning and evening salivary testosterone levels. according (Box A) the kind of antidepressant used in 
men and women combined, and (Box B) social phobia (SO) subscale score (part of the Fear Questionnaire) in women only. The black reference line shows the mean score in non-
users of antidepressants. The size of each square is proportional to the number of participants. Verticle lines indicate standard errors. Scores are adjusted for sex, age, menstrual 
status, years of education, smoking status, prevalent cardiovascular disease, and northern European ancestry. In Box B, testosterone values were additionally adjusted for SSRI use. P 
values are (Box A) by analysis of covariance (with * P < 0.01 for the difference with non-users of antidepressants), or (Box B) for linear trend in analysis of covariance.
-0.6
-0.4
-0.2
0.0
0.2
0.4
0.6
TC
A
(n=
48)
Ot
her
 an
tid
epr
ess
ant
(n=
106
)
Esc
ital
op
ram
(n=
8) Se
rtr
alin
e
(n=
30)
Flu
vox
am
ine
(n=
35) Flu
ox
etin
e
(n=
46) Cit
alo
pra
m
(n=
77) Par
ox
etin
e
(n=
146
)
Me
an
 sa
liv
ary
 te
sto
ste
ro
ne
 le
ve
l 
(st
and
ard
 sc
ore
)
Overall P = 0.001 -0.6
-0.4
-0.2
0.0
0.2
Me
an
 sa
liv
ary
 te
sto
ste
ro
ne
 le
ve
l 
(st
and
ard
 sc
ore
)
Social phobia (SO) score
P < 0.001
for linear trend 
in women
≤5 6−10 11−15 16−20 11−25 26−30 31−35 ≥36
A B
*
*
Figure 4.1. The mean standard scores (with error bars representing standard errors) for morning and evening 
salivary esto terone levels, according (Box A) the kind of a tidepressant us d in men and women combi ed, a d 
(Box B) social phob a (SO) bscale score (part of the Fe r Question air ) i  women nly. The black refer nce line 
shows the mea  c re in nonusers of anti epressants. The size of each square is proportional to the number of 
participants. Vertical lines indicate standard errors. Scores are adjusted for sex, age, menstrual status, years of edu-
cation, smoking status, prevalent cardiovascular disease, and northern European ancestry. In Box B, testosterone 
values were additionally adjusted for SSRI use. P values are (Box A) by analysis of covariance (with * P < 0.01 for the 
difference with non-users of antidepressants), or (Box B) for linear trend in analysis of covariance.
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Discussion
We found that depressive disorder, generalized anxiety disorder, social phobia, and 
agoraphobia were associated with lower salivary testosterone levels in women, but not in 
men. Remarkably, SSRI use was associated with elevated testosterone levels in both men 
and women. While morning testosterone levels were higher than evening testosterone 
levels, we found that within-person correlation indicated rank-order stability over the day. 
Our study therefore provides support for the usefulness, validity and reliability of the non-
invasive method of testosterone measurement in saliva. It also points to the importance 
of taking confounding variables into account, especially of sex, age, menstrual cycle, time 
of the day, and smoking status. The associations between smoking and physical activity 
with higher testosterone levels (Shiels et al., 2009) and between oral contraceptive use 
and lower testosterone levels (Edwards & O’Neal, 2009; Liening et al., 2010) are in line with 
previous findings.
Testosterone levels were lower in female patients with current depression versus 
female controls. Previous studies in women are relatively scarce (Bolour & Braunstein, 
2005), in part because blood levels of free testosterone in women were rather unreliable 
(Bachmann et al., 2002), until recently. Previous studies in men (Almeida et al., 2008; Bar-
rett-Connor et al., 1999; Hintikka et al., 2009; Rhoden & Morgentaler, 2004; Seidman, 2003; 
Shores et al., 2005; Wang et al., 2009) found lower testosterone levels in men with depres-
sive symptoms compared to male controls, which we could not confirm. Some previous 
epidemiological studies found no relationship between low testosterone and depressive 
symptoms (Araujo et al., 1998; Berglund et al., 2011). However, androgen activity is not 
only the effect of bioavailable androgens but also the responsiveness of the androgen 
receptor in target cells. The androgen receptor gene (located on the X chromosome) 
contains a polymorphic CAG repeat sequence affecting androgen sensitivity. Previous 
studies yielded inconsistent results; CAG repeat length and depressive symptoms were 
positively associated (Härkönen et al., 2003), unrelated (T’Sjoen et al., 2005), or associated 
only in subgroups of black men (Colangelo et al., 2007) or patient groups (Schneider 
et al., 2011). In another study, low testosterone levels were associated with depressive 
symptoms in men with short CAG repeat lengths only (Seidman et al., 2001). As we did 
not take into account the CAG repeat length polymorphism, this may explain our null-
finding in depressed men. Trials with testosterone administration showed inconsistent 
evidence for antidepressant properties, more so in hypogonadal than in eugonadal men 
(Amiaz & Seidman, 2008). These studies were done in participants who did (Harrison G. 
Pope et al., 2010; Harrison G. Pope, Cohane, Kanayama, Siegel, & Hudson, 2003; Zarrouf, 
Artz, Griffith, Sirbu, & Kommor, 2009) or did not (Giltay et al., 2010) suffer from a depres-
sive disorder. In supraphysiologic dosages, testosterone may induce euphoria and other 
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symptoms of hypomania (Pope, Kouri, & Hudson, 2000; Yates, Perry, MacIndoe, Holman, 
& Ellingrod, 1999).
Yet, we included twice as many women than men in our study. Our findings of low 
testosterone levels in social anxiety disorder, generalized anxiety disorder, and agorapho-
bia are not in line with the previous smaller studies that found no relationship between 
social anxiety and basal salivary testosterone levels (Gerra et al., 2000; Maner et al., 2008). 
Yet, among the psychiatric disorders under study, particularly those that were character-
ized by social withdrawal (i.e., depression, social anxiety and agoraphobia) and high social 
anxiety scores were associated with low testosterone levels in women. No association 
with panic disorder was found. These findings fit previous notions that reduced testos-
terone was particularly evident for those primates and humans who behaved socially 
submissive and showed increased levels of social fear behavior, such as social withdrawal 
(Archer, 2006; Bos et al., 2010; Gleason et al., 2009; Liening & Josephs, 2010; Sapolsky, 
1991; van Honk et al., 1999, 2010). This could suggest that low testosterone is rather a 
consequence than a cause of the affective symptoms.
Nevertheless, there are putative biological mechanisms that point to a causal role 
of low testosterone. First, affective symptoms are importantly mediated by the ‘fear 
network’ involving the amygdala, hippocampus, and prefrontal cortex, while exogenous 
and endogenous testosterones significantly modulated local activity and interregional 
connectivity in the prefrontal cortex and the amygdala during social affective behavior 
(Hermans et al., 2008a; Volman, Toni, et al., 2011). Neurons in the amygdala (Cooke, 2006; 
Sarkey et al., 2008), hippocampus (Bao et al., 2008; Wang et al., 2008) and neocortex 
(Sarkey et al., 2008) indeed specifically express androgen receptors. Second, there may 
be an imbalance between testosterone and cortisol (van Honk et al., 2010; Viau, 2002). 
Androgens may downregulate the hypothalamo–pituitary–adrenal (HPA) axis in a direct 
way via androgen receptors which are expressed in corticotropin-releasing factor (CRF) 
producing neurons in the hypothalamus and which suppressed the promoter region of 
the CRF gene (Bao et al., 2008; Wang et al., 2008). Elevated plasma cortisol levels and 
hyperactivity of CRF neurons in the paraventricular nucleus (PVN) of the hypothalamus 
are consistent neurobiological findings in depressive and anxiety disorders (Belmaker & 
Agam, 2008; Vreeburg et al., 2009, 2010; Wang et al., 2008), and the expression of andro-
gen receptors is low in post-mortem brain tissue from patients with depression (Wang 
et al., 2008). Therefore, our findings fit with the idea that low bioavailable testosterone 
increases the risk to several psychiatric disorders, that social anxiety and submission 
induces a lowering of androgens, or both.
The use of SSRIs is associated with sexual problems, such as lowered libido and dif-
ficulties with sexual arousal or orgasm (Clayton et al., 2006; Gregorian et al., 2002; Serretti 
& Chiesa, 2009). These side effects normally continue for as long as the individual is taking 
the medication and may partly be explained by increased prolactin levels in some cases 
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(Madhusoodanan, Parida, & Jimenez, 2010), that subsequently may also induce gyneco-
mastia and galactorrhoea. As androgens are pivotal for sexual function, we were inter-
ested in the relationship between antidepressant use and testosterone. Remarkably, we 
found that SSRI users had higher salivary testosterone levels versus participants who did 
not use antidepressants, which is hard to reconcile with their sexual side effects, although 
SSRIs may have induced androgen antagonism or the higher testosterone levels may be 
associated with treatment-induced increases in prosocial behavior. The mechanisms of 
these side effects are likely complex, involving not only endocrine (e.g., prolactin and sex 
hormonal) but also directly effects on the central and peripheral nervous systems involved 
in sexual function. Besides systemic effect on the circulating free testosterone level, SSRIs 
(and current smoking) may have had a local effect on salivary glands, as antidepressants 
reduce the salivary flow through muscarinic acetylcholine receptor occupancy, induc-
ing the common complaint of a dry mouth. But effects such as a dry mouth are more 
commonly observed during TCA use, which in our study was not associated with higher 
testosterone levels (Scully, 2003).
Our study had some limitations. First, Salivettes were used for the assessment of 
salivary testosterone, where a passive drooling device would have been preferable. 
Since we observed a systematic elevation, all Salivette samples need to be collected and 
handled in the same way in order to yield reliable statistical results as done in the present 
study. As the difference in results was non-random (i.e., higher levels of testosterone using 
Salivettes as compared to passive drool saliva samples but with a strong correlation), the 
internal validity of this study was high. Second, our analyses were cross-sectional and 
therefore cannot indicate the causal direction. Third, we needed to rely on saliva sampling 
at the homes of the participants, but as we pooled either four or two saliva samples, 
compliance and timing with the sampling instructions seemed less of an issue. Fourth, 
most participants had “(either remitted or current)” anxiety or depressive disorders, and 
therefore the control group without any lifetime psychiatric diagnosis was relatively small. 
Nevertheless, noncompliance with instructions could have resulted in some measure-
ment error. The CV of testosterone was around 10%, which error may have biased our 
findings somewhat toward the null hypothesis. All saliva samples were visually inspected 
for potential discoloration but not tested biochemically for potential blood contamina-
tion (Granger et al., 2004). The strengths of our study included the large sample size, the 
‘gold standard’ use of multiple samples that were combined (Brambilla et al., 1996), and 
the inclusion of patients with several anxiety disorders. We also confirmed findings of low 
testosterone levels found in participants who were female, using oral contraceptives, and 
were older, and high testosterone levels found in participants who smoke, which support 
the validity of salivary testosterone as a measure of androgenic activity.
We conclude that saliva samples are useful for non-invasive screening purposes. 
Salivary testosterone levels were significantly lower in female patients with depression, 
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generalized anxiety disorder, social anxiety disorder, and agoraphobia. These findings 
stress the role of testosterone in social affective symptomatology in women. Future stud-
ies should explore whether testosterone treatment or augmentation is beneficial and safe 
not only in male but also in female patients with low androgenic status.

5
Dare to approach: Single dose 
testosterone administration promotes 
threat approach in patients with Social 
Anxiety Disorder
Enter, D., Spinhoven, P., & Roelofs, K. (2016). Clinical 
Psychological Science, 4(6), 1073–1079.
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Abstract
Persistent fear and avoidance in patients with Social Anxiety Disorder (SAD) has been 
associated with reduced testosterone levels. Because threat avoidance is a major main-
taining factor in SAD, and because testosterone administration promotes social approach, 
we tested whether testosterone administration can directly facilitate threat approach 
behavior in SAD. In a double-blind, placebo-controlled study, 17 female participants with 
SAD received a single dose of testosterone before performing a well-established social 
Approach–Avoidance Task. This objective implicit measure of social motivational action-
tendencies requires participants to approach or avoid visually presented emotional faces. 
After testosterone administration, the patients showed increased approach-tendencies to 
angry facial expressions. These results suggest that testosterone can counteract persistent 
automatic social avoidance-tendencies in SAD. This finding advances our understanding 
of steroid involvement in the regulation of social motivational action in general and in 
SAD in particular, and may have important clinical implications, promoting testosterone’s 
candidacy for pharmacological treatment-enhancement studies.
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Introduction
Social Anxiety Disorder (SAD) is the most common anxiety disorder, characterized by 
an intense fear of social situations in which the individual may be scrutinized by others 
(American Psychiatric Association, 2013). Avoidance behavior is one of the core charac-
teristics of SAD and plays a crucial role in its persistence as it hinders extinction of fear in 
social situations (Clark & Wells, 1995). Previous work showed that women with SAD have 
reduced endogenous testosterone levels, which were also related to the severity of social 
phobia symptoms (Giltay et al., 2012). Despite mounting evidence for the social approach 
facilitating properties of testosterone administration (Enter, Spinhoven, & Roelofs, 2014; 
Terburg et al., 2012), to date no studies have tested whether testosterone administration 
can alleviate actual social avoidance behavior in SAD.
Testosterone is important in the regulation of social motivational behavior, and 
enhances social approach motivation while reducing social fear in a socially challenging 
environment (Archer, 2006; Bos et al., 2012; Radke et al., 2015; Terburg & van Honk, 2013). 
Also in socially anxious individuals it can increase fixations to the eyes of emotional faces 
(Enter, Terburg, Harrewijn, Spinhoven, & Roelofs, 2016). Recently, we have shown that 
testosterone promotes actual social approach behavior in healthy women (Enter et al., 
2014). After a single dose testosterone administration the participants showed reduced 
automatic avoidance of social threat (i.e., angry facial expressions) and relative increased 
threat approach- tendencies. Such effects would be of particular interest for SAD, as social 
avoidance is a major characteristic and an important factor in the persistence of the dis-
order. Therefore, testing whether testosterone can alleviate social avoidance-tendencies 
in SAD would be of theoretical and clinical importance.
We set out to test whether testosterone administration promotes threat approach in 
SAD by using a well-established objective and implicit measure of social motivational be-
havior: the Approach-Avoidance Task (AAT; Heuer et al., 2007; Roelofs et al., 2010; Roelofs, 
Minelli, et al., 2009; Roelofs, van Peer, 2009; Volman, Roelofs, et al., 2011; Volman, Toni, 
et al., 2011). This reaction time task requires participants to approach and avoid socially 
aversive and appetitive visually presented stimuli (angry and happy faces, respectively) 
by pulling a joystick towards themselves (approach) or pushing the joystick away from 
themselves (avoidance). Angry faces with direct gaze constitute a potent threat stimulus, 
that elicit avoidance responses, particularly in socially anxious individuals (Adams et al., 
2003; Öhman, 1986; Roelofs et al., 2010).
Based on the approach-enhancing and social-anxiolytic role of testosterone in social 
motivational behavior, we predict that administration of testosterone to SAD participants 
would reduce threat avoidance and increase threat approach-tendencies to angry faces 
on the AAT.
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Methods
Participants
Participants with SAD were recruited from outpatient anxiety departments of mental 
health centers, through advertisements on the internet, and in local newspapers. Inclusion 
criterion was a total score of >60 on the Liebowitz Social Anxiety Scale (LSAS; Liebowitz, 
1987), representing the cut-off score for the presence of social anxiety disorder (Rytwinski 
et al., 2009).5 In addition, participants were screened with the Mini International Neuro-
psychiatric Interview script (M.I.N.I.; Lecubier et al., 1997) to determine the presence of a 
DSM-IV diagnosis of generalized SAD. Only female participants were included, because 
there are as yet no known parameters (e.g., dose and time course) for inducing neurophysi-
ological effects in men after administration of a single dose of testosterone cyclodextrin 
(Tuiten et al., 2000). Both women using single-phase contraceptives and normally cycling 
women participated in the study (Hermans et al., 2010). Exclusion criteria were age < 18 
and > 50, use of (psychotropic) medication, somatic illnesses, neurological conditions, 
psychotic disorder, current comorbid diagnosis of mood or anxiety disorders other than 
SAD, history of head injury, left-handedness, peri- or postmenopause, and pregnancy or 
breast feeding. After initial screening of 24 socially anxious participants, 17 participants 
fulfilled all DSM-IV criteria for generalized SAD at the time of testing and were selected 
for this study. This group had a mean age of 22.8 years (SD = 5.0), and a LSAS total score 
of 78.6 (SD = 14.3), see Table S5.1 for additional participant characteristics. All participants 
had completed or were following higher education, had normal or corrected-to-normal 
vision, were unaware of the aim of the study, provided written informed consent, and 
received a financial compensation of €80 and a travel allowance. Data on ethnicity were 
not recorded. The study was approved by the Medical Ethics Committee of the Leiden 
University Medical Centre, and was in accordance with the declaration of Helsinki.
Testosterone administration
In a double-blind, randomized, placebo-controlled, crossover design participants 
received a single dose of 0.5 mg testosterone suspended in a clear solution (0.5 ml) with 
0.5 mg hydroxypropyl-beta-cyclodextrin, 0.005 ml ethanol 96%, and distilled water. The 
matched placebo contained the same ingredients, except testosterone. Participants were 
asked to hold the liquid under their tongue for 60 seconds. During sublingual administra-
tion of 0.5 mg testosterone with cyclodextrin as carrier, testosterone is directly absorbed 
into the bloodstream. In females, such a dose yields a sharp increase of 20-25 nmol/l in 
plasma testosterone levels within 15 minutes, which declines to baseline levels within 
5 N.B. One participant scored 56 on the LSAS but was included because she met the DSM-IV diagnostic 
criteria.
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the next 90 minutes (van Rooij et al., 2012). Pharmacodynamic effects are measurable ap-
proximately four to six hours after testosterone intake (Bos et al., 2012; Tuiten et al., 2000).
Approach-Avoidance Task (AAT)
During this reaction time (RT) task participants responded to happy, angry, and 
neutral facial expressions presented on a computer screen, by pulling a joystick either 
towards their body (approach movement) or pushing it away from their body (avoidance 
movement). Pulling or pushing the joystick increased or decreased the size of the picture 
respectively, giving the impression of moving towards or moving away from the partici-
pant. Usually, response latencies are shorter for affect-congruent (e.g., happy-approach; 
angry-avoid) as compared to affect incongruent response conditions (e.g., angry-ap-
proach; happy-avoid). This task has previously been used by Enter and colleagues (2014). 
A detailed description is available in the Supplemental Information.
Procedure
Participants were tested individually at two identical testing sessions with two days 
in between. Testing sessions started at either 930h or 1330h, and participants were tested 
on the same time of day on both sessions. Four and a half hours after administration of 
testosterone or placebo participants performed the AAT in a dimly lit and sound attenu-
ated room. After completion of the two sessions participants had to indicate in which 
session they thought to have had testosterone or placebo. Responses of six of the 17 par-
ticipants were correct, which is at chance-level, Binomial P(X = 6) = 0.094, confirming that 
participants were unaware of the condition. Before the first testing day the participants 
completed additional questionnaires, including the Dutch versions of the Beck Depres-
sion Inventory (BDI: Beck, Rush, Hollon, & Emery, 1979) and the Social Phobia and Anxiety 
Inventory (SPAI: Turner et al., 1989; see Table S6.1).
Statistical analyses
RT outliers were filtered using a <150 and >1500 ms cut-off. A cut-off of three stan-
dard deviations from the mean was used for defining outliers in the remaining RTs. Error 
rates were calculated after removal of outliers. For each participant, the median of the 
remaining RTs (91%) for the correct responses (RT1) was calculated per cell (defined by: 
Emotion and Movement). Following Enter and colleagues (Enter et al., 2014) AAT-effect 
scores were computed for each participant and for each emotion separately by subtract-
ing median pull RTs from corresponding median push RTs (e.g., RT angry push – RT angry 
pull; RT happy push – RT happy pull; RT neutral push – RT neutral pull). As a result, more 
negative AAT-effect scores (push is faster than pull) reflect a relative avoidance tendency.
To test effects of testosterone administration on approach-avoidance tendencies to 
emotional faces, AAT-effect scores were entered in a two-way repeated measures Analy-
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sis of Variance (rmANOVA) with Condition (testosterone, placebo) and Emotion (angry, 
happy, neutral) as within-subject factors. Greenhouse-Geisser correction was used when 
appropriate (uncorrected degrees of freedom are reported together with the correction 
factor epsilon (ε)). In addition, we tested whether AAT-effect scores were significant in 
certain conditions (i.e., differed from zero) using one sample t-tests. Alpha was set at 
.05 and effect sizes are reported in partial eta squared (ηp2). Finally, we checked whether 
avoidance behavior to angry faces in the placebo condition was associated with sever-
ity of social anxiety symptomatology by computing Spearman’s correlation coefficient 
between baseline corrected AAT-effect scores and SPAI total scores.
Results
Table 5.1 provides an overview of the outcomes for RTs. The task was well performed, 
as indicated by low error rates (9%).
Table 5.1. Mean RTs (ms ± SEM) for approach (pull) and avoidance (push) responses to angry,happy, and neutral faces 
per condition.
Valence
Placebo Testosterone
Push Pull Push Pull
Angry 425 (38) 429 (33) 447 (55) 438 (63)
Happy 431 (44) 424 (35) 435 (45) 447 (51)
Neutral 421 (35) 428 (32) 431 (47) 447 (51)
In line with our hypotheses, the two-way rmANOVA for the AAT-effect scores, with 
Condition (Placebo, Testosterone) and Emotion (angry, happy, neutral) as within-subject 
factors, revealed a significant Condition x Emotion interaction, F(1.22,19.5) = 4.95, p = 
.032, ε = .608, ηp2 = .236 and a significant effect of Emotion, F(1,16) = 6.25, p = .024, ηp2 
= .281. There were no significant Condition effects for each Emotion separately (all Fs < 
2.6, ps > .13), but separate two-way rmANOVAs for each pair of emotions demonstrated 
a significant Condition x Emotion interaction for angry vs happy faces, F(1,16) = 6.25, p = 
.024, ηp2 = .281, and for angry vs neutral faces, F(1,16) = 4.61, p = .047, ηp2 = .224, but not 
for happy vs neutral faces, F(1,16) = 0.561, p = .465, ηp2 = .034. As expected, these find-
ings pointed towards a specific effect of testosterone on the AAT-effect scores for angry 
faces, compared to happy and neutral faces. Indeed, when looking into each condition 
separately, one-way rmANOVAs for Emotion (angry, happy, neutral) revealed a significant 
effect for Emotion in the testosterone condition, F(1.43,22.95) = 4.90, p = .026, ε = .717, ηp2 
= .234, but not in the placebo condition, F(1.44,23.0) = 1.22, p = .300, ε = .718, ηp2 = .071. 
Separate follow-up analyses for each pair of emotions showed that the AAT-effect scores 
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in the testosterone condition were markedly higher for angry faces compared to happy 
and neutral faces, by revealing a significant main effect of Emotion for angry vs happy, 
F(1,16) = 6.94, p = .018, ηp2 = .303, and angry vs neutral, F(1,16) = 16.14, p = .001, ηp2 = .502, 
but not for happy vs neutral faces, F(1,16) = 0.098, p = .759, ηp2 = .006. Taken together, 
these results suggest a significant increase of approach-tendencies towards angry faces 
by testosterone in SAD participants, see Figure 5.1.
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Figure 5.1. Mean Approach-Avoidance Task (AAT) effect scores (ms) for approach and avoidance movements to 
angry and happy faces in the placebo and testosterone condition. Participants show significant approach tenden-
cies toward angry faces after testosterone administration, compared with happy faces. For display purposes, mean 
scores are baseline corrected (i.e., AAT effect scores for neutral faces subtracted from the AAT effect scores of angry 
and happy faces, respectively). Of note, baseline corrected AAT effect scores for angry faces showed a significant 
treatment effect, F(1, 16) = 4.61, p = .047, ηp2 = .224, and differed significantly from zero in the testosterone condi-
tion, t(16) = 4.02, p = .001, indicating threat approach. *p < .05. **p < .01.
Next we checked whether avoidance behavior to angry faces in the placebo condi-
tion was associated with social anxiety symptomatology. A significant negative correla-
tion between the baseline corrected AAT-effect scores and the SPAI scores, r = -.660, p = 
.004, indicated that those patients who had stronger avoidance tendencies also had more 
severe social anxiety symptoms. Social anxiety scores did not modulate the testosterone 
effects (SPAI: all Fs < 1.81, ps > .199). There were also no such effects when taking LSAS as 
symptom severity measure (All Fs < 0.757, ps > .398).
In order to test whether this threat-approach enhancing effect of testosterone is 
comparable to the effect previously observed in healthy participants, we added the 
AAT-effect scores based on the reaction times (operationalized as movement initiation 
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times at 7° displacement instead of 30°) of the previously published group of healthy par-
ticipants (Dorien Enter et al., 2014c) as a control group (HC).6 We conducted a three-way 
rmANOVA, with Condition (placebo, testosterone) and Emotion (angry, happy, neutral) as 
within-subject factors, and Group (SAD, HC) as between-subjects factor. Age was added 
as a standardized covariate because the HC-group has a higher age-range. Similar to the 
previous analyses in both groups separately, this analysis revealed a significant Condition 
x Emotion interaction, F(2,76) = 4.61, p = .013, ηp2 = .108. There were no significant effects 
of Age (all ps > .37, ηp2 ≤ .02) or Group (all ps > .33, ηp2 < .03), the latter indicating that SAD 
participants benefitted to a similar extent from testosterone as the non-anxious group. 
Separate follow-up analyses for each pair of Emotions showed that the AAT-effect scores 
in the testosterone condition tended to be higher for angry faces compared to happy 
and neutral faces, by revealing a significant main effect of Emotion for angry vs neutral, 
F(1,38) = 9.52, p = .043, ηp2 = .200, a trend-level significant effect of Emotion for angry 
vs happy, F(1,38) = 3.19, p = .082, ηp2 = .077, but a non-significant effect of Emotion for 
happy vs neutral faces, F(1,38) = 0.284, p = .597, ηp2 = .007. There were no effects of Group 
(all ps > .17, ηp2 < .04), nor age (all ps > .27, ηp2 < .03). Therefore, these results indicate 
that testosterone promotes similar threat approach-tendencies in non-anxious healthy 
participants and participants suffering from generalized SAD.
The effects of testosterone on AAT-effect scores were not affected by administration 
order, time of testing, or use of contraceptives (see supplemental information).
Discussion
The present findings show that single dose testosterone administration can lead to 
increased approach of social threat cues in women with SAD. This is the first study in SAD 
showing that testosterone directly influences automatic approach-avoidance actions and 
promotes approach behavior that directly affects the perceived distance of the social 
threat (Rinck & Becker, 2007).
Angry faces play an important role in social communication as they convey social 
dominance and are being perceived as a threat, especially by socially anxious individu-
als (Adams et al., 2003; Öhman, 1986). In our study, testosterone administration leads to 
a significant increase in approach of angry faces, relative to happy and neutral facial 
expressions. This finding is in agreement with literature that shows that testosterone 
reduces fear and sensitivity to threat, and enhances social dominance related behavior 
(Archer, 2006; Bos et al., 2012; Enter et al., 2014; Terburg & van Honk, 2013). Our previous 
study showed that testosterone promotes actual threat approach behavior in healthy 
6 This group was tested using similar inclusion criteria and the same study-setup.
Testosterone promotes threat approach
67
participants (Enter et al., 2014), and the current study extends these findings by showing 
that testosterone also promotes social threat approach in participants with generalized 
SAD. Socio-neuroendocrine models of SAD propose that individuals with SAD display 
exaggerated socially submissive behavior, which is associated with social avoidance and 
low endogenous testosterone levels (Gilbert, 2001; Giltay et al., 2012; Hermans & van 
Honk, 2006; Öhman, & Wiens, 2003; Sapolsky, 1991; Weisman, et al., 2011). An increase in 
threat approach behavior after administration of testosterone would be the result of an 
enhanced motivational tendency towards social dominance in this socially submissive 
group (Archer, 2006; Bos et al., 2012; Enter et al., 2014; Terburg & van Honk, 2013). This 
interpretation fits recent findings that testosterone can promote gaze behaviour towards 
the eye-regions in healthy and socially anxious individuals (Enter et al., 2016; Terburg et 
al., 2012).
Performance on the AAT depends on the coordinating role of the anterior prefrontal 
cortex and its connection with the amygdala and other brain regions (Volman, Verhagen, 
et al., 2013; Volman, Roelofs, et al., 2011). This neural circuit is important for the regulation 
of social emotional behavior, and frontal-amygdala crosstalk during operation of the AAT 
is influenced by endogenous testosterone levels (Volman, Toni, et al., 2011). Studies fea-
turing testosterone administration showed that testosterone affects neural responsive-
ness of brain areas involved in social approach such as amygdala and striatum towards 
socially salient stimuli (Hermans et al., 2008; van Wingen et al., 2010). Moreover, the way 
testosterone affects the amygdala depends on motivational context and it specifically 
promotes threat approach during performance of the AAT (Radke et al., 2015). Typically, 
these neural circuits show altered functioning in SAD. Neuroimaging studies in SAD have 
consistently shown increased activation of the amygdala and connected frontal-striatal 
circuits when participants were exposed to threatening facial expressions (Fouche et al., 
2013), and it has been proposed that the amygdala is not properly regulated by cortical 
areas during social threat in SAD (Cremers et al., 2015; Freitas-Ferrari et al., 2010). Future 
neuroimaging research should elucidate whether testosterone administration also pro-
motes threat approach in SAD by influencing activity in these neural circuits underlying 
social motivational behavior.
A few methodological issues are relevant to consider with regard to this study. First, 
following previous hormone administration studies featuring clinical participants on the 
AAT (van Peer et al., 2009), we selected the movement initiation time (7° joystick rotation) 
and not the full movement time (30° joystick rotation) as an outcome measure. It has 
been proposed that the initiation time reflects the time necessary for neural processes 
involved in stimulus evaluation, response selection, and programming the execution of 
motor movements while the movement time includes the neuro-muscular response 
(Rotteveel & Phaf, 2004). The latter usually shows a general slowing in patient samples 
with affective disorders, such as anxiety and depression, compared to HC (Sabbe, Hulstijn, 
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van Hoof, Tuynman-Qua, & Zitman, 1999; Volman, Toni, et al., 2013). Since we aimed to test 
effects on the cognitive affective processes reflected in the initiation time, we selected 
this measure for our analyses instead of the actual movement execution which may be 
confounded by general slowing in SAD. Second, previous studies featuring the AAT found 
that socially anxious participants show typical social avoidance behavior in response to 
angry faces (Heuer et al., 2007; Roelofs et al., 2010; van Peer et al., 2009, but see Roelofs 
et al., 2009). Although our results seem to point towards a relatively stronger tendency 
to avoid angry compared to happy faces in the placebo condition (see figure 5.1), this 
effect did not reach significance in the present study. Despite this absence of avoidance 
of angry faces on a group level, we found that avoidance of angry faces was stronger for 
more severely affected patients, as indicated by a significant correlation between baseline 
corrected AAT-effect scores for angry faces and SPAI scores. In addition, it should be noted 
that testosterone can evoke strong placebo responses (Handelsman, 2011), therefore we 
cannot exclude the possibility that placebo effects have contributed to decreased avoid-
ance of angry faces in the placebo condition. Third, our sample size is small, even though it 
falls within a range that is common for SAD studies, and is employed in a powerful within 
subjects design. Future studies including a larger number of participants should replicate 
these findings and would also have the power to investigate the role of individual differ-
ences in endogenous testosterone levels. Finally, as a consequence of the testosterone 
administration method, only female participants were tested in this study (Tuiten et al., 
2000). Future research should investigate whether testosterone administration to men 
has similar effects as suggested by similarities in social behavior related to endogenous 
and exogenous testosterone across sexes (Goetz et al., 2014; Hermans et al., 2008).
The finding that testosterone promotes social approach motivation in SAD may have 
clinical implications. A large proportion of SAD patients (up to 50%) does not recover 
after current evidence based psychological and pharmacological treatments (Hofmann 
& Bögels, 2006; Stein & Stein, 2008), and there is a need for new treatment strategies that 
enhance remission rates. A novel line of research has shown that treatment effects are 
augmented by pairing exposure therapy with a pharmacological agent (Hofmann et al., 
2014; Singewald, Schmuckermair, Whittle, Holmes, & Ressler, 2015). Given our promising 
findings showing that testosterone promotes actual social approach behavior in SAD 
during a social challenge, and since exposure therapy is aimed at reduction of social 
avoidance behavior, it would be interesting for future investigations to explore whether 
adding testosterone as a pharmacological enhancer in the first few therapy sessions can 
boost efficacy of exposure therapy in SAD. In addition, future studies should test for dose-
response relationships before administering testosterone in clinical practice.
In conclusion, this is the first study in SAD that shows that testosterone counteracts 
automatic avoidance behavior by promoting social approach-tendencies that have a di-
rect effect on the perceived distance of the social threat. These findings support theories 
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on the role of testosterone in the regulation of social motivational behavior and concur 
with the predictions of socio-neuroendocrine models of SAD. These findings also may 
have clinical implications as social avoidance plays a crucial role in the persistence of 
SAD. The finding that this core characteristic can directly be influenced by single dose 
testosterone administration may encourage exploration of testosterone administration 
as a means to enhance therapy efficacy.
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Supplemental Information
Supplemental Methods
Table S5.1: Participant Characteristics (n = 17).
M SD
Age (years) 22.8 5.0
LSAS total 78.6 14.3
SPAI total 99.84 21.0
BDI 16.5 11.5
Data are presented in mean and standard deviation. Abbreviations: LSAS, Liebowitz Social Anxiety Scale; SPAI, 
Social Phobia and Anxiety Inventory; BDI, Beck Depression Inventory.
Approach-Avoidance Task (AAT)
During this reaction time (RT) task participants responded to emotional face pic-
tures presented on a computer screen, by pulling a joystick either towards their body 
(approach movement) or pushing it away from their body (avoidance movement; task 
adapted from (Heuer et al., 2007). Pulling or pushing the joystick increased or decreased 
the size of the picture respectively, giving the impression of moving towards or moving 
away from the participant. The speed of the size change was proportional to the ampli-
tude of the joystick movement. As soon as the joystick reached its target position (i.e., 
the required direction; full movement involved a 30º rotation from the upright position) 
the picture disappeared from the screen. The time between the onset of the stimulus 
and its disappearance from the screen was recorded with <1 ms accuracy at 7°, 15°, 22°, 
and 30° rotation, with the reaction time set to 7° displacement. After each completed 
trial the participant moved the joystick back to its central position and initiated a new 
trial by pressing the fire button near the top of the joystick. Face stimuli were selected 
from the Karolinska Directed Emotional Faces database based on quality of emotional 
expression (Goeleven et al., 2008; Lundqvist et al., 1998). Happy, angry, and neutral facial 
expressions were taken from the same model (five male and five female models in all) and 
each picture was presented either with a yellowish or a grayish filter. In addition, checker-
boards (10 yellow, 10 gray) were included as non-facial control stimuli.7 This resulted in a 
7 Checkerboard stimuli yielded significantly slower reaction times (p ≤ .04; RTs (ms ± SEM) for placebo 
condition: push 451 (10), pull 436 (9); testosterone condition: push 462 (12), pull 245 (15)). It is likely 
that this slowing is caused by an oddball effect as they were outnumbered by the facial stimuli (i.e., 20 
checkerboards to 60 emotional faces). Therefore the checkerboard stimuli have not been included in the 
main analyses.
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total of 80 different stimuli, which were presented in random order. All participants were 
instructed to push on yellow stimuli and to pull on gray stimuli, and to respond as fast 
and as accurately as possible. Usually, response latencies are shorter for affect-congruent 
(e.g., happy-approach; angry-avoid) as compared to affect incongruent response condi-
tions (e.g., angry-approach; happy-avoid). Before the real test started, participants were 
presented with eighteen practice trials, which were similar to the test trials except for the 
fact that the pictures showed different models.
Supplemental Results
To check whether the effects of testosterone on AAT-effect scores were affected by 
administration order, time of testing or use of contraceptives, we separately added these 
factors as between-subjects factors to the model. These analyses showed no influence 
of contraceptive use (all ps > .25, ηp2 < .09). Nor were there main or interaction effects for 
Order (all ps > .39, ηp2 < .05), or time of testing (all ps > .23, ηp2 ≤ .09). Most importantly, 
the Condition x Emotion interaction remained significant after including these factors 
into the model (all ps > .04 ηp2 > .20); and trend-level significant after including the factor 
Order into the model (p = .057, ε = .595, ηp2 = .21).
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Single dose testosterone 
administration alleviates gaze 
avoidance in women with Social 
Anxiety Disorder
Enter, D., Terburg, D., Harrewijn, A., 
Spinhoven, P., & Roelofs, K. (2016). 
Psychoneuroendocrinology, 63, 26–33.
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Abstract
Gaze avoidance is one of the most characteristic and persistent social features in 
people with Social Anxiety Disorder (SAD). It signals social submissiveness and hampers 
adequate social interactions. Patients with SAD typically show reduced testosterone 
levels, a hormone that facilitates socially dominant gaze behavior. Therefore we tested 
as a proof of principle whether single dose testosterone administration can reduce gaze 
avoidance in SAD. In a double-blind, within-subject design, 18 medication-free female 
participants with SAD and 19 female healthy control participants received a single dose 
of 0.5 mg testosterone and a matched placebo, at two separate days. On each day, their 
spontaneous gaze behavior was recorded using eye-tracking, while they looked at angry, 
happy, and neutral facial expressions. Testosterone enhanced the percentage of first fixa-
tions to the eye-region in participants with SAD compared to healthy controls. In addition, 
SAD patients’ initial gaze avoidance in the placebo condition was associated with more 
severe social anxiety symptoms and this relation was no longer present after testosterone 
administration. These findings indicate that single dose testosterone administration can 
alleviate gaze avoidance in SAD. They support theories on the dominance enhancing 
effects of testosterone and extend those by showing that effects are particularly strong in 
individuals featured by socially submissive behavior. The finding that this core character-
istic of SAD can be directly influenced by single dose testosterone administration calls for 
future inquiry into the clinical utility of testosterone in the treatment of SAD.
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Introduction
Social Anxiety Disorder (SAD) is a common anxiety disorder, characterized by per-
sistent fear and avoidance of social situations (American Psychiatric Association, 2013). 
SAD has been related to a ubiquitous social hierarchy system, with individuals with SAD 
displaying socially submissive as opposed to socially dominant behavior (Hermans & van 
Honk, 2006; Maner et al., 2008; Weisman et al., 2011). Typical submissive behavior, such as 
avoidance of eye contact plays a crucial role in the persistence of the disorder by hinder-
ing extinction of fear in social situations (Clark & Wells, 1995; Stein & Stein, 2008). Especially 
angry facial expressions with direct gaze signal social scrutiny or a potential dominance 
challenge and elicit avoidance tendencies in highly socially anxious individuals (Öhman, 
1986; Roelofs et al., 2010). Indeed, eye-tracking studies investigating gaze behavior in 
SAD, have demonstrated avoidance of the eye-region of angry faces (Horley, Williams, 
Gonsalvez, & Gordon, 2004; Moukheiber et al., 2010; Moukheiber, Rautureau, Perez-Diaz, 
Jouvent, & Pelissolo, 2012). Because avoidance behavior is the major maintaining factor in 
SAD, it is relevant to develop interventions that directly target this behavior (Clark & Wells, 
1995; Gamer & Büchel, 2012; Hofmann et al., 2014; Roelofs et al., 2010).
SAD is associated with reduced endogenous testosterone levels (Giltay et al., 2012), 
and because testosterone is known to reduce social avoidance (Enter et al., 2014; 
Terburg et al., 2012), it is striking that so far no studies have tested the direct effects of 
testosterone administration in SAD. Testosterone has an important role in the regulation 
of social motivational behavior: It has socially anxiolytic effects, and is associated with 
social dominance and approach behavior (Bos et al., 2012; Enter et al., 2014; Terburg & 
van Honk, 2013). Based on recent findings indicating that testosterone administration in 
healthy females promotes reactive social dominant gaze behavior to angry faces (Terburg 
et al., 2012; Terburg, Hooiveld, Aarts, Kenemans, & van Honk, 2011), we predicted that 
testosterone administration would alleviate submissive gaze avoidance to angry faces in 
individuals with SAD.
We tested this hypothesis in a double-blind and placebo controlled within-subject 
study. A total of 18 medication-free participants with SAD and 19 healthy control par-
ticipants received a single dose of 0.5 mg testosterone and a matched placebo in two 
sessions. In each session, their spontaneous gaze behavior was recorded while they 
looked at angry, happy, and neutral facial expressions. Gaze avoidance of eye contact was 
reliably indexed as relative reduction of initial gaze fixations on the eye-region (Becker & 
Detweiler-Bedell, 2009; Gamer & Büchel, 2012; Gamer, Zurowski, & Büchel, 2010; Garner, 
Mogg, & Bradley, 2006). We predicted that testosterone administration in contrast to 
placebo would reduce gaze avoidance and increase the number of first fixations to the 
eyes of angry faces in particular in SAD.
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Method
Participants
Characteristics of the participant groups are presented in Table 6.1 (see also Table 
S6.1 and S6.2, Supplemental Information). Participants with social anxiety disorder (SAD) 
were recruited from outpatient anxiety departments of mental health centers, through 
advertisements on the internet, and in local newspapers. Inclusion criterion was a total 
score of > 60 on the Liebowitz Social Anxiety Scale (Liebowitz, 1987; Rytwinski et al., 
2009). In addition participants were screened with the Mini International Neuropsychiat-
ric Interview script (Lecubier et al., 1997) to determine the presence of a DSM-IV diagnosis 
of generalized Social Anxiety Disorder. Healthy control (HC) participants were recruited 
via advertisements in community centers, on the internet, and in local newspapers. Only 
female participants were included, because there are as yet no known parameters (e.g., 
dose and time course) for inducing neurophysiological effects in men after administra-
tion of a single dose of testosterone (Tuiten et al., 2000). Both women using single-phase 
contraceptives (11 HC, 15 SAD), and normally cycling women (8 HC, 3 SAD) participated 
in the study (e.g., Hermans et al., 2010). Exclusion criteria were age < 18 and > 50, use of 
(psychotropic) medication, somatic illnesses, neurological conditions, psychotic disorder, 
history of head injury, left-handedness, peri- or postmenopause, and pregnancy or breast 
feeding (for both HC and SAD groups), recent or past psychiatric problems (only HC group), 
and current comorbid diagnosis of mood or anxiety disorders other than SAD (only SAD 
group). After initial screening of 24 subjects for both groups, 19 SAD and 19 HC partici-
pants were selected on basis of matching for age and level of education (all participants 
were following or completed higher education). Data of one SAD participant was lost due 
to technical failure, leaving 18 SAD and 19 HC participants for analyses. Thirteen of the 18 
SAD participants met full DSM-IV criteria for gSAD at the time of testing; the other five had 
sub-syndromal SAD (i.e., they did no longer fulfill DSM-IV criterion E: the symptoms lead 
to significant burden in social or occupational functioning at time of testing). See Table 
S6.2 for the demographic characteristics of this group of 13 participants with syndromal 
SAD. Our primary aim was to test effects in participants who fulfill all DSM-IV criteria for 
generalized SAD (SAD syndromal group) but for transparency reasons we will also report 
analyses for all participants, including the five who were in remission (SAD combined). 
All participants had normal or corrected-to-normal vision, were unaware of the aim of 
the study, provided written informed consent, and received financial compensation. The 
study was approved by the Medical Ethics Committee of the Leiden University Medical 
Centre, and was in accordance with the declaration of Helsinki.
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Testosterone administration
In a double-blind, randomized, placebo-controlled, cross-over design participants 
received a single dose (0.5 ml) of 0.5 mg testosterone suspended in a clear solution with 
0.5 mg hydroxypropyl-beta-cyclodextrin, 0.005 ml ethanol 96%, and distilled water. The 
matched placebo contained the same ingredients, except the testosterone. Participants 
were asked to hold the liquid under their tongue for 60 seconds. During sublingual ad-
ministration of 0.5 mg testosterone cyclodextrin, testosterone is directly absorbed into 
the bloodstream. In females, such a dose yields a sharp increase of 20-25 nmol/l in plasma 
testosterone levels within 15 minutes, which declines to baseline levels within the next 90 
minutes (van Rooij et al., 2012). Previous research applying this method has convincingly 
shown consistent psychophysiological and behavioral effects approximately 4-6 hours 
after administration, therefore this time interval was also applied in the current study (Bos 
et al., 2012; Enter et al., 2014; Tuiten et al., 2000).
Passive Viewing Task
Face stimuli were selected from the NimStim set of facial expressions (Tottenham et al., 
2009). Happy, Angry, and Neutral facial expressions were taken from the same model (four 
male and four female models), cut out in an oval shape (368 x 515 pixels) to remove distract-
ing features, and presented with a grayish filter on an equiluminant gray background. One 
face at the time was shown on the middle of the screen (9.3° x 12.9° visual angle; screen 
resolution 1280 x 1024 pixels), in such a way that the pre-trial fixation cross was situated on 
the nasal bridge below the eyes. Stimuli were repeated three times, resulting in 72 random-
ized trials in total. Trials started when the participant maintained a fixation on the central 
fixation cross for 1000 ms. Stimulus presentation time was 5000 ms, followed by an intertrial 
interval (blank gray screen) of 4000-7000 ms. Three breaks were offered throughout the task, 
and could be terminated by a button press. Participants sat at a distance of 60-65 cm from 
the screen and were instructed to look at the fixation cross, and then look at the pictures 
without further instructions except for not moving their head.
Table 6.1. Group Characteristicsfor the Healthy Control (HC) group and the combined group of participants with syn-
dromal and sub-syndromal Social Anxiety Disorder (SAD).
HC (n = 19) SAD (n = 18) t(35) p-Value
Age (years) 25.2 (4.0) 23.1 (4.6) 1.49 .145
LSAS anxiety 9.5 (7.2) 41.5 (6.2) -14.49 <.001
LSAS avoidance 7.8 (6.3) 35.4 (7.4) -12.21 <.001
LSAS total 17.3 (12.9) 76.8 (12.5) -14.25 <.001
BDI 2.5 (2.2) 13.5 (11.9) -3.86 .001
Data are presented in mean and standard deviation. Abbreviations: LSAS, Liebowitz Social Anxiety Scale; BDI, Beck 
Depression Inventory.
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Procedure
Participants were tested individually at two identical testing sessions with two days in 
between. Testing sessions started at either 0930 or 1330 h, and participants were tested 
on the same time of day on both sessions. Four hours after administration of testosterone 
or placebo participants were seated in a dimly lit and sound attenuated room, where they 
performed a standard nine-point calibration procedure, followed by the Passive Viewing 
Task. In addition to gaze behavior, EEG and facial mimicry were recorded, results of which 
will be reported elsewhere.
Data acquisition and statistical analyses
Eye movements were recorded with a Tobii T120 binocular infrared eye tracker (Tobii 
Technology, Danderyd, Sweden), sampling at 120 Hz, with 0.5° accuracy. Oval Areas of 
Interest (AOIs) were created around each eye for each picture separately and excluded 
the inter-ocular space (Figure 2c). Gaze fixations were defined as the average location 
of all subsequent gaze points within 1.5° visual angle, with a minimal duration of 100 
ms excluding the initial gaze points on the central fixation cross (Tobii Technology, Dan-
deryd, Sweden). Calculated parameters were Percentage First Fixations (i.e., 100 times the 
amount of first fixations in the eye AOI divided by the total amount of first fixations) and 
the duration of first fixations. In addition, Percentage Total Fixations (i.e., 100 times the 
amount of fixations in the eye AOI divided by the total amount of fixations) and Fixation 
Duration were calculated for fixations during the total stimulus presentation time.
To account for data loss due to eventual motion and eye blink artifacts, we applied 
a cut-off of at least 150 data points per trial (25% of the possible 600 data points in each 
trial, 120Hz sampling-rate and 5 second presentation) for trial inclusion in the analysis. Us-
ing this filter criterion 4.7% of the trials were discarded which was not different between 
groups, treatment condition or their interaction (all ps > .23).
Parameters were entered in a three-way repeated measures Analysis of Variance 
(rmANOVA) with Treatment (placebo, testosterone) and Emotion (angry, happy, neutral) 
as within-subject factors, and Group (HC, SAD) as between-subjects factor. Alpha was 
set at .05 (two-tailed) and effect sizes are reported in partial eta squared (ηp2). Green-
house-Geisser correction was used when appropriate (uncorrected degrees of freedom 
are reported together with the correction factor epsilon (ε)). The statistics will be first 
reported for the combined group of participants with syndromal and sub-syndromal SAD 
participants (SAD combined, n = 18), and will be subsequently repeated for the target 
group of participants who still fulfilled all criteria for SAD at the time of testing (SAD 
syndromal, n = 13).
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Table 6.2. First fixations (percentage ± SEM) towards the eye-region of angry, happy, and neutral facial expressions 
after administration of placebo and testosterone for Healthy Control participants (n = 19) and the combined group of 
participants with syndromal and sub-syndromal Social Anxiety Disorder (n = 18).
Emotion
Healthy Controls Social Anxiety Disorder
Placebo Testosterone Placebo Testosterone
Angry 43 (6) 36 (6) 30 (6) 37 (8)
Happy 49 (7) 42 (6) 36 (7) 37 (9)
Neutral 48 (7) 40 (6) 41 (8) 40 (9)
Results
Percentage first fixations
The percentage first fixations to the eye region for each condition, emotion and 
group are presented in Table 6.2. First we conducted a three-way rmANOVA with all 
emotions in the analysis for the percentage first fixations, with Treatment (placebo, 
testosterone) and Emotion (angry, happy, neutral) as within-subject factors, and Group 
(HC, SAD) as between-subjects factor. There was no significant Treatment x Emotion x 
Group interaction; this counted both when including the SAD (combined) group, F(2,70) 
= 1.04, p = .360, and when including the SAD (syndromal) group, F(2,60) = 1.13, p = .331. 
However, a significant Treatment x Group interaction was present both when including 
the SAD (combined) group, F(1,35) = 6.67, p = .014, ηp2 = .16, and when including the SAD 
(syndromal) group, F(1,30) = 7.39, p = .011, ηp2 = .20, indicating that testosterone affects 
gaze behavior in the HC and SAD groups in a differential manner (Figure 6.1). There were 
no significant post-hoc effects involving Group with all emotions in the analyses, all Fs < 
1.83, ps > .285, but a main effect of Emotion (both with the SAD (combined) group, F(2,70) 
= 7.32, p = .002, ηp2 = .17, and with the SAD (syndromal) group, F(2,60) = 5.12, p = .009, 
ηp2 = .15), indicated relative avoidance of angry versus happy faces faces (both with SAD 
(combined), F(1,35) = 10.52, p = .003 ηp2 = .23, and with SAD (syndromal), F(1,30) = .8.41, 
p = .007, ηp2 = .22) and angry versus neutral faces (both with SAD (combined), F(1,35) = 
10.46, p = .003 ηp2 = .23, and with SAD (syndromal), F(1,30) = 8.06, p = .008, ηp2 = .21) across 
groups.
Because of our specific hypothesis on the effects of testosterone on the first fixations 
towards the eyes of angry faces in SAD, we checked whether the Treatment x Group 
effect would hold for angry faces alone. Indeed, the significant Treatment x Group interac-
tion remained for angry faces. This occurred both when including the SAD (combined) 
group, F(1,35) = 8.41, p = .006, ηp2 = .19, and when including the SAD (syndromal) group, 
F(1,30) = 9.53, p = .004 ηp2 = .24 (Figure 6.2a). A similar rmANOVA did not reveal significant 
Treatment x Group effects for first fixations on the eyes of happy and neutral faces (again 
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both when including the SAD (combined) group, happy: F(1,35) = 3.22, p = .085, neutral: 
F(1,35) = 1.61, p = .213; and when including the SAD (syndromal) group, happy: F(1,30) = 
3.40, p = .075, neutral: F(1,30) = 1.63, p = .211). These findings confirm that testosterone 
increases the first fixations towards the eye region of angry faces in SAD versus HC.
To further explore the Treatment X Group effect of the omnibus analysis, we conduct-
ed analyses for each group separately. A two-way rmANOVA with Treatment (placebo, 
testosterone) and Emotion (angry, happy, neutral) for the percentage first fixations in the 
SAD group revealed a significant Treatment x Emotion interaction. This counted both for 
the SAD (combined) group, F(2,32) = 4.43, p = .020, ηp2 = 0.21, and for the SAD (syndromal) 
group, F(2,24) = 3.56, p = .044, ηp2 = 0.23. In addition, there was a significant main effect of 
Emotion in the SAD (combined) group, F(1.5,25.8) = 5.54, p = .016, ε = .759, ηp2 = .25, but 
not in the SAD (syndromal) group: F(1.4,16.9) = 2.76, p = .105, ε = .702, ηp2 =.19, nor did 
this analysis yield a significant main effect of Treatment in either group, all Fs < 1.28, all 
ps > .280. Subsequent one-way rmANOVA’s for each emotion separately yielded a trend 
towards a significant main effect of Treatment for Angry faces, F(1,17) = 4.09, p = .059, ηp2 
= .19, in the SAD (combined) group. Critically, the Treatment effect of testosterone for 
Figure 6.1. First fixation data for angry, happy, and neutral facial expressions. Percentage (mean ± SEM) first fixa-
tions towards the eyes of angry, happy and neutral facial expressions after administration of placebo and tes-
tosterone for Healthy Control participants (HC, n = 19) and the combined group of participants with syndromal 
and sub-syndromal Social Anxiety Disorder (SAD combined, n = 18). A significant Treatment x Group interaction 
indicates that testosterone differentially affects gaze behavior in SAD and HC groups. The Treatment x Group effect 
remains significant when tested for angry faces alone but not when tested for happy or neutral faces.**p < .01, *p 
< .05, °p < .06.
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angry faces was significant in the SAD (syndromal) group, F(1,12) = 4.90, p = .047, ηp2 = 
.29, suggesting that testosterone increased first fixations to the eye-region of angry faces 
within the SAD patients (Figure 2a). There was no such effect for Happy (F(1,17) = 0.12, p 
= .729 (SAD combined); F(1,12) = 0.39, p = .543 (SAD syndromal)), or Neutral faces (F(1,17) 
= 0.15, p = .706 (SAD combined); F(1,12) = 0.02, p = .968 (SAD syndromal)).
Separate analyses for the SAD participants per condition showed significant avoid-
ance of the eyes of angry faces, when compared to neutral faces in the placebo condition. 
This Emotion effect was present both in the SAD (combined) group, F(1,17) = 11.73, p = 
.003, ηp2 = .41, and in the SAD (syndromal) group, F(1,12) = 7.01, p = .021, ηp2 = .37. There 
was also significant avoidance for angry faces when compared to happy faces, in the 
SAD (combined) group, F(1,17) = 6.07, p = .025, ηp2 = .26, which was a trend in the SAD 
(syndromal) group, F(1,12) = 3.95, p = .070, ηp2 = .25. There were no such effects for happy 
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Figure 6.2. First fixation data for angry facial expressions and correlation with social anxiety scores in SAD. A) Per-
centage (mean ± SEM) first fixations towards the eyes of angry facial expressions after administration of placebo 
and testosterone for Healthy Control participants (HC, n = 19) and participants with generalized Social Anxiety 
Disorder who met the full DSM-IV criteria on the day of testing (SAD syndromal, n = 13). In SAD participants tes-
tosterone enhanced the percentage of first fixations to the eyes of angry faces, whereas HCs showed the opposite 
pattern.**p < .01, *p ≤ .05, ◦p < .06. B) A significant correlation between percentage first fixations on angry eyes and 
LSAS social anxiety scores in the placebo condition indicated that SAD participants (n = 13) with stronger anxiety 
symptomatology showed increased gaze avoidance of angry eye contact. C) Example of an angry facial expression 
and corresponding Area of Interest (AOI) map, with the eye AOI depicted in white. 
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versus neutral faces, not when including the SAD (combined) group, F(1,17) = 4.08, p = 
.059, nor when including the SAD (syndromal) group, F(1,12) = 2.02, p = .180. These gaze 
avoidance effects for the eyes of angry faces in the SAD group were no longer present 
in the testosterone condition, all Fs < 0.89, ps > .398. To further explore the nature of the 
avoidance effects in the placebo condition in the subgroup of participants who met the 
full DSM-IV criteria for SAD, we tested whether gaze avoidance towards the eye-regions 
was correlated to the symptom severity. A significant correlation between percentage 
first fixations on angry eyes and social anxiety scores in the placebo condition, r = -.561, 
p = .046, indeed indicated that participants with stronger social anxiety symptomatology 
showed relatively greater gaze avoidance of angry eye contact (Figure 6.2b). This effect 
was no longer present after testosterone administration, r = -.384, p = .195. A similar cor-
relation existed for the first fixations towards the eyes of happy faces, r = -.575, p = .040, 
and neutral faces, r = -.590, p = .034, which became a trend after testosterone administra-
tion: happy, r = -.498, p = .083, and neutral, r = -.502, p = .080. Interestingly, none of these 
effects was significant in the SAD (combined) group, all rs < -.404, all ps > .097.
Together these analyses within the SAD group indicate that initial gaze avoidance of 
eye contact is related to the severity of social anxiety symptomatology in individuals with 
SAD, and that the avoidance of angry eyes in particular can be alleviated by single dose 
testosterone administration.
In contrast, in the HC group the two-way rmANOVA with Treatment (placebo, testos-
terone) and Emotion (angry, happy, neutral) showed no significant Treatment x Emotion 
interaction, F(2,36) = 0.03, p = .974. However, a main effect of Treatment, F(1,18) = 9.06, 
p = .008, ηp2 = .34, indicated a relative decrease in the number of first fixations on the 
eye-regions of faces after testosterone (Figure 1). A main effect of Emotion, F(2,36) = 3.60, 
p = .038, ηp2 = .17, showed that the HC, like the SAD group, showed relatively less first 
fixations to the eye-region of angry faces, relative to happy, F(1,18) = 4.80, p = .042, ηp2 = 
.21, but not relative to neutral faces, F(1,18) = 1.88, p = .187. However, avoidance of angry 
eye-contact in the HC group in the placebo-condition was not related to the level of 
social anxiety (all rs < .328.; all ps > .170), as was observed for the syndromal SAD group.
First fixation duration, percentage total fixations, and total fixation duration
Separate three-way rmANOVAs with Treatment (placebo, testosterone) and Emotion 
(angry, happy, neutral) as within-subject factors, and Group (HC, SAD) as between-subjects 
factor, revealed neither Treatment, nor Group effects for first fixation duration, percentage 
total fixations, or total fixation duration, not when including the SAD (combined) group, 
all Fs < 1.53, ps > .225), nor when including the SAD (syndromal) group, all Fs < 2.25, ps > 
.148 (see Table S6.3 and S6.4). In addition, none of these measurements was significantly 
related to symptom severity in the SAD (combined) group (all ps > .391), nor the SAD 
(syndromal) group (all ps > .05).
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Checks for confounding factors
No significant relationship between depression symptoms (Beck Depression Inven-
tory score, (Luteijn & Bouman, 1988) and percentage first fixations emerged in the SAD 
(combined) group, all rs < -.230, ps > .358, nor in the SAD (syndromal) group, all rs < -.454, 
ps > .119. Finally, the effects of testosterone on the percentage first fixations in the SAD 
participants remained after controlling for testing order and other possibly confounding 
variables such as time of testing and use of contraceptives (see Supplemental Informa-
tion).
Discussion
This study shows that a single dose testosterone administration can alleviate gaze 
avoidance, which is one of the core communicative features of social anxiety and Social 
Anxiety Disorder (SAD) in particular (Weeks, Howell, & Goldin, 2013). In accordance with 
previous research, avoidance of eye contact was correlated to severity of social anxiety 
symptoms. Critically, we showed that administration of testosterone led to an increase 
of initial fixations to the eyes of facial stimuli in SAD compared to healthy control (HC) 
participants. This finding supports theories on the anxiolytic and social dominance 
enhancing properties of testosterone and extends those models by indicating that the 
avoidance-reducing effect of testosterone is context dependent and only present in 
individuals featured by clinical avoidance behavior.
The first eye movement or first fixation has previously been used as a reliable measure 
of overt attention towards or away from a social threat stimulus (Becker & Detweiler-
Bedell, 2009; Gamer et al., 2010; Garner et al., 2006). The latter authors argued that initial 
orienting to the eyes is relevant for not only adequate social information processing, but 
also for preparation of approach and avoidance behavior (Bradley, 2009). In our study, 
participants showed significant avoidance of the eyes of angry faces when compared to 
happy and neutral facial expressions. It is probable that they quickly detected the threat-
ening eyes of angry faces preceding their first avoiding eye movement upon stimulus 
onset (Armstrong & Olatunji, 2012; Becker & Detweiler-Bedell, 2009; Garner et al., 2006). 
This behavior can be defined as gaze avoidance (i.e., the prevention of threatening eye 
contact by avoiding to directly gaze at the dominant threat), and is in concurrence with 
the hypervigilance-avoidance theory (Bögels & Mansell, 2004). Most importantly, in our 
sample we see the clinical relevance of first fixations on the eye-region in patients with 
SAD confirmed by the correlation between this measure and the severity of anxiety 
symptoms in the placebo condition: increased social anxiety scores were associated with 
reduced initial fixations on the eyes of the facial stimuli in patients with SAD and not in 
HC. This finding concurs with literature that shows that gaze avoidance of eye contact is a 
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typical feature of SAD, and is related to symptom severity (Clark & Wells, 1995; Moukheiber 
et al., 2010, 2012; Stein & Stein, 2008). Our finding that testosterone specifically affects 
the first fixation, and decreases the amount of eye-area avoiding eye movements (by 
enhancing the amount of first fixations towards the eyes), is in agreement with literature 
that suggests that testosterone biases the brain towards social dominance by influencing 
early automatic mechanisms (Bos et al., 2012; Radke et al., 2015; Terburg & van Honk, 
2013). Moreover, this finding is in line with earlier findings showing that testosterone 
influences actual social motivational behavior. In healthy females testosterone promotes 
relative increase of threat approach action tendencies (Enter et al., 2014) and increases 
social dominant gaze behavior by prolonging stares into the eyes of angry faces (Terburg 
et al., 2012). We extend these findings by showing that testosterone administration also 
leads to a reduction of submissive gaze avoidance of angry eye contact in participants 
who suffer from social anxiety disorder.
This behavior is likely caused by the influence of testosterone on the neural pathways 
that mediate automatic motivational tendencies. Testosterone affects the amygdala 
and connected frontal-striatal circuits (Hermans et al., 2008; Radke et al., 2015), which 
typically show altered functioning in SAD (Fouche et al., 2013). Interestingly, reduced 
striatal dopamine (D2) receptor binding is related to subordinate social status in female 
Cynomolgus monkeys (Grant et al., 1998) and similarly, deviating striatal functioning has 
also been found in SAD (Freitas-Ferrari et al., 2010). It is known that testosterone enhances 
dopamine levels in the ventral striatum (de Souza Silva et al., 2009), which in turn can 
lead to increased reward sensitivity and augmented motivational behavior (Cools, 2008; 
Enter, Colzato, & Roelofs, 2012). Interestingly, and in line with the current findings in SAD, 
effects of testosterone administration on striatal functioning have previously been found 
to be particularly pronounced in individuals who are scoring low on reward-seeking 
behavior (Hermans et al., 2010). This may suggest that the dominance enhancing effect 
of testosterone in the current study is related to increased reward sensitivity. An increase 
in eye-contact may lead to an encounter with a possibly rewarding outcome, such as 
increased social status and its benefits. Indeed, it has been shown that the reward value 
of a stimulus has an effect on eye-movements: humans automatically orient their eyes 
towards potentially rewarding stimuli (Hickey, Chelazzi, & Theeuwes, 2010; Hickey & van 
Zoest, 2012). Hence, it could be that testosterone increases the reward-sensitivity of the 
socially submissive individual, which leads to augmented behavioral responses towards 
a potentially rewarding stimulus; in this case in increased first fixations to the eyes of 
facial stimuli (Bos et al., 2012; van Honk et al., 2004). In addition, the behavioral effects 
of testosterone may also be influenced by anxiolytic processes via glucocorticoid path-
ways, steroid receptors, and gamma-aminobutyric acid (GABA) receptors (e.g., Terburg 
& van Honk, 2013). Future studies combining testosterone administration, eye tracking 
and neuroimaging techniques should elucidate the neuroendocrine mechanisms in the 
Testosterone alleviates gaze avoidance
85
gaze enhancing effect of testosterone in SAD and the extent to which such effects could 
reflect or are mediated by anxiolytic processes.
In contrast to the SAD group, the healthy controls showed a tendency towards dimin-
ished first fixations on the eye-region of facial expressions. This finding is consistent with 
earlier studies showing a testosterone-induced reduction in social cognition: after testos-
terone administration healthy female participants showed less facial mimicry - which is 
a measure of empathy - of angry and happy facial expressions (Hermans, Putman, & van 
Honk, 2006), reduced conscious recognition of angry faces (van Honk & Schutter, 2007), 
and decreased performance on the Reading the Mind in the Eye Task (RMET), which as-
sesses the ability to infer the mental state of another by reading subtle cues expressed 
by the eyes (van Honk, Schutter, et al., 2011). In addition, reduced eye-contact has been 
associated with a decline in empathy (Cowan, Vanman, & Nielsen, 2014). Together, these 
findings concur with the notion that testosterone promotes approach motivation in 
order to facilitate self-oriented dominance seeking behavior (Bos et al., 2012).
The differential findings for patients and controls are in line with literature that sug-
gests that social context determines how testosterone affects social status (i.e., social 
reward) promoting behavior (Eisenegger et al., 2011; Terburg & van Honk, 2013; van 
Honk, Terburg, & Bos, 2011). Both the social environment and individual differences have 
been shown to influence the modulatory effects of testosterone (Mehta & Josephs, 2010). 
Concerning the latter, van Honk and colleagues (van Honk, Schutter, et al., 2011) found 
that the quantity of prenatal testosterone exposure predicted the effects of administered 
testosterone on cognitive empathic ability in adult participants. Similarly, social anxiety 
seemed to modulate the effects of both endogenous and exogenous testosterone on 
behavioral responses towards social dominance threat (Enter et al., 2014; Maner et al., 
2008). Therefore, it is not curious that our study, which entails two disparate groups of 
participants, finds differential effects of testosterone on gaze behavior towards the eye-
region of emotional faces. Future research should address the mechanisms underlying the 
differential effects of testosterone on gaze behavior in healthy controls and participants 
with SAD.
A few interpretational issues should be discussed with regard to the present find-
ings. First, one might perceive the result in the healthy controls (i.e., a tendency towards 
diminished first fixations towards angry eyes) to be in conflict with a study by Terburg and 
colleagues (2012), who showed that testosterone administration in healthy females pro-
longs dominant staring into the eyes of angry faces. However, the two studies probably 
captured two different types of subordinate gaze behavior (Terburg, Aarts, & van Honk, 
2012b), namely gaze aversion (i.e., rapid breaking of eye-contact with a more dominant 
conspecific, and thus signaling submission and ending the threatening encounter; (Ter-
burg et al., 2012), versus gaze avoidance (i.e., the prevention of threatening eye contact 
by avoiding to directly gaze at the dominant threat in the first place) in the present study. 
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Crucially, we show that this type of subordinate gaze behavior is also affected by testos-
terone administration; hence presenting the first evidence that testosterone diminishes 
not only submissive gaze aversion in healthy participants (Terburg et al., 2012), but also 
submissive gaze avoidance in socially anxious individuals. In addition, we show that 
the effect of testosterone on gaze avoidance is context dependent and only present in 
individuals featured by clinical avoidance behavior. Second, our findings were specific 
for the first fixations, whereas the gaze variables during the total stimulus presentation 
time were not affected by testosterone. This finding concurs with literature that suggests 
that testosterone biases the brain towards social dominance by influencing automatic 
processes (e.g., Terburg & van Honk, 2013). In addition, this early automatic measure is 
probably less vulnerable to other influences, such as effects of top-down control, fatigue, 
and repetition than the later measures. More research is required to test the specificity 
of the effects of testosterone for initial gaze behavior. Third, in contrast to our hypothesis 
the gaze avoidance alleviating effect of testosterone was not specific for angry faces. 
Nevertheless, although the Treatment x Group effect did not interact with Emotion, sepa-
rate analyses revealed that the Treatment x Group effect was only significant for angry 
faces and did not hold when testing this effect for happy or neutral faces in isolation. 
These results show that the alleviating effect of testosterone on gaze avoidance in SAD 
patients compared to healthy controls also holds for angry faces, although this effect is 
not specific for angry faces. Fourth, we found no group-effect in initial gaze-avoidance 
in the placebo condition (see also Moukheiber et al., 2010, 2012). However, avoidance 
for angry versus neutral and happy faces was found across groups and replicated in the 
SAD group. Most interestingly, gaze-avoidance in the placebo condition was significantly 
associated with social anxiety levels in SAD patients but not in healthy participants. These 
findings suggest that gaze avoidance was uniquely related to the symptom severity in 
SAD patients and future research using larger groups is needed to determine whether 
initial gaze avoidance is a specific trait for SAD. Finally, only female participants were 
tested in this study, which was a consequence of the testosterone administration method 
(Tuiten et al., 2000). Future research should not only replicate these results in larger fe-
male samples, but also should investigate whether testosterone administration to men 
has similar effects, as suggested by similarities in social behavior related to endogenous 
and exogenous testosterone across sexes (Goetz et al., 2014; Hermans et al., 2008). In 
addition, as is customary with this testosterone administration paradigm, we aimed to 
control for steroid hormone level fluctuations associated with the menstrual cycle by 
including women on single-phase contraceptives, and naturally cycling women who 
were tested in the preovulatory phase (e.g., Hermans et al., 2010; van Honk, Schutter, et al., 
2011). Although the effects of testosterone on first fixations remained while statistically 
controlling for contraceptive use, future studies ideally control for hormone fluctuations 
by only testing participants who are on single-phase contraceptives, or by directly assess-
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ing estradiol levels, especially given the evidence that this hormone possibly mediates 
testosterone-effects on social dominance (Terburg & van Honk, 2013; Ziomkiewicz, Wich-
ary, Gomula, & Pawlowski, 2015).
In terms of clinical implications, the present results may encourage further inves-
tigation of whether testosterone could have clinical utility in the treatment of SAD. 
Forty to 50% of patients does not benefit from current evidence based psychological 
and pharmacological treatments (Hofmann & Bögels, 2006; Stein & Stein, 2008), and 
improving therapy efficacy by pharmacological enhancement seems a promising new 
venue (Hofmann et al., 2014; Singewald et al., 2015). Testosterone acts on the social 
motivational system and enhances social approach motivation while reducing social fear 
and avoidance in a socially challenging environment (Enter et al., 2014). Thus, it may be 
worthwhile to further explore whether testosterone can act as an adjunct in exposure 
therapies, where boosting prosocial behavior in the first few sessions is essential for 
therapy outcome. Nevertheless, it should be noted that there is still much unclear about 
the working mechanisms of testosterone and of pharmacological add-ons for exposure-
based therapy. It is possible that, besides the potentially beneficial effects of testosterone 
on dopamine transmission, its effects on the GABA system might not only work anxiolytic 
but could also potentially interfere with extinction learning, something worth investigat-
ing in future research (Singewald et al., 2015).
In conclusion, a single dose administration of testosterone alleviates gaze avoidance 
by increasing initial gaze towards the eye-region of facial expressions in participants with 
Social Anxiety Disorder. These findings support the role of testosterone in dominance-
enhancing behavior and suggest need for study of testosterone administration as a 
means to enhance therapy efficacy in Social Anxiety Disorder.
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Supplemental Information
Supplemental methods
Table S6.1. Additional characteristics for the Healthy Control (HC) group and the combined group of participants with 
syndromal and sub-syndromal Social Anxiety Disorder (SAD).
HC (n = 19) SAD (n = 18) t(35) p-Value
SPAI social phobia 47.6 (26.5) 120.4 (22.7) -8.96 <.001
SPAI agoraphobia 10.9 (10.1) 23.6 (10.8) -3.67 .001
SPAI difference 36.6 (22.1) 96.9 (19.9) -8.68 <.001
Data are presented in mean and standard deviation. Abbreviations: SPAI, Social Phobia and Anxiety Inventory.
Table S6.2. Characteristics for the Healthy Control (HC) and the group with syndromal Social Anxiety Disorder (SAD).
HC (n = 19) SAD (n = 13) t(30) p-Value
Age (years) 25.2 (4.0) 23.0 (4.7) 1.34 .162
LSAS anxiety 9.5 (7.2) 42.7 (6.8) -13.10 <.001
LSAS avoidance 7.8 (6.3) 35.6 (8.5) -10.65 <.001
LSAS total 17.3 (12.9) 78.3 (14.3) -12.53 <.001
SPAI social phobia 47.6 (26.5) 128.2 (20.0) -9.29 <.001
SPAI agoraphobia 10.9 (10.1) 26.8 (10.1) -4.34 <.001
SPAI difference 36.6 (22.1) 101.4 (20.0) -8.45 <.001
BDI 2.5 (2.2) 18.5 (12.3) -4.66 <.001
Data are presented in mean and standard deviation. Abbreviations: LSAS, Liebowitz Social Anxiety Scale; SPAI, 
Social Phobia and Anxiety Inventory; BDI, Beck Depression Inventory.
Supplemental results
Checks for confounding factors
To check whether the effects of testosterone on the percentage first fixations was af-
fected by testing order or by time of testing (i.e., testing session starting at either 930h or 
1330h), we added these variables as between-subjects factors in separate analyses to the 
three-way rmANOVA with Treatment (placebo, testosterone) and Emotion (angry, happy, 
neutral) as within-subject factors, and Group (HC, SAD) as between-subjects factor. This 
analysis showed that the critical Treatment x Group interaction remained significant in 
both cases: when including the SAD (combined) group (Order: F(1,34) = 7.65, p = .009, 
ηp2 = .184, and Time: F(1,34) = 6.33, p = .017, ηp2 = .157), and when including the SAD 
(syndromal) group (Order: F(1,29) = 8.67, p = .006, ηp2 = .230, and Time: F(1,29) = 7.00, p = 
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.013, ηp2 = .194). Furthermore, to rule out the possibility that fluctuating hormone levels 
over the menstrual cycle would account for the observed effects, we checked whether 
the Treatment x Group interaction remained in the subgroup using single-phase contra-
ceptives, which was the case, both when including the SAD (combined) group (F(1,24) = 
5.76, p = .025, ηp2 = .193) and when including the SAD (syndromal) group (F(1,19) = 7.85, 
p = .011 ηp2 = .292).
Table S6.3. First fixation duration (ms ± SEM) on the eyes and offset time of first fixations (ms ± SEM) for angry, happy, 
and neutral facial expressions after administration of placebo and testosterone for Healthy Control participants (HC, n = 
19) and the combined group of participants with syndromal and sub-syndromal Social Anxiety Disorder (SAD, n = 18).
Emotion
HC SAD
Placebo Testosterone Placebo Testosterone
First fixation duration
Angry 364 (36) 330 (24) 324 (26) 306 (33)
Happy 436 (62) 376 (31) 377 (39) 325 (21)
Neutral 379 (36) 360 (30) 365 (27) 322 (27)
First fixation offset time
Angry 323 (14) 323 (14) 330 (15) 312 (16)
Happy 326 (15) 336 (14) 336 (16) 312 (16)
Neutral 325 (15) 332 (12) 341 (16) 312 (15)
Table S6.4. Percentage fixations (percentage ± SEM) on the eyes and duration of fixations (ms ± SEM) on the eyes for 
the total stimulus presentation time for angry, happy, and neutral facial expressions after administration of placebo and 
testosterone for Healthy Control participants (HC, n = 19) and the combined group of participants with syndromal and 
sub-syndromal Social Anxiety Disorder (SAD, n = 18).
Emotion
HC SAD
Placebo Testosterone Placebo Testosterone
% fixations
Angry 32 (3) 31 (3) 27 (4) 27 (4)
Happy 35 (4) 34 (3) 30 (4) 29 (4)
Neutral 37 (3) 36 (3) 32 (4) 31 (4)
Fixation duration
Angry 360 (19) 360 (20) 350 (16) 327 (18)
Happy 358 (20) 367 (20) 361 (19) 338 (17)
Neutral 361 (23) 362 (16) 357 (17) 336 (19)
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Table S6.5. Total number of fixations (count ± SEM) and total dwell time (ms ± SEM) for the total stimulus presentation 
time for angry, happy, and neutral facial expressions after administration of placebo and testosterone for Healthy Control 
participants (HC, n = 19) and the combined group of participants with syndromal and sub-syndromal Social Anxiety 
Disorder (SAD, n = 18).
Emotion
HC SAD
Placebo Testosterone Placebo Testosterone
Total number of fixations
Angry 261 (17) 276 (13) 270 (12) 279 (17)
Happy 262 (14) 265 (14) 163 (13) 281 (19)
Neutral 265 (14) 267 (14) 265 (13) 281 (17)
Total dwell time
Angry 82 (5) 88 (3) 86 (4) 85 (5)
Happy 84 (5) 87 (4) 85 (4) 86 (5)
Neutral 84 (4) 86 (4) 87 (3) 86 (5)
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Abstract
Testosterone plays an important role in social threat processing. Recent evidence 
suggests that testosterone administration has socially anxiolytic effects, but it remains 
unknown whether this involves early automatic or later, more controlled, processing-
stages. We investigated the acute effects of testosterone administration on social threat 
processing in 19 female patients with Social Anxiety Disorder (SAD) and 19 healthy 
controls. Event-related potentials (ERPs) were recorded during an emotional Stroop task 
with subliminally presented faces. Testosterone induced qualitative changes in early ERPs 
(<200 ms after stimulus onset) in both groups. An initial testosterone-induced spatial 
shift reflected a change in the basic processing (N170/VPP) of neutral faces, which was 
followed by a shift for angry faces suggesting a decrease in early threat vigilance. These 
findings suggest that testosterone specifically affects early automatic social information 
processing. The decreased vigilance for angry faces explains how testosterone can de-
crease threat avoidance, which is particularly relevant for SAD.
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Introduction
Testosterone has an important role in the regulation of social motivational behavior. 
A surge in testosterone has anxiolytic effects and facilitates social dominance and ap-
proach behavior in socially challenging situations (Archer, 2006; Bos et al., 2012; Terburg & 
Van Honk, 2013). Especially an angry looking face with direct gaze is perceived as a signal 
of social threat, as it can signal an impending aggressive encounter (Öhman, 1986). In 
line with this notion, recent single dose administration studies show that testosterone 
promotes approach action tendencies to angry faces on a social approach-avoidance 
task (Enter, Spinhoven, & Roelofs, 2014, 2016). In addition it facilitated socially dominant 
gaze behavior as indicated by increased fixation to the eyes of angry faces (Enter et al., 
2016; Terburg et al., 2016; Terburg et al., 2012).
At the neural level, testosterone has been found to enhance the reactivity of the 
amygdala towards angry facial expressions (Goetz et al., 2014; Hermans et al., 2008), and 
to reduce its connectivity with circuits involving the orbitofrontal or prefrontal cortex, 
thalamus, brainstem, and striatum (van Wingen et al., 2010; Volman, Toni et al., 2011). 
However, using a social approach-avoidance task, in which angry and happy faces have to 
be approached or avoided by pulling or pushing a joystick, Radke and colleagues (2015) 
showed that testosterone increased amygdala responses specifically during approach of 
angry faces, but decreased amygdala responses during angry face avoidance, suggesting 
that testosterone modulates social threat processing in a motivation-specific manner. 
However, little is known about the temporal dynamics of these effects, and it remains 
unknown whether they involve early automatic or later, more controlled, stages of social 
threat processing. Gaining insight into these processes would be of particular interest for 
Social Anxiety Disorder (SAD), as this frequent and persistent disorder is characterized by 
increased early automatic vigilance and biased goal-directed processing of social threat 
(for reviews see e.g., Bar-Haim, Lamy, Pergamin, Bakermans-Kranenburg, & van IJzendoorn, 
2007; Gilboa-Schechtman & Shachar-Lavie, 2013; Staugaard, 2010) as well as by decreased 
salivary levels of basal testosterone (Giltay et al., 2012).
In the current study we therefore investigate the effects of testosterone on social 
threat processing in participants with SAD and healthy participants, using temporally 
fine-grained recordings of the event-related brain potentials (ERPs) during an emotional 
Stroop task with subliminally presented angry, happy and neutral faces. We performed 
a spatiotemporal clustering analysis (Brunet, Murray, & Michel, 2011; Murray, Brunet, & 
Michel, 2008) on the ERPs, as this method has several advantages compared to conven-
tional ERP amplitude analyses. Most importantly, it can tease apart the following two ERP 
effects: 1) topographic modulations, which reflect a change in neural sources, indicating 
the activation of different cognitive processes (a qualitative change in processing), and 
2) amplitude modulations, which, in absence of a concurrent topographic modulation, 
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reflect increases or decreases in response strength of a common cognitive process (a 
quantitative change in processing) (see e.g., Murray et al., 2008; Pourtois, Delplanque, Mi-
chel, & Vuilleumier, 2008). Furthermore, this method may be more sensitive in detecting 
differences between groups or task conditions (Murray et al., 2008), as it includes the full 
range (instead of only a limited number) of channels and time windows, and it can detect 
topographic changes even when amplitude is low. Particularly for pharmacological inter-
ventions like testosterone, which modulates multiple parts of the emotion circuitry (see 
e.g., Bos et al., 2012; van Wingen et al., 2010), effects are unlikely to be bound to single 
ERP peaks.
Based on previous EEG studies showing increased amplitudes for subliminally pre-
sented angry (compared to neutral) faces especially on early ERP components such as 
the frontocentral P2 or VPP, the N2, and the EPN (Balconi & Lucchiari, 2005, 2007; van Peer 
et al., 2010) we expected increased processing of angry faces in the early (<250 ms) time 
window. Some studies with supraliminal stimuli suggest that this effect may be amplified 
in socially anxious compared to non-anxious participants, but overall electrophysiologi-
cal evidence for hypervigilance to social threat in social anxiety is still inconsistent (see 
Schulz, Mothes-Lasch, & Straube, 2013 for a review).
Most importantly, based on the social-anxiolytic and approach-promoting effects of 
testosterone (Archer, 2006; Terburg & Van Honk, 2013) we expected that testosterone ad-
ministration compared to placebo would reduce processing of angry versus neutral and 
happy faces, particularly in SAD patients who are characterized by a social threat bias as 
well as lower endogenous testosterone levels. Finally, based on behavioral findings sug-
gesting that effects of testosterone are most pronounced for preconscious processing of 
threat (Van Honk et al., 2000) we hypothesized that these effects may be predominantly 
manifested in the early automatic processing stages.
Methods
Participants
Participant characteristics are presented in Table 7.1. Participants for the Social Anxi-
ety Disorder (SAD) group were recruited from outpatient anxiety departments of mental 
health centers, through advertisements on the internet, and in local newspapers. Inclu-
sion criterion was a total score of > 60 on the Liebowitz Social Anxiety Scale (Liebowitz, 
1987; Rytwinski et al., 2009). In addition these participants were screened with the Mini 
International Neuropsychiatric Interview script (M.I.N.I.; Lecubier et al., 1997) to verify the 
DSM-IV diagnosis of generalized Social Anxiety Disorder. One participant (LSAS score 56) 
scored just below the LSAS cutoff but was included as she did fulfill the DSM-IV diagnostic 
criteria. Healthy control (HC) participants were recruited via advertisements in community 
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centers, on the internet, and in local newspapers. Only female participants were included, 
because the parameters (e.g., dose and time course) for inducing neurophysiological ef-
fects in men with a single dose administration of testosterone are as yet unknown (Tuiten 
et al., 2000). Both women using single-phase contraceptives and normally cycling women 
participated in the study. All participants had normal or corrected-to-normal vision. Exclu-
sion criteria were age < 18 and > 50, use of (psychotropic) medication, somatic illnesses, 
neurological conditions, recent or past psychiatric problems (HC only), psychotic disorder, 
history of head injury, left-handedness, peri- or postmenopause, and pregnancy or breast 
feeding. Initially, 24 participants were included in each group. However, as these groups 
differed significantly in age (F(1,46) = 12.59, p =.001, ηp2 = 0.21), and there is no appropriate 
method to statistically control for such an effect in the analyses (Miller & Chapman, 2001), 
a subset of 19 SAD and 19 HC participants (age F(1,36) = 2.78, p = .104, see table 7.1) was 
selected on basis of matching for age (Field, 2009; see also Enter, Terburg, et al., 2016). 
Thirteen of the 19 SAD participants met full DSM-IV criteria for generalized SAD at the 
time of testing; the other five had sub-syndromal SAD (i.e., they fulfilled all criteria at 
the telephone screening but the symptoms did no longer lead to significant burden in 
social or occupational functioning [DSM-IV criterion IV] at time of testing). All participants 
provided written informed consent, and received financial compensation. The study was 
approved by the Medical Ethics Committee of the Leiden University Medical Centre, and 
was in accordance with the declaration of Helsinki.
Table 7.1. Group Characteristics.
Variable HC (n = 19) SAD (n = 19) p-Value
Order (testosterone first) n = 8 n =11 .330
Age 25.3 (4.1) 23.0 (4.5) .104
LSAS social anxiety 9.4 (7.1) 43.2 (6.7) <.001
LSAS avoidance 7.7 (6.2) 37.0 (7.8) <.001
LSAS total 17.1 (12.8) 80.2 (13.5) <.001
SPAI social phobia 47.6 (26.6) 122.6 (23.4) <.001
SPAI agoraphobia 10.9 (10.1) 23.5 (10.2) .001
SPAI difference 36.7 (22.2) 99.2 (21.5) <.001
BDI 2.5 (2.2) 14.7 (11.9) <.001
Note. Data are presented in mean and standard deviation. Abbreviations: HC, Healthy Controls; SAD, Social Anxiety 
Disorder; LSAS, Liebowitz Social Anxiety Scale; SPAI, Social Phobia and Anxiety Inventory; BDI, Beck Depression 
Inventory. P-values indicate group differences.
Testosterone Administration
In a double-blind, randomized, placebo-controlled, cross-over design participants 
received a single dose of 0.5 mg testosterone suspended in a clear solution (0.5 ml) with 
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0.5 mg hydroxypropyl-beta-cyclodextrin, 0.005 ml ethanol 96%, and distilled water. The 
matched placebo contained the same ingredients, except for the testosterone. Partici-
pants were asked to hold the liquid under their tongue for 60 s. The order of placebo and 
testosterone administration was counterbalanced across subjects and groups (see Table 
1). In females, this dose yields a sharp increase of 20–25 nmol/l in plasma testosterone 
levels within 15 min, which declines to baseline levels within the next 90 min (van Rooij 
et al., 2012). Previous research applying this procedure (see Bos et al., 2012 for a review; 
Eisenegger, Naef, Snozzi, Heinrichs, & Fehr, 2010; Enter et al., 2014; Enter, Spinhoven, et al., 
2016; Enter, Terburg, et al., 2016; Tuiten et al., 2000) has convincingly shown consistent 
psychophysiological and behavioral effects approximately 4–6 h after administration, 
therefore this time interval was also applied in the current study.
Procedure
Participants were tested individually at two identical testing sessions with two days 
in between. Testing sessions started at either 09:30 or 13:30 h, on the same time at both 
sessions. Five hours after testosterone or placebo intake, participants were seated in a 
dimly lit and sound attenuated room, where they performed the Emotional Stroop Task 
while EEG was recorded simultaneously. Between testosterone or placebo intake and the 
Emotional Stroop task, participants had a two hour resting period in a private recreation 
room (without television or internet access) where they could read and rest, followed 
by a standard lunch and several unrelated tasks of which the results will be reported 
elsewhere (i.a., Enter et al., 2014; Enter, Spinhoven, et al., 2016; Enter, Terburg, et al., 2016).
Emotional Stroop Task
Face stimuli were selected from the Pictures of Facial Affect (Ekman & Friesen, 1976) 
and the Karolinska Directed Emotional Faces (Lundqvist et al., 1998) databases. Angry, 
happy, and neutral facial expressions were taken from the same model (four male and 
four female models), cut out in an oval shape to remove distracting features, gray-scaled, 
and presented with a red, green or blue filter on a black background. Masking stimuli 
consisted of oval configurations of randomly cut and reassembled fragments of face 
stimuli (Van Honk et al., 1998). The total stimulus set consisted of 72 target face stimuli (8 
actors x 3 expressions x 3 colors) and 6 masks (2 versions x 3 colors) (see also van Peer et 
al., 2010b). Stimulus presentation and response logging were controlled using E-prime 
software, a Serial Response Box (Psychology Software Tools, inc.) and a custom-made 
manual response box.
Participants started with a practice block of nine trials in which only masks were 
presented. Next, they completed the 72 randomized trials. Each trial started with a 750 
ms fixation cross, followed by a very brief (16.7 ms, 2 frames at 120 Hz) exposure to a 
target face, which was replaced by a mask of the same color. Participants were instructed 
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to categorize this color as fast as possible by pressing the corresponding button, and 
their response triggered offset of the masks. New trials started after a random inter-trial 
interval of 2-4 s.
Incorrect responses were excluded from the analyses. Reaction time (RT) outliers 
were filtered using a < 200 and > 1300 ms cut-off, and subsequently all RTs exceeding 2.5 
SD from the individual participants’ mean were removed. These trials were also excluded 
from the EEG analyses. Of the remaining latencies (HC: 94%, SAD: 95%), the means were 
calculated per group and condition and log-transformed because of a skewed distribu-
tion.
To determine whether participants were capable of consciously perceiving the 
masked facial expressions, they were asked to complete an awareness check at the end 
of the second testing session (see Supplemental Information).
Electrophysiological Recording and Analyses
The EEG was recorded at 512 Hz with an Active-Two system (BioSemi, Amsterdam, 
The Netherlands) from 32 active electrodes referenced to an active common mode 
sense and with a passive driven right leg ground electrode. All electrodes were mounted 
in an elastic cap and distributed over the head surface according to the international 
extended 10–20 system. Horizontal and vertical EOGs were recorded using four bipolar 
electrodes placed on the outer canthi of the eyes and in the inferior and superior areas of 
the left orbit. Signals were processed offline using Brain Vision Analyzer software (Version 
2.1). Bad EEG channels were interpolated using a topographic interpolation (maximum 
three channels for each individual data set, M = 0.29, SD = 0.57). Subsequently, EEG data 
were re-referenced to an average reference, filtered with a 0.1-Hz high-pass filter (24 db/
oct), and epoched from 200 ms before until 800 ms after stimulus onset. After baseline 
correction on the pre-stimulus interval, data were corrected for the effects of eye blinks 
and eye movements using a standard procedure (Gratton, Coles, & Donchin, 1983), and 
epochs containing artifacts (amplitude values > 100 or < -100 μV, a difference of 150 
μV between the lowest and the highest amplitude within 200 ms, a difference > 75 μV 
between two subsequent sampling points, or a period of 100 ms with activity < 0.50 μV), 
were removed. Finally, data were averaged to individual ERPs for each facial expression 
type (happy, angry, and neutral, M = 21.5, SD = 1.7 trials per category), excluding trials 
with incorrect responses or outlier RTs (see RT analyses in section 2.4). See Supplemental 
Information for an overview of the number of remaining trials and grand average ERPs per 
group and condition. The data of two participants (one HC and one SAD) were excluded 
because of an excessive number of artifacts (< 15 trials left in one or more conditions), 
resulting in 36 participants (18 HC, 18 SAD) for the statistical analyses.
Spatiotemporal Clustering Spatiotemporal clustering analysis was performed using 
the Cartool software by Denis Brunet (version 3.53, brainmapping.unige.ch/cartool, 
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Brunet et al., 2011) to identify dominant topographic maps of the scalp electric field in 
the grand-averaged ERP data, and to compare the expression of these maps over time 
and across groups and experimental conditions. Each topographic map, which usually 
remains stable for several tens of milliseconds, has been proposed to reflect a period of 
coherent synchronized activation of large-scale neural networks (functional microstate, 
see e.g., Lehmann, 1987). Different topographic maps reflect the activation of different 
neural networks or microstates (e.g., Michel, Seeck, & Landis, 1999), and the typical finding 
of a sequence of different maps is suggested to represent successive information pro-
cessing steps (see e.g., Lehmann, 1987). Segmentation of the post-stimulus time window 
was performed using the Topographic - Atomize and Agglomerate Hierarchical Cluster-
ing (T-AAHC) procedure, with rejection of segments smaller than 4 time frames (~ 8 ms) 
and merging of clusters that correlated above 0.92. The optimal spatiotemporal solution 
explaining the whole data set was determined by using an objective cross-validation 
(CV) and modified Krzanowski-Lai (KL) criterion (Pascual-Marqui, Michel, & Lehmann, 
1995). The resulting dominant topographic maps (see Figure 1) were fitted back to the 
individual average ERPs, using a noncompetitive spatial fitting procedure with rejection 
of segments < 4 time frames. This procedure provides a quantitative value (the global 
explained variance [GEV], reflecting the goodness of fit) for the representation of each 
map across participants and conditions. The maps were fitted within four different time 
intervals, based on the conventional time windows of the corresponding ERP compo-
nents (80-120 ms [P1, Map #2]; 120-200 ms [N170/VPP, Map #3 and #4]; 180-300 ms [P2, 
Map #5 and #6]; 275-800 ms [P3/LPP, Map#7 to #10]). The first map (Map #1, 0-80 ms) was 
excluded from the analyses, as the corresponding ERP component (C1) is known to be 
exogenous and pre-attentive (Pratt, 2011).
Global Field Power Changes in neural response strength were determined by calcu-
lating the global field power (GFP) with Cartool (Brunet et al., 2011). GFP is equivalent 
to the standard deviation of the scalp electric field, with large values corresponding to 
moments of high synchronized neural activity (e.g., Lehmann, 1987). For each participant 
and condition, mean GFP was calculated in three time intervals that were symmetrically 
centered around the peaks in the grand average (see Figure 3): 80-120 ms, 125-185 ms, 
and 215-275 ms. As for the spatiotemporal results, the first peak (~70 ms), corresponding 
to the C1 component, was excluded from the analyses.
Statistical Analyses
All data were analyzed with the Statistical Package for the Social Sciences (SPSS 
21) using repeated-measures analyses of variance (ANOVA) with Treatment (placebo, 
testosterone) and Valence (angry, happy, neutral) as within-subject factors, and Group 
(HC, SAD) as between-subjects factor. Separate ANOVAs were performed on each time 
interval of the spatiotemporal clustering and GFP data. The spatiotemporal clustering 
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analyses included the additional factor Map in case more than one map was present 
in the respective time interval. Significant interactions were followed by tests of simple 
effects with rmANOVA’s at each level of the relevant factors, to determine the nature 
of the interaction. Finally, several control analyses were conducted, first to check that 
the findings were not influenced by awareness of the subliminal stimuli, and second 
to check for the influence of possible confounding factors such as order of treatment, 
time of testing, or use of contraception. The results of these analyses are reported in the 
Supplemental Information, and did not differ notably from the results reported below. 
All statistical analyses used a two-tailed alpha of .05. Effect sizes of significant results are 
reported as the proportion of explained variance (partial eta squared [ηp2]).
Results
Behavioral Results
The response latencies for each group and condition are presented in Table 7.2. The 
statistical analysis revealed a significant main effect of Valence, F(2,72) = 3.34, p = .041, ηp2 
= .09. Post hoc pairwise comparisons indicated that, as expected, the response latencies 
were significantly slower for angry, F(1,36) = 4.64, p = .038, ηp2 = 0.11, and happy, F(1,36) = 
4.90, p = .033, ηp2 = 0.12, compared to neutral faces, suggesting an interference effect for 
emotional faces. Response latencies for happy and angry faces did not differ significantly, 
F(1,36) = 0.12, p = .73. In contrast to the EEG findings, the behavioral results showed no 
significant effects of Treatment or Group (all ps > .05).
Table 7.2. Mean (ms ± SEM) Color Naming Latencies.
Valence
HC (n = 19) SAD (n = 19)
Placebo Testosterone Placebo Testosterone
Angry 458 (14) 451 (15) 453 (14) 442 (15)
Happy 461 (15) 457 (16) 448 (15) 447 (16)
Neutral 451 (13) 435 (14) 448 (13) 437 (14)
Spatiotemporal Clustering
The spatiotemporal clustering procedure revealed ten distinct dominant field topog-
raphies (maps) that together explained 92% of the total ERP variance (see Figure 7.1A and 
B). Results of the subsequent spatial fitting procedure, reflecting the representation of 
these maps (in terms of global explained variance, GEV) across participants, conditions, 
and time, are reported below. We report only statistical results including interactions of 
Treatment or Group with Valence and Map, as these reflect the effects of interest of the 
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current study: Testosterone- or SAD-related topographic (i.e., qualitative) differences in 
emotion-related face processing. See Supplemental Information for additional results.
Effects of testosterone administration. In line with the hypothesis that testosterone 
affects early processing of emotional faces, the rmANOVA of GEV in the N170/VPP time 
interval (120-200 ms post-stimulus, Maps #3 and #4) showed a significant interaction of 
Treatment x Valence x Map, F(2,68) = 5.87, p = .004, ηp2 = 0.147 (see Figure 2). Follow-up 
analyses (i.e., rmANOVA Group x Treatment x Valence per map) revealed that the Treat-
ment x Valence interaction was significant for both maps (Map #3, F(2,68) = 3.61, p = 
.032, ηp2 = .096; Map #4, F(2,68) = 4.09, p = .021, ηp2 = .107). The first map (Map #3) reflects 
the typical spatiotemporal pattern of the N170/VPP component (see Figure 1C). Follow-
up tests per Valence for this map showed a significant effect of Treatment, reflecting a 
decrease in GEV after testosterone administration, compared to placebo, for neutral faces, 
F(1,34) = 6.84, p = .013, ηp2 = 0.167, and a trend in the same direction for happy faces, 
F(1,34) = 3.91, p= .056, ηp2 = .103, but not for angry faces, F(1,34) = 3.15, p = .579, ηp2 = 
.009. This finding suggests that testosterone administration resulted in a reduction of the 
representation (goodness of fit) of the N170/VPP pattern during neutral (and happy) but 
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Figure 7.1. Results of the T-AAHC Segmentation Procedure. a) and b) The sequence of 10 distinct topography so-
lutions are shown under GFP curves for both groups (HC left, SAD right) and all experimental conditions. Each color 
(and number) labels a period of distinct and stable electric field topography. Time 0 indicates onset of the face 
stimulus (16.7 ms) followed by a mask. c) Topographical properties of the 10 maps, with colors and numbers corre-
sponding to the segmentation in panel a and b. Maps are oriented with the nasion upward and left scalp leftward. 
Blue denotes negative and red positive scalp potentials. Of note: The timing and topography of these maps sug-
gest they correspond to the C1 (map #1, <80 ms), P1 (map #2, 80-120 ms), N170/VPP (map #3 and #4, 120-200 ms), 
occipital P2 (map #5 and #6, 180-300 ms), and P3/LPP (maps #7-10, 275-800 ms) ERP components, respectively.
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not angry face processing. The effect of Valence was not significant in either Treatment 
condition (placebo F(2,68) = 1.57, p = .22; Testosterone F(2,68) = 1.99, p = .14).
The second map in this time interval (Map #4), which has a relatively more positive 
occipito-parietal topography (see Figure 7.1C), reflects the activation of a different set 
of neural sources. In contrast to Map #3, post hoc analyses of the significant Treatment 
x Valence interaction for this map showed a significant effect of Valence in the placebo 
condition, F(2,68) = 3.61, p = .05, ε = 0.69, ηp2 = 0.10, but not in the testosterone condition, 
F(2,68) = 0.93, p = .40. In the placebo condition, GEV was significantly increased for angry 
compared to happy faces, F(1,34) = 7.21, p = .011, ηp2 = 0.175, whereas the difference 
between angry and neutral or happy and neutral faces were both nonsignificant (both ps 
> .05). Furthermore, follow-up tests by Valence showed that compared to placebo, testos-
terone administration selectively reduced the GEV for angry faces, F(1,34) = 7.12, p = .012, 
ηp2 = .173. The effect of Treatment was not significant for happy or neutral faces (both ps > 
.05). These findings suggest that this second configuration of neural activity (map #4) was 
activated mainly during the processing of angry faces in the placebo condition, possibly 
reflecting an initial threat bias, which disappeared after testosterone administration.
No significant interactions including Treatment and Valence were present in any of 
the other time intervals (80-120 ms, 180-300 ms, or 275-800 ms), suggesting that testos-
terone-induced qualitative changes in emotion-related face processing were limited to 
the N170/VPP processing stage.
Effects of SAD. No significant effects involving the factor Group were present in any 
of the time windows (all ps > .05), suggesting that there were no significant qualitative 
differences in emotion-related face processing between SAD and HC participants.
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Figure 7.2. Results of the Fitting Procedure. Global Explained Variance of map #3 and map #4 from 120-200 ms 
post-stimulus (corresponding to the time window of the N170/VPP) for the different experimental conditions, 
averaged over all participants. Results showed a significant interaction of Treatment x Valence x Map. *p < .05
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Global Field Power
Global Field Power was analyzed to test for differences in response amplitude be-
tween groups and conditions, independent of changes in topography. The means for the 
time intervals of interest are presented in Table 7.3. The results showed a trend towards 
a main effect of Group in the first time interval (80-120 ms), F(1,34) = 4.00, p = .054, ηp2 
= 0.105, suggesting that the P1 amplitude tended to be increased for SAD compared to 
HC participants, see Figure 3. No other effects reached significance, in any of the time 
intervals (all ps > .05).
Table 7.3. Means (± SEM) of the Global Field Power.
Time window
HC (n = 19) SAD (n = 19)
Valence Placebo Testosterone Placebo Testosterone
80-120 ms (P1) Angry 3.9 (0.2) 4.1 (0.2) 3.3 (0.2) 3.5 (0.2)
Happy 4.0 (0.2) 3.9 (0.2) 3.4 (0.2) 3.4 (0.2)
Neutral 4.1 (0.3) 3.8 (0.2) 3.3 (0.3) 3.5 (0.2)
125-185 ms (N170/VPP) Angry 4.5 (0.3) 4.5 (0.4) 4.4 (0.3) 4.6 (0.4)
Happy 4.6 (0.4) 4.5 (0.4) 4.4 (0.4) 4.5 (0.4)
Neutral 4.6 (0.4) 4.4 (0.4) 4.5 (0.4) 4.6 (0.4)
215-275 ms (P2) Angry 5.3 (0.5) 5.3 (0.5) 5.1 (0.5) 5.4 (0.5)
Happy 5.3 (0.6) 5.5 (0.6) 5.3 (0.6) 5.5 (0.6)
Neutral 5.6 (0.6) 5.2 (0.5) 5.1 (0.6) 5.5 (0.5)
Discussion
In this study we investigated the effects of single dose testosterone administration 
on social threat processing in socially anxious and non-anxious participants, by recording 
event-related brain potentials (ERPs) during an emotional Stroop task with subliminally 
presented angry, happy and neutral faces. The spatiotemporal clustering results show 
that testosterone selectively affects the early automatic processing of emotional faces, 
suggesting a reduced initial processing of neutral faces followed by a decreased process-
ing bias for angry faces, while leaving later processes (>200 ms) unaffected. These effects 
occurred independent of clinical status of the participants and will be discussed in detail 
below.
The time interval 120-200 ms post-stimulus showed two distinct topographic pat-
terns, which reflect the activity of different neural populations (e.g., Michel et al., 1999) 
and indicate the presence of two consecutive information processing steps (microstates, 
e.g., Lehmann, 1987). Both of these were affected by testosterone, but in a different man-
ner. The spatiotemporal characteristics of the first pattern correspond to the N170/VPP 
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ERP complex, which is considered to reflect the early stages of face perception and basic-
level categorization (see e.g., Rossion & Jacques, 2011). This pattern showed a significant 
reduction in global explained variance after testosterone administration, compared to 
placebo, for neutral faces, which suggests that testosterone changes the neural sources 
involved in the initial face perception process for neutral but not for angry faces.
The second topographic pattern (map #4), with a relatively more positive occipito-
parietal topography, reflects the subsequent activation of a different cognitive process. 
This finding is consistent with evidence suggesting that the N170/VPP complex on the 
scalp reflects the activity of multiple neural sources overlapping in time, and represents 
the intermixed processing of several sources of facial information, including not only 
basic structural but also high-level (e.g., expression, identity) features (Hinojosa, Mercado, 
& Carretie, 2015; Rossion & Jacques, 2011). These processes may not be distinguishable 
with traditional ERP amplitude measures, but can be teased apart by investigating 
topographic modulations (see e.g., Murray et al., 2008). Moreover, this second pattern 
was more pronounced during the processing of angry (compared to happy) faces in the 
placebo condition, suggesting that it may reflect an early processing bias for social threat. 
This is consistent with recent studies suggesting that the N170 time window is differen-
tially sensitive to emotional expressions, and most strongly responds to angry faces (see 
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Figure 7.3. Global Field Power (GFP) by Group. Values are averaged per Group (HC, Healthy Controls, n = 18; SAD, 
Social Anxiety Disorder, n = 18) over all experimental conditions (Treatment x Valence). Boxes indicate the time 
windows used for computing the averages for each ERP component: 80-120 ms (P1), 125-185 ms (N170/VPP), and 
215-275 ms (P2) post-stimulus.
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Hinojosa et al., 2015 for a meta-analysis). Some authors (e.g., Del Zotto & Pegna, 2015; 
Hinojosa et al., 2015) have suggested that this emotional modulation of the N170 may 
reflect emotional attention processes driven by the amygdala (see also Conty, Dezecache, 
Hugueville, & Grèzes, 2012), to allow for rapid responses to threat. Most interestingly, this 
angry face advantage disappeared after testosterone administration, which suggests that 
testosterone eliminated this early processing bias for social threat.
Taken together, our results reveal that testosterone differentially affects the process-
ing of threatening (angry) and non-threatening (neutral and happy) face stimuli in very 
early processing stages. These findings may reflect the neural processes underlying previ-
ous behavioral findings of threat-specific effects of testosterone (for a review see Bos et 
al., 2012). In particular, the testosterone-induced reduction in early threat vigilance may 
explain previous behavioral findings of anxiolytic-like, or approach promoting, effects. 
For example, studies in healthy participants have shown that testosterone administra-
tion reduced the attentional bias to fearful faces (Van Honk et al., 2005), as well as the 
conscious recognition (Van Honk & Schutter, 2007), behavioral avoidance (Enter et al., 
2014), and gaze aversion (Terburg et al., 2012) of angry faces. Testosterone was also found 
to decrease behavioral avoidance (Enter, Spinhoven, et al., 2016) and gaze aversion (Enter, 
Terburg, et al., 2016) in patients with SAD. In apparent contrast to these behavioral find-
ings, several fMRI studies have shown that testosterone increased amygdala responses 
during the processing of angry faces (Goetz et al., 2014; Hermans et al., 2008). However, 
using an approach-avoidance task, Radke et al. (2015) showed that such increased amyg-
dala responses were specifically related to threat approach behavior, while testosterone 
decreased amygdala responses during threat avoidance. Thus, the effects of testosterone 
on amygdala activity appear to be context-dependent. Based on these findings, and in 
line with the behavioral findings described above, it was suggested that, by modulat-
ing amygdala responses, testosterone biases humans toward approach, and away from 
avoidance, of social threat (Radke et al., 2015; see also Enter et al., 2014; Enter, Spinhoven, 
et al., 2016). Our findings are in line with such an approach promoting or threat reduc-
ing effect of testosterone, and suggest that testosterone-induced modulations of neural 
activity may happen already, and predominantly, during the earliest stages of angry face 
processing. More research is needed to directly investigate the relation between spatial 
and temporal effects of testosterone on neural activity (e.g., combined fMRI and EEG), and 
how these relate to behavior, including the role of motivational context.
In addition to these effects of testosterone, our results showed a marginally sig-
nificant group difference in Global Field Power, reflecting stronger early (80-120 ms post 
stimulus) neural responses for SAD compared to HC participants. This is consistent with 
the increased P1 amplitude in high socially anxious participants reported in some previ-
ous ERP studies (Peschard, Philippot, Joassin, & Rossignol, 2013; Rossignol, Campanella, 
Bissot, & Philippot, 2013; Rossignol, Philippot, Bissot, Rigoulot, & Campanella, 2012), which 
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has been suggested to reflect a general hypervigilance to face stimuli. However, we did 
not find group differences in the processing of angry faces (see also Mühlberger et al., 
2009, but cf. Kolassa & Miltner, 2006; Schulz et al., 2013), or enhanced amplitudes for 
angry compared to neutral or happy faces (cf., Balconi & Lucchiari, 2005, 2007; van Peer 
et al., 2010). Overall, ERP evidence for hypervigilance to social threat in social anxiety is 
still rather inconsistent (see Schulz et al., 2013 for a review). This may be partly due to 
limitations of the conventional ERP analysis method, such as the inability to differentiate 
between amplitude and topographic changes (quantitative and qualitative changes, see 
e.g., Murray et al., 2008), a strong reference-dependence (Murray et al., 2008; Rellecke, 
Sommer, & Schacht, 2012), and a small (and often different) selection of electrodes and 
time windows that are included in the analyses. These limitations can be overcome by 
using reference-free multichannel spatiotemporal clustering methods (e.g., Michel et al., 
1999; Murray et al., 2008; Pourtois et al., 2008) as was done in the present study. It would 
be recommendable for future research to include similar measures to produce more ro-
bust findings and further elucidate the nature of social threat processing in SAD and HC.
On a behavioral level, color naming latencies were significantly slower for angry and 
happy compared to neutral faces, reflecting the typical Emotional Stroop interference-
effect (see e.g., Bar-Haim et al., 2007). In contrast to the ERP findings there were no group 
or treatment effects on this measure, which is not uncommon (although cf. Van Honk et 
al., 2005). Previous studies have reported significant effects on early ERPs in the absence 
of behavioral effects with supraliminal (Kolassa & Miltner, 2006; van Peer et al., 2010b) as 
well as subliminal task versions (van Peer et al., 2010). It has been suggested that reac-
tion times in the Emotional Stroop paradigm result from later processes than attentional 
capture (see e.g., Bar-Haim et al., 2007), which can explain why they do not reflect the 
changes in early automatic processing that we found in our ERP measures.
Finally, a few limitations of this study should be discussed. First, as is common in 
testosterone administration studies, only female participants were tested because the 
parameters for neurophysiological effects of a single dose of testosterone cyclodextrin in 
men are as yet unknown (Tuiten et al., 2000b). Future research should investigate whether 
testosterone administration has similar effects in men, as is suggested by some studies 
showing similarities in social behavior across sexes related to both exogenous (Goetz 
et al., 2014) and endogenous testosterone (Van Honk et al., 1999; but cf. Maner, Miller, 
Schmidt, & Eckel, 2008 for gender differences in testosterone responses to dominance 
threat in socially anxious men and women). Second, we used a subliminal version of the 
Emotional Stroop task, as previous studies suggested that effects of testosterone are 
more pronounced for preconscious processing of threat (Van Honk et al., 2000, 2005). 
However, the backward masking assumedly prevented further cognitive processing of 
the stimuli (Van Honk et al., 2000; van Peer et al., 2010), which may explain the absence of 
ERP effects in later processing stages. Third, not all socially anxious participants met the 
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criteria for a clinical diagnosis of generalized SAD at the time of testing, and the groups 
were relatively small, which may have attenuated the power to detect group differences. 
Finally, the electrode configuration used did not allow us to include electrodes at posi-
tions P7 and P8 of the extended 10-20 electrode system, which are the sites where the 
N170 amplitude is typically maximal. This might be an alternative explanation for why we 
did not find valence or group differences in amplitude (GFP) at the time of the N170 peak.
In conclusion, our findings suggest that testosterone changed the initial basic face 
perception process for neutral faces, and decreased a subsequent attentional bias for 
social threat, in socially anxious and non-anxious participants. These findings indicate that 
testosterone specifically affects the early automatic processing of social cues, and pro-
vides support for the notion that testosterone affects biologically prepared motivational 
processes (e.g., Radke et al., 2015; Van Honk et al., 2005), which may be key to changes in 
social motivational behavior, such as decreased threat avoidance.
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Supplemental Information
Supplemental Results
Grand average ERPs
After artifact rejection, the epoched EEG data were averaged to individual ERPs 
for each facial expression type, excluding trials with incorrect responses or outlier RTs. 
Table S7.1 presents the number of remaining trials per group and condition. A rmANOVA 
showed no significant effect of Testosterone or Group differences on these trial numbers. 
Figure S7.1 and Figure S7.2 present the average waveforms per group and condition, for 
a selection of electrodes. The spatiotemporal clustering analysis and calculation of Global 
Field Power were performed on the basis of the average waveforms from all 32 electrodes.
Table S7.1. Mean (± SEM) number of trials per condition for ERPs.
Valence
HC (n = 18) SAD (n = 18)
Placebo Testosterone Placebo Testosterone
Angry 20.7 (0.4) 21.4 (0.4) 21.5 (0.4) 21.7 (0.4)
Happy 21.3 (0.4) 21.0 (0.4) 21.8 (0.4) 22.0 (0.4)
Neutral 22.2 (0.4) 21.6 (0.4) 21.4 (0.4) 21.3 (0.4)
Awareness Check
To determine whether participants were capable of consciously perceiving the 
masked facial expressions, they were asked to complete an awareness check at the end 
of the second testing session. This adapted version of the task comprised a subset of 48 
masked faces (each actor and expression was presented twice). The instructions explicitly 
stated that the stimuli consisted of briefly presented faces, and participants were asked 
to indicate (if necessary by guessing) whether the emotional expression of these faces 
was angry, happy or neutral by pressing the corresponding response button. Awareness 
check data were missing for one participant (SAD), due to technical problems.
Awareness of the subliminal faces was tested with a binomial test (n = 48, p = 0.33) 
on the number of correct responses for each participant. Four participants (2 HC, 2 SAD) 
scored above chance level (≥ 22 correct responses, p < .05). The mean number of correct 
responses of the remaining participants was 15.8 (SD = 2.5). To check that the findings 
reported in the main text of this article were not influenced by awareness of the sub-
liminal stimuli, the analyses were repeated excluding the participants that scored above 
chance-level (n=4) and the participant with missing data on the awareness check (see 
Results of Control Analyses below).
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Additional Results of Main Analyses
Spatiotemporal clustering In the main text of this article, of the spatiotemporal 
clustering analyses only the results including interactions of Treatment or Group with 
Valence and Map are reported, as these reflect the effects of interest of the current study: 
Testosterone- or SAD-related differences in emotion-related face processing. For the sake 
of completeness, all other significant results from these analyses are reported below. In 
addition to the three-way interaction of Treatment x Valence x Map reported in the main 
text, the analysis of the second time window (120-200 ms, Map #3 and #4) showed a 
significant main effect of Map, F(1,34) = 81.36, p < .001, ηp2 = .71, reflecting a higher GEV 
for Map #3 compared to Map #4. The following time window (180-300 ms, Map #5 and 
#6), also showed a significant main effect of Map, F(1,34) = 57.89, p < .001, ηp2 = 0.63, 
as well as a significant interaction of Valence x Map, F(2,68) = 3.99, p = .023, ηp2 = 0.11. 
Follow-up analyses showed that the GEV of Map #6 was significantly higher than the GEV 
of Map #5 for all faces (all Fs > 32.50, ps < .001). Furthermore, results showed a trend effect 
of Valence for Map #6, F(2,68) = 2.88, p = .063, ηp2 = 0.08, resulting from an increased GEV 
for happy compared to angry faces, F(1,34) = 5.55, p = .024, ηp2 = 0.14. None of the other 
follow-up tests reached significance (all ps > .05). Finally, analyses of the last time window 
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Figure S7.1. Grand average ERP waveforms per condition for healthy control participants on selected electrodes. 
The x-axis indicates the time interval from -200 until +800 ms relative to the onset of the face stimulus. The y-axis 
indicates the amplitude in μV, with negative plotted up, and crosses the x-axis at time 0.
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(275-800 ms, Map #7 to #10) showed a significant main effect of Map, F(3,102) = 42.32, p < 
.001, ηp2 = 0.55, as well as a significant interaction of Treatment x Map, F(3,102) = 3.40, p = 
.038, ε = 0.68, ηp2 = 0.09. Follow-up pair wise comparisons showed that the GEV of Map #7 
was higher compared to the GEV of all other Maps (all Fs > 39.0, ps < .001), but the effect 
of Treatment was not significant for any single Map (all Fs > 2.98, ps > .05).
Results of Control Analyses
In addition to the analyses of interest, several control analyses were conducted. First, 
to check that the findings were not influenced by awareness of the subliminal stimuli, the 
analyses were repeated excluding the participants that scored above chance-level (n = 4) 
and the participant with missing data on the awareness check. Second, to verify whether 
the findings were influenced by possible confounding factors such as Order of treatment 
(testosterone first, placebo first), Time of testing (morning, afternoon), or use of Contra-
ception (yes, no), the analyses were repeated with these factors (one-by-one) included 
as an additional between-subject factor. The results of these analyses are reported below.
Spatiotemporal clustering When the participants with above-chance scores or miss-
ing data on the awareness check were excluded from the analyses, the interaction of 
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Figure S7.2. Grand average ERP waveforms per condition for Social Anxiety Disorder participants on selected 
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112
Chapter 7
Treatment x Valence x Map in the N170/VPP time interval, as well as the significant follow-
up tests, reported in the main text, remained significant (all ps < .05). Furthermore, the 
decrease in GEV of Map #3 after testosterone administration compared to placebo for 
happy faces, which was marginally significant (p=.056) in the original analysis, became 
significant in this control analysis, F(1,29) = 5.47, p = .026, ηp2 = .159.
The interaction of Treatment x Valence x Map in the N170/VPP time interval, as well 
as the significant follow-up tests reported in the main text, also remained significant (all 
ps < .05) when time of testing or treatment order were included as a factor in the analysis. 
Only when use of contraception was included, the interaction of Treatment x Valence for 
Map #3 in the follow-up tests was no longer significant. More importantly, however, none 
of these possible confounding factors significantly interacted with Valence and Map (all 
ps > .05), suggesting these factors did not result in qualitative changes in emotion-related 
face processing.
Global Field Power. Control analyses showed that when the participants with above-
chance scores or missing data on the awareness check were excluded from the analyses, 
the effect of Group in the first time interval (80-120 ms, p = .054), reflecting a tendency 
towards higher P1 amplitudes for SAD patients, remained marginally significant, F(1,29) = 
4.13, p = .052, ηp2 = .13. Furthermore, this effect became significant, F(1,32) = 4.59, p = .040, 
ηp2 = .13, when treatment order was included as a control factor in the analysis, but was 
reduced when time of testing, F(1,32) = 3.34, p = .077, ηp2 = .10), or use of contraception, 
F(1,32) = 1.78, p = .19, were taken into account. Most importantly, however, none of these 
factors showed a significant interaction with Group (all ps > .05).
Behavioral results. When the participants with above-chance scores or missing data 
on the awareness check were excluded from the analyses, the main effect of Valence on 
response latencies, as well as the significant follow-up tests reported in the main text, re-
mained significant (all ps < .05). The same was true when order of treatment was included 
in the analysis (all ps < .05). When oral contraception or time of testing were included, the 
Valence effect was reduced to a marginally significant effect, F(2,68) = 2.66, p = .077, ηp2 = 
.07. More importantly, however, none of these possible confounding variables interacted 
significantly with the effect of Valence (all ps > .05).
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Testosterone plays a crucial role in the regulation of social behavior. It promotes 
social dominance, which entails enhanced approach motivation, and reduced fear and 
threat sensitivity. Evidence for the causal effects of testosterone on social motivational 
behavior thus far was scarce, and lacking with regard to SAD. The main aim of this thesis 
was to elucidate the role of testosterone in the neuroendocrine mechanisms underlying 
social fear and avoidance in SAD. We hypothesized that 1) SAD is associated with reduced 
testosterone levels compared to healthy controls, and 2) that administering testosterone 
to patients with SAD will alleviate social fear and avoidance, and will promote prosocial 
behavior. The first hypothesis was tested by assessing salivary testosterone levels in a large 
group of people including SAD patients, and healthy controls. We tested the second hy-
pothesis by investigating the effects of single dose testosterone administration in women 
with SAD as compared to healthy controls, on several indexes of social motivational 
behavior. This methodology was also used to investigate underlying neuroendocrino-
logical mechanisms. In addition, considering the interactions between testosterone and 
striatal dopamine signaling, we explored the interaction between striatal dopaminergic 
polymorphisms and social approach-avoidance tendencies.
This chapter summarizes the empirical chapters and presents a theoretical integra-
tion of the findings. It will conclude with a discussion of the strengths and limitations, and 
will make suggestions for future research and clinical perspectives.
Summary of empirical chapters
Chapter 2 describes a first study on how genetic variations, which influence the 
functioning of the mesolimbic reward system, affect social approach-avoidance action 
tendencies. An implicit social approach-avoidance task (AAT) was performed by two 
groups of healthy participants carrying different variants of the dopamine transporter 
(DAT) gene. One group carried the 9-repeat allele, which is associated with increased 
striatal dopamine levels and has been found to be related to increased sensitivity to 
reward, the other group consisted of non-9-repeat carriers. Results showed that the DAT1 
9-repeat carriers performed increased emotion-driven action tendencies in reaction to 
stimuli that communicate a motivational drive to the observer: They showed stronger 
tendencies to approach appetitive social stimuli (i.e., happy expressions), and to avoid 
aversive stimuli (i.e., angry expressions), compared to non-9-repeat carriers. These results 
suggest that striatal dopaminergic polymorphisms affect motivational responses to 
social-emotional cues.
Chapter 3 tested whether single dose testosterone administration diminishes threat 
avoidance and promotes actual behavioral approach actions that have an immediate 
effect on the relative distance of the social threat stimulus. Healthy individuals performed 
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an implicit social AAT featuring angry, happy, and neutral facial expressions. Participants 
showed significantly diminished avoidance tendencies to angry faces after testosterone 
administration. Testosterone did not affect approach–avoidance tendencies to social af-
filiation (happy) faces. Thus, single dose testosterone administration reduces automatic 
avoidance of social threat and promotes relative increase of threat approach tendencies 
in healthy females.
Chapter 4 mapped salivary testosterone levels of 722 male and 1380 female par-
ticipants of The Netherlands Study of Depression and Anxiety (NESDA; Penninx 2008). 
The results confirmed our first hypothesis, and showed that female patients with social 
phobia had lower salivary testosterone levels than female controls with no lifetime his-
tory of depressive or anxiety disorders. In addition, there was a linear trend for decreasing 
testosterone levels with increased social phobia scores.
Chapter 5 presents a study that tests the effects of testosterone on actual social ap-
proach–avoidance action tendencies in females with SAD. Using the same implicit social 
AAT as in chapter 3, we investigated whether administering a single dose of testosterone 
could counteract the automatic social avoidance tendencies in women with SAD. After 
testosterone administration, the participants showed increased approach tendencies to 
angry facial expressions, but not happy expressions. These results suggest that testos-
terone indeed can counteract persistent automatic social avoidance tendencies in SAD, 
confirming our second hypothesis.
Chapter 6 tested the hypothesis that administering a single dose of testosterone 
promotes social dominant gaze behavior and thus will be able to alleviate submissive 
gaze avoidance in individuals with SAD. The spontaneous gaze behavior of participants 
with SAD and of control participants was recorded using eye-tracking, while they looked 
at angry, happy, and neutral facial expressions. Testosterone enhanced the percentage of 
first fixations to the eye-region in participants with SAD compared to healthy controls. 
In addition, SAD patients’ initial gaze avoidance in the placebo condition was associated 
with more severe social anxiety symptoms. This relation was no longer present after 
testosterone administration. These findings indicate that single dose testosterone admin-
istration can alleviate gaze avoidance in SAD.
Chapter 7 investigated the effects of testosterone on social threat processing in 
participants with SAD and control participants, using temporally fine-grained recordings 
of event-related brain potentials (ERPs) during an emotional Stroop task with subliminally 
presented angry, happy and neutral faces. Spatiotemporal clustering analysis on the ERPs 
showed that testosterone induced two qualitative changes in early face processing (<200 
ms after stimulus onset) in participants with and without SAD. An initial testosterone-
induced spatial shift reflected a decrease of the typical basic processing (N170/VPP) 
of neutral faces, which was followed by a specific change for angry faces, suggesting 
a specific modulation of early threat vigilance. We found no effects in later processing 
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stages. These findings suggest that testosterone specifically affects early automatic, social 
information processing.
Integration of findings
Basal testosterone in SAD
Our first prediction was confirmed by the finding that female patients with social 
phobia had lower salivary testosterone levels than female controls with no lifetime his-
tory of depressive or anxiety disorders. Also, higher social phobia scores were associated 
with lower testosterone levels. Our findings fit previous notions in animal and human 
research which associate reduced testosterone with social submissiveness and increased 
levels of social fear behavior, such as social withdrawal (Bedgood et al., 2014; Mehta & 
Josephs, 2010; Sapolsky, 1990, 1991; van Honk et al., 1999). They concur with the socio-
neuroendocrine models of SAD which propose that this disorder and its persistent social 
avoidance originates from social subordination stress (Gilbert, 2001; Hermans & van 
Honk, 2006). Individuals with SAD show increased vigilance for (dominance) threat in 
social interactions, and engage in subordinate behavior in order to enhance their survival 
chances by avoiding potential harm from others (Gilbert, 2001; Hermans & van Honk, 
2006; Weisman et al., 2011). In this light it is interesting to note that several studies suggest 
that individuals with SAD perceive themselves as being of low social rank, as behaving 
submissively (Weisman et al., 2011), and also tend to rate others as more dominant and 
less friendly, compared to non-anxious individuals (Aderka, Haker, Marom, Hermesh, & 
Gilboa-Schechtman, 2013; Haker, Aderka, Marom, Hermesh, & Gilboa-Schechtman, 2014).
Testosterone alleviates avoidance in SAD
Second, we predicted that administering testosterone to patients with SAD will al-
leviate social fear and avoidance, and will promote prosocial behavior. We tested this 
prediction on two indices of social motivational behavior: approach-avoidance tenden-
cies and gaze avoidance.
Previous testosterone administration studies in healthy and high anxious participants 
have shown that there is a causal relationship between a surge in testosterone and reduc-
tion of fear and sensitivity to threat, and increased social dominance related behavior 
(Bos et al., 2012; Terburg & van Honk, 2013). However, so far evidence was constrained to 
processing of perceptual information and gaze behavior. Chapter 3 extends our knowl-
edge by confirming the causal effect of testosterone on automatic social motivational 
action. This is the first study showing that testosterone directly influences behavioral 
approach actions that have an immediate effect on the relative distance of the social 
threat stimulus (Rinck & Becker, 2007). Chapter 5 extends these findings by showing that 
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testosterone also promotes social threat approach in participants with generalized SAD, 
characterized by exaggerated threat avoidance. Thus, both in healthy participants, and in 
participants with SAD, testosterone is able to promote social threat approach, indicating 
an enhanced motivational tendency toward social dominance (Archer, 2006; Bos et al., 
2012; Radke et al., 2015; Terburg & van Honk, 2013).
Chapter 6 shows that administering a single dose of testosterone also promotes 
social gaze behavior, by increasing the initial fixations to the eyes of facial stimuli in SAD 
compared to healthy control (HC) participants. In addition, higher social phobia scores 
were associated with increased gaze avoidance of angry eye contact, stressing the clinical 
relevance of this measure. This study indicates that a single dose testosterone administra-
tion can alleviate gaze avoidance, which is one of the core communicative features of 
social anxiety and SAD in particular (Horley et al., 2003, 2004; Weeks et al., 2013). These 
findings support theories on the anxiolytic and social dominance enhancing properties 
of testosterone, and corroborate our findings on threat approach action tendencies in 
SAD.
Interestingly, unlike the studies in chapters 3 and 5 which found similar effects of 
testosterone on Approach-Avoidance tendencies in healthy and SAD participants, our 
eye-tracking study yielded contrasting findings for the control group. We argued that this 
finding could be attributed to the influence of environmental and individual differences 
on the modulatory effect of testosterone on social status promoting behavior (Eiseneg-
ger et al., 2011; van Honk, Terburg, et al., 2011). For example, research has shown that 
a previous winning or losing experience, height of endogenous cortisol levels, extent 
of social anxiety, or amount of prenatal testosterone exposure influences the effects 
of testosterone on social behavior (Gleason et al., 2009; Maner, Miller, Schmidt, & Eckel, 
2008; Mehta & Josephs, 2010; Honk, Schutter, et al., 2011). The context-dependency of 
testosterone effects may also contribute to the differential findings for healthy controls 
in the eye-tracking study and the similar findings on the AAT, in that there are notable 
differences between the tasks. The AAT used in Chapters 3 and 5 measures the automatic 
behavioral tendencies towards a social stimulus, reflecting the primary underlying moti-
vational disposition. Participants are confronted with a facial stimulus to which they are 
subsequently required to respond with a behavioral action. The gaze behavior captured 
in the eye-tracking task also reflects automatic behavioral tendencies, but in addition 
has a communicative function. Avoidance of eye contact signals social subordination 
and prevents an aggressive encounter, whereas seeking (angry) eye-contact is typical 
behavior for socially dominant individuals. Due to the setup of the eye-tracking task, 
no behavioral action was required and eye-contact could be avoided in the first place, 
which may have contributed to a more socially submissive behavioral gaze pattern in 
SAD compared to the healthy controls. Nevertheless, future studies should elucidate the 
exact interpretation of effects.
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In sum, the findings from Chapters 3, 5, and 6 confirm our second hypothesis and 
indicate that single dose testosterone administration is able to counteract automatic 
social avoidance behavior, and to promote approach behavior in SAD. In addition, they 
are in agreement with literature which suggest that the effects of testosterone depend 
on individual and environmental differences.
Neuroendocrine mechanisms
Thirdly, we investigated underlying neuroendocrine mechanisms of testosterone on 
social motivational behavior. Chapter 7 indicates that testosterone differentially affects 
the processing of threatening (angry) and non-threatening (neutral and happy) face 
stimuli in very early stages. These findings suggest that testosterone alters early vigilance 
to social threat. In addition, they indicate that no deviation exists between participants 
with and without SAD on this level of processing.
These findings may reflect the neural processes underlying our findings of threat-
specific effects of testosterone on social motivational behavior in Chapters 3, 5, and 6. 
fMRI studies have shown that testosterone administration increased amygdala responses 
during the processing of angry faces (Goetz et al., 2014; Hermans et al., 2008), and a study 
featuring the Approach-Avoidance Task showed that such increased responses were 
specifically related to threat approach behavior, while testosterone decreased amygdala 
responses during threat avoidance (Radke et al., 2015). Based on these findings, it can be 
argued that our findings of increased threat approach may be caused by the modulation 
of amygdala responses by testosterone, biasing social motivational tendencies toward 
approach, and away from avoidance, of social threat. Our findings in Chapter 7 suggest 
that such testosterone-induced modulations of neural activity may happen already dur-
ing the earliest stages of angry face processing.
In addition, testosterone reduces connectivity between the PFC and the amygdala 
(van Wingen et al., 2010a; Volman et al., 2016; Volman, Toni, et al., 2011). fMRI studies prob-
ing the relation between endogenous testosterone and social approach action showed 
that testosterone modulates prefrontal brain activity and prefrontal–amygdala connec-
tivity when people had to control their automatic social approach–avoidance tendencies 
(Volman et al., 2016; Volman, Toni, et al., 2011), indicating that prefrontal control of the 
amygdala has been reduced when testosterone was higher. Neuroimaging studies in SAD 
have shown increased activation of the amygdala and alterations in frontal-amygdala 
coupling in response to threatening facial expressions (Cremers & Roelofs, 2016; Fouche 
et al., 2013). These findings suggest that the amygdala is not properly regulated during 
threatening situations in SAD. Although much is still unknown about the neural correlates 
of Approach-Avoidance behavior in SAD, it is likely that testosterone biases the amygdala 
towards social approach action in a similar fashion as in healthy persons.
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Possible endocrine mechanisms underlying these neural patterns may lie in the 
upregulation of dopamine levels by testosterone in the PFC (Aubele & Kritzer, 2011; van 
Honk, Terburg, et al., 2011). In addition, testosterone and its metabolites bring about 
anxiolytic actions in brain areas involved in the fight-flight response, via steroid receptors 
and γ-aminobutyric acid (GABA-A) receptors in the amygdala, hypothalamus, and PAG 
(among other areas; McHenry et al., 2014), as well as inhibition of the HPA-axis (Hermans 
et al., 2007; Viau, 2002). Also, a testosterone-induced increase of the neuropeptide vaso-
pressin in the amygdala might enhance the inclination towards dominance and social 
aggression (Bos et al., 2012; Terburg & van Honk, 2013).
Importantly, testosterone reduces punishment sensitivity and promotes reward 
seeking behavior. Testosterone enhances dopamine levels in the ventral striatum (de 
Souza Silva et al., 2009; Hermans et al., 2010), which is associated with prediction of the 
value of rewards (Cools, 2008). In Chapter 2 we show that increased striatal dopamine 
transmission is associated with augmented approach-avoidance behavior in pursue of 
social reward (i.e., approaching happy and avoiding angry faces). It is likely that dopa-
mine modulates the effects of testosterone in stimulating approach motivation (Depue 
& Morrone-Strupinsky, 2005; Johnson, Leedom, & Muhtadie, 2012). The specific effects 
of testosterone on approach behavior towards social threat faces are typically related 
to an enhancement of the motivation to obtain higher social status (Öhman, 1986). An 
encounter with an angry facial expression may lead to a possibly rewarding outcome, 
such as increased social status and its benefits. In SAD striatal activity has been shown to 
be deviating (Freitas-Ferrari et al., 2010) and there are indications for a social-motivational 
imbalance in SAD. Results suggest that patients show a reduced motivation to obtain 
social reward and relative increased motivation to avoid social punishment (Cremers et 
al., 2014). It is conceivable that administering testosterone to these individuals dampens 
punishment sensitivity and increases motivation to pursue social reward.
Taken together, the neuroendocrine mechanisms underlying our findings of a 
testosterone-induced increase in social approach behavior may lie in changes in social 
threat processing by the amygdala and connected frontal-striatal circuits. Testosterone 
biases the amygdala to social threat approach, reduces prefrontal control, and increases 
reward sensitivity. Our EEG findings suggest that actions of testosterone happen already 
at very early processing stages, and that deviations underlying psychopathology may 
arise at later stages.
Strengths, limitations, and future perspectives
Strengths
The general strengths of the presented studies will be discussed in this paragraph.
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First, in the testosterone-administration studies, we used a within-subjects design, 
which is a powerful method to detect changes related to the experimental manipulation 
because the same subjects are tested in both placebo and testosterone conditions. In ad-
dition, testosterone administration was double-blind and randomized, which minimizes 
the possibility of expectations - fueled by the widespread ideas on testosterone - of 
participant and experimenter influencing the results.
Second, the used testosterone administration method is well-established in healthy 
women. Its pharmacodynamic profile has been determined using a reliable automatic 
and non-habitual measure (Tuiten et al., 2000a). In addition, over a decade of research ap-
plying this method has convincingly shown psychophysiological and behavioral effects 
(see for a review Bos et al., 2012).
Third, we measured social avoidance with two different indexes of social motivational 
behavior. The AAT is a well-established, objective measure of social motivational tenden-
cies, gaze avoidance is considered a core characteristic of SAD.
Fourth, for our neurocognitive tasks we carefully selected a target stimulus that has 
proven to be potent in eliciting avoidance in individuals with SAD (i.e., angry facial expres-
sions; (Horley et al., 2004; Roelofs, van Peer et al., 2009; van Peer et al., 2009). In addition, 
an angry looking face with direct gaze is a signal of social dominance (Öhman, 1986), and 
testosterone, as regulator of social motivational behavior, has shown to specifically modu-
late automatic behavioral responses (Terburg et al., 2012) as well as neural responses to 
particularly this stimulus (Goetz et al., 2014; Hermans et al., 2010, 2008).
Finally, we selected our participants based on strict criteria, of which the two most 
important were exclusion of participants using psychotropic medication, which affects 
brain activity, and exclusion of individuals with a current comorbid diagnosis of major 
depressive disorder, which affects social threat processing (Bar-Haim et al., 2007) and the 
neuromuscular response (Sabbe et al., 1999). A consequence is that our selected SAD 
sample is possibly not an adequate representation of SAD in the general population, 
which might limit the generalizability of our results.
Limitations
Several limitations should be considered with regard of the presented findings. These 
are discussed in detail in the empirical chapters; the following paragraph will present the 
most important limitations in general.
First, the testosterone administration studies in chapters 3, 5, 6, and 7 only featured 
female participants. This is a consequence of the fact that the administration of testoster-
one cyclodextrin has only been validated in women (Tuiten et al., 2000). Future studies 
should test our hypotheses in samples containing male participants. We expect similar 
results since the effects of testosterone on social motivation are comparable across sexes 
(Hermans et al., 2007; van Honk et al., 1999, 2001; van Honk & Schutter, 2007). This hy-
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pothesis is validated by a recent testosterone administration study in healthy men which 
replicated earlier findings in healthy women on brain activity in response to angry facial 
expressions (Goetz et al., 2014; Hermans et al., 2008a), however it has not yet been tested 
how this translates to social motivational behavior.
Second, as is customary with the used testosterone administration paradigm, we 
aimed to control for steroid hormone level fluctuations associated with the menstrual 
cycle by including women on single-phase contraceptives, and naturally cycling women 
who were tested in the pre-ovulatory phase (e.g., Hermans et al., 2010; van Honk, Schut-
ter, et al., 2011). Although the effects of the testosterone administration studies remained 
after statistically controlling for contraceptive use, future studies ideally deal with hor-
mone fluctuations by only testing participants who are on single-phase contraceptives, 
or by directly assessing estradiol levels, especially given evidence that this hormone 
likely mediates testosterone-effects on social dominance (McHenry et al., 2014; Stanton & 
Schultheiss, 2007; Terburg & van Honk, 2013; Ziomkiewicz et al., 2015).
Third, due to the combination of strict inclusion criteria, a time-consuming testing 
schedule, and the particulars of SAD, it was difficult to recruit participants. To be able 
to complete the study we had to loosen our inclusion criteria, which resulted in an age 
difference between the SAD and the HC groups. We were able to control for this issue 
by age-matching our groups before analyses (chapters 6 and 7). This resulted in smaller 
participant groups than initially aimed for, but they still fall within the range of previously 
reported samples of 15 up to 23 participants with SAD (eye-tracking studies, see for a 
review (Armstrong & Olatunji, 2012); AAT-studies, (e.g., Roelofs, van Peer et al., 2009; van 
Peer et al., 2009). In addition, previously conducted investigations featuring testosterone 
administration to groups consisting of 12 up to 20 healthy participants in a randomized, 
placebo-controlled, within-subjects design reported significant multi-way interaction 
effects for a variety of paradigms (see for a review Bos et al., 2012). Although our sample 
is probably not too small for genuine positive effects, future studies should replicate our 
findings in larger samples.
Finally, there is as yet no evidence that the neurocognitive tasks presented in this 
thesis reflect actual behavior in real life social settings. Although validation with an actual 
behavioral approach test is still lacking for the social AAT, for the spider phobia AAT it has 
been shown that the magnitude of avoidance on the spider AAT predicts the distance 
kept in an actual spider approach task (Klein, Becker, & Rinck, 2011; Rinck & Becker, 2007). 
There are several studies that have shown that avoidance of angry faces on the social AAT 
is related to social anxiety (Heuer et al., 2007; Roelofs et al., 2010) and, on the contrary, that 
aggressive samples show social threat approach on the same task (von Borries et al., 2012). 
Importantly, Chapter 5 showed that the magnitude of the AAT effect score for angry vs 
neutral faces was correlated to symptom severity in patients with SAD; this observation 
validates the currently used social AAT version in SAD. Furthermore, avoidance of eye 
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contact has been clinically observed to be a typical characteristic of SAD (Stein & Stein, 
2008; Weeks et al., 2013). The used eye-tracking task was newly developed for this study, 
based on previous research (Horley et al., 2003, 2004). In chapter 6 we see the clinical 
relevance of first fixations on the eye-region confirmed by the correlation between this 
measure and the severity of symptoms in the SAD sample in the placebo condition.
Suggestions for future research
In addition to the above mentioned suggestions for future investigation, this para-
graph proposes several ideas for future research which might help answer outstanding 
questions.
To date there is still much unclear about the neuroendocrine mechanisms underly-
ing deviations in social motivational behavior in SAD. Research featuring neuroimaging 
techniques should shed more light on this matter. Future studies could combine the AAT 
with fMRI, endogenous testosterone measurements (e.g., Volman, Toni, et al., 2011), and/
or testosterone administration to find out how testosterone modulates social approach-
avoidance behavior in SAD. In addition, it would be interesting to try to probe the func-
tioning of the emotion-network (e.g., fear reduction by GABA-ergic mechanisms) and the 
reward-network (dopaminergic mechanisms, e.g, whether testosterone indeed facilitates 
dopaminergic projections from the amygdala to the striatum) in SAD, by using single-
photon emission computed tomography (SPECT) or positron emission tomography 
(PET) scanning (e.g., Schneier et al., 2009; van der Wee et al., 2008), in combination with 
testosterone administration. This would be particularly interesting in combination with 
genotyping for androgen and dopaminergic receptor genes. Furthermore, we presented 
a first EEG study on the effects of administered testosterone on early threat processing 
and future research featuring EEG or magnetoencephalography (MEG) should further 
elucidate the temporal dynamics of these processes in both healthy individuals and those 
with SAD.
As noted in the previous paragraph, it is not yet known how the behavioral effects 
captured by our neurocognitive tasks translate to behavior in actual social settings. It 
would be an interesting approach to combine testosterone administration with virtual 
reality paradigms (e.g., Morina, Brinkman, Hartanto, Kampmann, & Emmelkamp, 2015), 
or with a controlled social interaction environment, to assess (gaze) avoidance in social 
interactions.
It is getting more and more clear that the effects of testosterone on social moti-
vational behavior are modulated by individual differences and social context. Future 
research should address the influence of social anxiety (e.g., Cremers & Roelofs, 2016), 
endogenous cortisol and testosterone levels (e.g., Mehta & Josephs, 2010b), the role of 
oxytocin and other hormones (e.g., van Honk, Bos, Terburg, Heany, & Stein, 2015), sex 
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differences (e.g., Welker et al., 2015), and prenatal testosterone exposure (e.g., 2D:4D ratio; 
van Honk, Schutter, et al., 2011), among others.
Finally, prospective developmental studies are needed to investigate whether re-
duced testosterone in women with SAD plays a (causal) developmental role or is rather a 
consequence of reduced social interaction resulting from social avoidance.
Clinical perspectives
The research studies presented in this thesis primarily aim to elucidate neuroendo-
crine mechanisms of social motivational behavior in the first place. Nevertheless, given 
our promising findings showing that testosterone promotes actual social approach ac-
tion tendencies in SAD during a social challenge, it would be of theoretical and clinical 
importance to test whether testosterone administration could benefit the treatment of 
SAD.
Exposure therapy is part of first-line treatment of SAD, and aims at fear extinction by 
repeated or prolonged exposure to feared social situations, which should lead to a reduc-
tion in fear and avoidance behavior. Although exposure therapy has proven effective, 
nonresponse rates in large clinical trials have been 50% or higher (Hofmann & Bögels, 
2006), and most individuals do not achieve remission. In an attempt to enhance exposure 
therapy efficacy, research has explored the augmentation effects of pharmacological 
agents thought to enhance the underlying mechanisms of action (e.g., extinction learn-
ing) of exposure therapy. This approach has potential as was shown by studies featuring a 
variety of pharmacological agents (e.g., Hofmann et al., 2014). Despite initially promising 
findings, the working mechanisms are still not entirely clear and studies yield mixed find-
ings. It is possible that these cognitive enhancers do not target the most optimal mecha-
nism for enhancement of exposure therapy, and an alternative approach targeting social 
motivational mechanisms directly might provide a more effective solution. Considering 
the alleviating effects of testosterone on actual social avoidance behavior in SAD, and 
considering that exposure therapy is also aimed at reduction of avoidance behavior, it 
would be of relevance to test whether single-dose testosterone administration - applied 
only a few times to enhance efficacy of the first few exposure sessions - can enhance 
therapy efficacy for SAD. Nevertheless, it should be noted that there is still much unclear 
about the working mechanisms of testosterone and of pharmacological add-ons for 
exposure therapy. It is possible that, besides the potentially beneficial effects of testoster-
one on dopamine transmission and glucocorticoid mechanisms, its effects on the GABA 
system might not only work anxiolytic but could also potentially interfere with extinction 
learning, something worth investigating in future research (Singewald et al., 2015).
Another interesting approach would be to explore whether the automatic avoid-
ance tendencies in SAD could be diminished by approach-avoidance training on the 
AAT. Research on this topic across various disciplines has shown positive results (Becker 
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et al., 2016). Two studies featuring socially anxious participants showed that, after being 
required to approach positive social stimuli on the AAT, they subsequently showed more 
approach behavior during social interactions, elicited more positive reactions by their 
interaction partners (Taylor & Amir, 2012), and reported better mood and less anxiety 
after a social challenge (Rinck et al., 2013). Single-dose testosterone administration might 
aid the training process by biasing the brain towards social approach, although this effect 
is likely specific for social threat faces.
Conclusion
This thesis aimed to elucidate the role of testosterone in the neuroendocrine 
mechanisms underlying social fear and avoidance in SAD. Despite the social approach-
enhancing and anxiolytic effects of testosterone, its role in fear and avoidance in SAD thus 
far was scarcely investigated.
Our findings indicate that baseline testosterone is lower in women with SAD and 
related to social anxiety symptoms. This is in line with animal and human research which 
associates reduced testosterone with social submissiveness and increased levels of social 
fear behavior, and confirms socio-neuroendocrine theories of SAD. Furthermore, in agree-
ment with our prediction, the findings show that single-dose testosterone administration 
is able to counteract persistent social avoidance tendencies in SAD, thereby confirming 
and extending earlier findings on the social dominance-enhancing theories of testoster-
one. In addition, the notion that testosterone affects automatic motivational processes is 
supported by the finding that testosterone affects early threat processing.
Future research should look further into the neuroendocrine mechanisms underly-
ing these behavioral effects, and consider exploring whether single-dose testosterone 
administration could benefit the treatment of SAD.
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Inleiding
Het hormoon testosteron speelt een belangrijke rol bij de regulatie van sociaal gedrag, 
samen met onder andere cortisol. Waar testosteron een angstremmende werking heeft 
en sociale toenadering bevordert, wordt cortisol juist geassocieerd met stress en sociale 
vermijding. Een disbalans in het functioneren van testosteron en cortisol kan leiden tot 
storingen in de regulatie van sociaal toenaderings- en vermijdingsgedrag. Dit is het geval 
bij de sociale angststoornis (SAD), waarbij verhoogde cortisolresponsen samenhangen 
met hardnekkige sociale vermijding. Over de rol van testosteron bij sociale angst was 
nog nauwelijks iets bekend en daar probeerde dit proefschrift meer duidelijkheid in te 
scheppen.
SAD is de meest voorkomende angststoornis en wordt gekarakteriseerd door een in-
tense angst voor sociale situaties waarin het individu de kans loopt kritisch beoordeeld te 
worden door anderen. Daardoor ontstaat de neiging om sociale interacties te vermijden. 
Dit vermijdingsgedrag speelt een belangrijke rol bij het instandhouden van de stoornis. 
Vermijding van oogcontact is karakteristiek voor mensen met SAD en wordt geassocieerd 
met typisch sociaal onderdanig gedrag dat als doel heeft om sociale dreiging te vermin-
deren. Een andere factor die in verband gebracht wordt met de hardnekkigheid van de 
stoornis is een veranderde verwerking van sociale informatie, waarbij het erop lijkt dat 
mensen met SAD een onbewuste voorkeur hebben voor negatieve informatie in hun 
omgeving, wat ertoe leidt dat de situatie als meer negatief beoordeeld wordt dan deze 
in werkelijkheid is.
Een goede regulatie van sociale toenadering en vermijding is van cruciaal belang 
voor succesvol functioneren. In reactie op een sociale stimulus, bijvoorbeeld een boos 
kijkend gezicht (sociale dreiging), zal de amygdala in het brein razendsnel een evalu-
atie maken van de situatie en automatisch toenaderings- of vermijdingsgedrag in gang 
zetten via neurotransmitters en hormonen. De amygdala wordt hierbij gereguleerd door 
de prefrontale cortex, die het mogelijk maakt om deze automatische neigingen bij te 
sturen. De prefrontale cortex reguleert ook het ventrale striatum, belangrijk in beloning 
en de regulatie van sociaal gedrag, welke ook verbonden is met de amygdala. Wanneer 
deze complexe neurale netwerken niet in balans zijn is er kans op psychopathologie, wat 
het geval is bij SAD. Verschillende onderzoeken hebben laten zien dat bovengenoemde 
hersengebieden afwijkend reageren op sociale dreiging in SAD, wat er waarschijnlijk op 
wijst dat de amygdala een verhoogde verwerking heeft van deze dreiging, en dat de pre-
frontale cortex niet goed in staat is om de amygdala te reguleren. Recente onderzoeken 
laten ook zien dat de het ventrale striatum anders functioneert, wat er op kan wijzen dat 
mensen met SAD minder gevoelig zijn voor sociale beloning en juist meer gevoelig voor 
straf.
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Testosteron beïnvloedt de werking van de amygdala en andere hersengebieden die 
betrokken zijn bij de regulatie van sociaal gedrag. Door testosteron wordt de amygdala 
meer geneigd tot het aansturen van toenaderingsgedrag en vermindert de remming 
door de prefrontale cortex. Er treden ook interacties op met andere hormonen en neu-
rotransmitters, waarbij de dopamine-verhogende effecten van testosteron in het ventrale 
striatum kunnen leiden tot verhoogde gevoeligheid voor sociale beloning en toename 
in motivationeel gedrag. Onderzoek met testosterontoediening bij gezonde en angstige 
vrouwen heeft laten zien dat testosteron angstremmend werkt, gevoeligheid voor straf 
vermindert, de gevoeligheid voor beloning juist verhoogt en leidt tot toenaderingsge-
drag dat gericht is op het verhogen van de sociale status.
SAD wordt gekenmerkt door verhoogde cortisolresponsen, hardnekkige sociale 
vermijding, verhoogde gevoeligheid voor dreiging en verlaagde gevoeligheid voor be-
loning, een gedragspatroon dat geassocieerd wordt met sociale onderdanigheid. Aan 
de andere kant zorgt testosteron juist voor een verhoging van sociale dominantie, wat 
inhoudt dat het angstremmend werkt, de gevoeligheid voor sociale beloning versterkt 
en toenaderingsgedrag bevorderd. Aangezien testosteron en cortisol antagonistisch 
werken is het heel interessant om uit te zoeken welke rol testosteron speelt bij SAD. Onze 
hypotheses waren 1) testosteronspiegels zijn verlaagd in personen met SAD, vergeleken 
met gezonde personen 2) toediening van testosteron bij personen met SAD zal de sociale 
angst en vermijding verminderen. Daarbij hebben we gekeken naar neuro-endocriene 
mechanismen. We hebben dit onderzocht door te kijken naar testosteron in speeksel in 
een grote groep deelnemers en in een aantal andere studies waarin testosteron werd 
toegediend en het effect daarvan op sociale toenadering en vermijding werd gemeten.
Methoden
In hoofdstuk 4 werden basale testosteronspiegels bepaald in speeksel, deze zijn een 
afspiegeling van de actieve hoeveelheid testosteron in het bloed en zijn globaal gerela-
teerd aan psychologische eigenschappen en gedrag.
De toediening van testosteron in hoofdstuk 3, 5, 6 en 7 maakt het mogelijk om een 
causaal verband vast te stellen tussen een tijdelijke verhoging in testosteronspiegels 
en sociaal motivationeel gedrag en hersenactiviteit. Testosteron werd via de mond in-
genomen en werd daar opgenomen in de bloedbaan. De farmacodynamiek van deze 
methode is alleen gevalideerd voor vrouwen, vandaar dat er alleen vrouwen deelnamen 
bij de toedieningsexperimenten die beschreven zijn in dit proefschrift.
De automatische neiging om iets toe te naderen of te vermijden kan objectief 
gemeten worden met een sociale approach-avoidance taak (AAT), welke ingezet is in 
hoofdstuk 2, 3 en 5. Deelnemers laten gezichten met een boze, lachende of neutrale 
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uitdrukking naar zich toe of van zich af bewegen op een computerscherm doordat ze 
een joystick naar zich toe trekken of van zich afduwen. Het toenaderen van lachende 
gezichten en het vermijden van boze gezichten is makkelijker, want dit stemt overeen 
met de automatische neigingen, en gaat dus sneller dan het toenaderen van boze en 
het vermijden van lachende gezichten. Mensen met sociale angst zijn over het algemeen 
sneller in het vermijden van boze gezichtsuitdrukkingen vergeleken met neutrale.
In hoofdstuk 7 werd vermijding van oogcontact gemeten door middel van een eye-
tracker. Deze gebruikt infrarood licht dat reflecteert op de oogbal en geregistreerd wordt 
door een camera, veranderingen in reflecties geven informatie over waar het oog naar 
kijkt. Oogbewegingen kunnen onderverdeeld worden in fixaties, wanneer de blik op een 
bepaalt punt rust voor 100ms, en saccades, de beweging van het oog tussen twee fixaties 
in.
Als laatste hebben we in hoofdstuk 8 elektro-encefalografie (EEG) gebruikt om vroege 
aandachtsprocessen te meten. Cognitieve processen in het brein veroorzaken elektrische 
potentiaalverschillen welke gemeten kunnen worden op de hoofdhuid. De analysetech-
niek die gebruikt is in dit proefschrift maakt het mogelijk om verschillende neurale 
bronnen en de sterkte van cognitieve processen te onderscheiden. De hersenactiviteit 
van deelnemers met en zonder SAD werd gemeten terwijl zij zo snel mogelijk moesten 
aangeven welke kleur een ovaal op een computerscherm had. Onbewust namen zij 
daarbij gezichten waar die heel kort voor de ovalen werden getoond. Deze gezichten 
hadden een boze, lachende of neutrale uitdrukking welke onbewust de reactiesnelheid 
van de deelnemers beïnvloedde.
Discussie
Onze eerste hypothese werd bevestigd door de bevindingen uit hoofdstuk 4: testos-
teronspiegels in speeksel zijn lager bij vrouwen met SAD (en bij depressie, gegenerali-
seerde angststoornis en agorafobie) ten opzichte van vrouwen zonder voorgeschiedenis 
van angst en depressie. Daarbij bleken lagere testosteronspiegels samen te hangen met 
ernstiger sociale angst. De bevindingen in deze vrouwen bevestigen onze hypothese dat 
SAD samenhangt met lagere testosteronspiegels en zijn in lijn met eerder onderzoek in 
dieren en mensen dat lage testosteronspiegels verbindt met sociale onderdanigheid en 
vermijding. Daarbij past het in socio-neuroendocriene modellen van SAD die poneren 
dat deze stoornis en bijbehorende hardnekkige vermijding ontstaan zijn vanuit sociale 
subordinatiestress. De groep mannen liet geen verlaagde testosteronspiegels zien in 
relatie tot SAD, dit kan komen door genetische factoren en door de twee keer zo kleine 
groepsgrootte, maar dit moet nog beter onderzocht worden.
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De tweede hypothese werd getoetst in de hoofdstukken 3, 5 en 6, waarbij testoster-
ontoediening werd gecombineerd met twee verschillende maten voor sociaal toenader-
ings- en vermijdingsgedrag: de AAT (3, 5) en kijkgedrag (6).
Hoofdstuk 3 laat zien dat testosteron daadwerkelijk in staat is om automatische moti-
vationele neigingen te beïnvloeden. Na inname van testosteron lieten gezonde vrouwen 
een duidelijke afname zien in de vermijding van boze gezichten, terwijl er geen verschil 
was in gedrag ten opzichte van lachende gezichten. Deze resultaten laten zien dat testos-
teron sociaal toenaderings- en vermijdingsgedrag kan beïnvloeden en de vermijding van 
sociale dreiging kan verminderen. Daarbij zijn ze in lijn met theorieën die dit hormoon 
verbinden met sociale dominantie, wat inhoudt dat het de motivatie om toe te naderen 
versterkt en angstremmend werkt. Hoofdstuk 5 trekt deze bevindingen door naar SAD en 
laat zien dat testosteron ook in staat is om de automatische neiging tot vermijding, die 
zo karakteristiek is voor deze stoornis, te beïnvloeden: na testosterontoediening bleken 
de vrouwen een toename te laten zien in het toenaderen van boze gezichten, maar geen 
verschil in hun reactie op lachende gezichten.
In hoofdstuk 6 werd gekeken naar een andere maat van sociale vermijding. Het spon-
tane kijkgedrag van vrouwen met SAD werd geregistreerd met een eye-tracker terwijl ze 
naar boze, lachende en neutraal kijkende gezichten keken. Testosteron verhoogde het 
aantal eerste fixaties naar de ogen van deze gezichten bij de deelnemers met SAD ten 
opzichte van de gezonde controle deelnemers. Daarbij lieten de deelnemers met SAD 
meer vermijding van oogcontact zien wanneer ze meer sociale angst klachten hadden, 
wat de klinische relevantie van deze maat benadrukt. Deze resultaten suggereren dat 
testosteron inderdaad de vermijding van oogcontact kan verminderen bij SAD, door de 
angstremmende en sociale dominantie-verhogende werking.
De gezonde deelnemers lieten een ander kijkpatroon zien dan de deelnemers met 
SAD: na testosterontoediening hadden ze de neiging om juist minder naar de ogen van 
de getoonde gezichten te kijken. Dit effect zou verklaard kunnen worden vanuit eerder 
waargenomen effecten van testosteron. Afhankelijk van de sociale context kan testos-
teron mensen minder sociaal maken en een egocentrische neiging om dominant te zijn 
bevorderen. De precieze oorzaak van het verschil in resultaten tussen de gezonde en SAD 
groepen is onduidelijk en er ligt een taak voor toekomstig onderzoek om dit te ontrafelen.
Bijelkaar genomen bevestigen de hoofdstukken 3, 5 en 6 onze tweede hypothese 
en laten zien dat testosteron inderdaad in staat is om sociale vermijding te verminderen 
en sociale toenadering te bevorderen bij vrouwen met SAD. Toekomstig onderzoek bij 
mannen zal moeten uitwijzen of dit ook zo uitwerkt voor deze groep. Op basis van eerder 
onderzoek valt te verwachten dat de effecten van testosteron op sociaal toenaderings- 
en vermijdingsgedrag bij mannen vergelijkbaar zullen zijn.
Als derde zijn de onderliggende neuro-endocriene mechanismen van bovenstaande 
processen onderzocht. Hoofdstuk 7 laat zien dat testosteron specifiek vroege (<200ms) 
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verwerkingsprocessen beïnvloedt en dat dit hetzelfde is voor vrouwen met en vrouwen 
zonder SAD. Daarbij wordt de verwerking van sociaal dreigende gezichten (boze) en niet-
dreigende (neutraal en lachend) gezichten verschillend beinvloed door testosteron. De 
resultaten laten zien dat een initiële verhoogde verwerking van sociale dreiging vermind-
erd wordt door testosteron, wat waarschijnlijk te verklaren valt vanuit de angstremmende 
werking van dit hormoon. Deze processen vormen mogelijk de basis van de hierboven 
beschreven effecten van testosteron op sociaal toenaderings- en vermijdingsgedrag 
en laten zien dat deze modulaties door testosteron al optreden gedurende de vroegste 
verwerkingsprocessen.
Een ander belangrijk werkingsmechanisme van testosteron is het verhogen van 
beloningsgevoeligheid, onder andere middels een toename van dopamine spiegels in 
het ventrale striatum. In hoofdstuk 2 laten we zien dat meer dopamine in het striatum 
samenhangt met verhoogde toenaderings- en vermijdingsreacties. Dit gedrag wordt 
geassocieerd met een hogere gevoeligheid voor sociale beloning en laat zien dat de 
striatale dopamine transmissie inderdaad een rol speelt in de regulatie van sociaal toena-
derings- en vermijdingsgedrag.
Samengenomen ziet het er naar uit dat de neuro-endocrine mechanismen achter 
onze bevindingen van testosteron op sociaal vermijdingsgedrag liggen in veranderingen 
in de verwerking van sociale dreiging door de amygdala en frontale-striatale netwerken. 
Testosteron zorgt voor een verhoogde aansturing van toenaderingsgedrag ten opzichte 
van sociale dreiging door de amygdala, vermindert prefrontale controle en verhoogt de 
gevoeligheid voor beloning. Deze werkingsmechanismen zijn met name interessant voor 
SAD, waarbij de automatische neiging tot sociale vermijding versterkt is, en de gevoe-
ligheid voor sociale beloning vermindert. Onze EEG bevindingen suggereren dat testos-
teron al inwerkt op heel vroege verwerkingsprocessen en dat afwijkingen in verwerking 
die samenhangen met psychopathologie pas later optreden. Toekomstig onderzoek 
zal moeten uitwijzen hoe neuro-endocrine processen precies sociaal toenaderings- en 
vermijdingsgedrag beïnvloeden in SAD, en waar de verschillen optreden met gezonde 
personen.
De bevindingen in dit proefschrift kunnen, behalve bijdragen aan kennis en inzicht, 
mogelijk ook van belang zijn voor de behandeling van SAD. Wanneer SAD niet behandeld 
wordt, kan dit leiden tot ernstige beperkingen in sociaal functioneren. Exposure therapie 
is een belangrijk onderdeel van de behandeling en is erop gericht sociale angst en vermi-
jding van sociale situaties te verminderen. Deze therapie helpt helaas niet alle patiënten, 
dus er wordt gezocht naar methoden om de effectiviteit te verbeteren. Aangezien 
testosteron sociale vermijding vermindert en toenadering-bevorderend werkt, zou het 
interessant zijn om te onderzoeken of toediening van testosteron voorafgaand aan een 
exposure-sessie de therapie effectiever maakt. Een andere benadering die onderzocht 
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zou kunnen worden is het met testosteron verhogen van de effectiviteit van het trainen 
van toenaderingsgedrag op de AAT als middel om de vermijding in SAD te verminderen.
Conclusie
Het doel van dit proefschrift was het verwerven van meer kennis over de rol van 
testosteron bij sociale angst. Onze bevindingen laten zien dat testosteronspiegels bij 
vrouwen met SAD verlaagt zijn en gerelateerd aan sociale angstklachten. Bovendien 
lieten we zien dat toediening van testosteron aan vrouwen met SAD in staat is om ver-
mijding te verminderen en sociale toenadering te bevorderen. Deze bevindingen passen 
in de socio-neuroendocriene modellen van SAD en bevestigen de rol van testosteron 
in sociaal motivationeel gedrag. Daarbij ondersteunt de vinding dat testosteron vroege 
aandachtsprocessen beïnvloedt de theorie dat dit hormoon inwerkt op automatische 
motivationele processen. De bevindingen kunnen mogelijk bijdragen aan een effectie-
vere behandeling van SAD.
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